' '
Deutsch | English    

Forschungsdatenbank PMU-SQQUID

GREIL RICHARD
Universitätsklinik für Innere Medizin 3 - Hämatologie, internistische Onkologie, Hämostaseologie, Infektiologie, Rheumatologie und Onkologisches Zentrum

Publikationen | Forscherprofil

732 Publikationen

2019

Beiträge in Fachzeitschriften

BIRC3 Expression Predicts CLL Progression and Defines Treatment Sensitivity via Enhanced NF-κB Nuclear Translocation.
Asslaber, D; Wacht, N; Leisch, M; Qi, Y; Maeding, N; Hufnagl, C; Jansko, B; Zaborsky, N; Villunger, A; Hartmann, TN; Greil, R; Egle, A;
Clin Cancer Res. 2019; 25(6):1901-1912
Originalarbeiten (Zeitschrift)
Intense Uptake of Liposomal Curcumin by Multiple Myeloma Cell Lines: Comparison to Normal Lymphocytes, Red Blood Cells and Chronic Lymphocytic Leukemia Cells.
Bolger, GT; Licollari, A; Bagshaw, R; Tan, AM; Greil, R; Vcelar, B; Majeed, M; Sordillo, P
ANTICANCER RES. 2019; 39(3): 1161-1168.
Originalarbeiten (Zeitschrift)
Pharmacokinetics of liposomal curcumin (Lipocurc™) infusion: effect of co-medication in cancer patients and comparison with healthy individuals.
Bolger, GT; Licollari, A; Tan, A; Greil, R; Vcelar, B; Greil-Ressler, S; Weiss, L; Schönlieb, C; Magnes, T; Radl, B; Majeed, M; Sordillo, PP;
Cancer Chemother Pharmacol. 2019; 83(2):265-275
Originalarbeiten (Zeitschrift)
Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial.
Egle, A; Melchardt, T; Obrtlíková, P; Smolej, L; Kozák, T; Steurer, M; Andel, J; Burgstaller, S; Mikušková, E; Gercheva, L; Nösslinger, T; Papajík, T; Ladická, M; Girschikofsky, M; Hrubiško, M; Jäger, U; Voskova, D; Pecherstorfer, M; Králiková, E; Burcoveanu, C; Spasov, E; Petzer, A; Mihaylov, G; Raynov, J; Oexle, H; Zabernigg, A; Flochová, E; Palášthy, S; Stehlíková, O; Doubek, M; Altenhofer, P; Weiss, L; Magnes, T; Pleyer, L; Klingler, A; Mayer, J; Greil, R;
Cancer Med. 2019; 8(4):-1405.
Originalarbeiten (Zeitschrift)
Prediction of Distant Recurrence Using EndoPredict Among Women with ER
Filipits, M; Dubsky, P; Rudas, M; Greil, R; Balic, M; Bago-Horvath, Z; Singer, CF; Hlauschek, D; Brown, K; Bernhisel, R; Kronenwett, R; Lancaster, JM; Fitzal, F; Gnant, M;
Clin Cancer Res. 2019; 25(13):3865-3872
Originalarbeiten (Zeitschrift)
Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR).
Gampenrieder, SP; Peer, A; Weismann, C; Meissnitzer, M; Rinnerthaler, G; Webhofer, J; Westphal, T; Riedmann, M; Meissnitzer, T; Egger, H; Klaassen Federspiel, F; Reitsamer, R; Hauser-Kronberger, C; Stering, K; Hergan, K; Mlineritsch, B; Greil, R;
Breast Cancer Res. 2019; 21(1):19
Originalarbeiten (Zeitschrift)
Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Gnant, M; Pfeiler, G; Steger, GG; Egle, D; Greil, R; Fitzal, F; Wette, V; Balic, M; Haslbauer, F; Melbinger-Zeinitzer, E; Bjelic-Radisic, V; Jakesz, R; Marth, C; Sevelda, P; Mlineritsch, B; Exner, R; Fesl, C; Frantal, S; Singer, CF
Lancet Oncol. 2019; 20(3):339-351
Originalarbeiten (Zeitschrift)
Baseline Absolute Lymphocyte Count and ECOG Performance Score Are Associated with Survival in Advanced Non-Small Cell Lung Cancer Undergoing PD-1/PD-L1 Blockade.
Huemer, F; Lang, D; Westphal, T; Gampenrieder, SP; Hutarew, G; Weiss, L; Hackl, H; Lamprecht, B; Rinnerthaler, G; Greil, R;
J Clin Med. 2019; 8(7):
Originalarbeiten (Zeitschrift)
Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL-2 and/or BIM.
Huemer, F; Melchardt, T; Jansko, B; Wahida, A; Jilg, S; Jost, PJ; Klieser, E; Katja, S; Magnes, T; Pleyer, L; Greil-Ressler, S; Rass, C; Greil, R; Egle, A;
Eur J Haematol. 2019; 102(5):437-441
Association between antibiotics use and outcome in patients with NSCLC treated with immunotherapeutics.
Huemer, F; Rinnerthaler, G; Lang, D; Hackl, H; Lamprecht, B; Greil, R;
Ann Oncol. 2019; 30(4):652-653
Originalarbeiten (Zeitschrift)
Plitidepsin: a potential new treatment for relapsed/refractory multiple myeloma.
Leisch, M; Egle, A; Greil, R;
Future Oncol. 2019; 15(2):109-120
Originalarbeiten (Zeitschrift)
Next Generation Sequencing in AML-On the Way to Becoming a New Standard for Treatment Initiation and/or Modulation?
Leisch, M; Jansko, B; Zaborsky, N; Greil, R; Pleyer, L
Cancers (Basel). 2019; 11(2):
Übersichtsarbeiten
Correction: The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab.
Magnes, T; Melchardt, T; Hufnagl, C; Weiss, L; Mittermair, C; Neureiter, D; Klieser, E; Rinnerthaler, G; Roesch, S; Gaggl, A; Greil, R; Egle, A;
Pharmacogenomics J. 2019;
Korrekturen
Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities: further results from the prospective PANTHER study with focus on obese patients.
Matikas, A; Foukakis, T; Moebus, V; Greil, R; Bengtsson, NO; Steger, GG; Untch, M; Johansson, H; Hellström, M; Malmström, P; Gnant, M; Loibl, S; Bergh, J;
Ann Oncol. 2019; 30(1): 109-114.
Originalarbeiten (Zeitschrift)
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.
Moreno, C; Greil, R; Demirkan, F; Tedeschi, A; Anz, B; Larratt, L; Simkovic, M; Samoilova, O; Novak, J; Ben-Yehuda, D; Strugov, V; Gill, D; Gribben, JG; Hsu, E; Lih, CJ; Zhou, C; Clow, F; James, DF; Styles, L; Flinn, IW;
Lancet Oncol. 2019; 20(1): 43-56.
Originalarbeiten (Zeitschrift)
HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer.
Rinnerthaler, G; Gampenrieder, SP; Greil, R;
Int J Mol Sci. 2019; 20(5):
Übersichtsarbeiten
Aging restricts the ability of mesenchymal stem cells to promote the generation of oligodendrocytes during remyelination.
Rivera, FJ; de la Fuente, AG; Zhao, C; Silva, ME; Gonzalez, GA; Wodnar, R; Feichtner, M; Lange, S; Errea, O; Priglinger, E; OSullivan, A; Romanelli, P; Jadasz, JJ; Brachtl, G; Greil, R; Tempfer, H; Traweger, A; Bátiz, LF; Küry, P; Couillard-Despres, S; Franklin, RJM; Aigner, L;
Glia. 2019; 67(8):1510-1525
Originalarbeiten (Zeitschrift)
Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with
Schlenk, RF; Weber, D; Fiedler, W; Salih, HR; Wulf, G; Salwender, H; Schroeder, T; Kindler, T; Lübbert, M; Wolf, D; Westermann, J; Kraemer, D; Götze, KS; Horst, HA; Krauter, J; Girschikofsky, M; Ringhoffer, M; Südhoff, T; Held, G; Derigs, HG; Schroers, R; Greil, R; Grießhammer, M; Lange, E; Burchardt, A; Martens, U; Hertenstein, B; Marretta, L; Heuser, M; Thol, F; Gaidzik, VI; Herr, W; Krzykalla, J; Benner, A; Döhner, K; Ganser, A; Paschka, P; Döhner, H;
Blood. 2019; 133(8):840-851
Originalarbeiten (Zeitschrift)
Cytotoxic Properties of Damiana (
Willer, J; Johrer, K; Greil, R; Zidorn, C; Cicek, SS
Molecules. 2019; 24(5):
Originalarbeiten (Zeitschrift)
Exome sequencing of the TCL1 mouse model for CLL reveals genetic heterogeneity and dynamics during disease development.
Zaborsky, N; Gassner, FJ; Höpner, JP; Schubert, M; Hebenstreit, D; Stark, R; Asslaber, D; Steiner, M; Geisberger, R; Greil, R; Egle, A;
Leukemia. 2019; 33(4):957-968
Originalarbeiten (Zeitschrift)

Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen

Antihormonal treatment with or without whole breast irradiation in low risk breast cancer patients after breast conserving surgery: 10-year results of the ABCSG 8A trial
Fastner, G; Sedlmayer, F; Widder, J; Metz, M; Geinitz, H; Kapp, K; Solkner, L; Greil, R; Jakesz, R; Gnant, M
BREAST. 2019; 44: S79-S79.
Abstracts (Zeitschrift)
Antihormones with or without irradiation in breast cancer: 10-year results of the ABCSG 8A trial
Fastner, G; Sedlmayer, F; Widder, J; Metz, M; Geinitz, H; Kapp, K; Solkner, L; Greil, R; Jakesz, R; Kwasny, W; Heck, D; Bjelic-Radisic, V; Balic, M; Stoger, H; Wieder, U; Zwrtek, R; Semmler, D; Horvath, W; Melbinger-Zeinitzer, E; Wiesholzer, M; Wette, V; Gnant, M
RADIOTHER ONCOL. 2019; 133: S132-S133.
Abstracts (Zeitschrift)

2018

Beiträge in Fachzeitschriften

Nonmetastatic pancreatic cancer : Improved survival with chemoradiotherapy > 40 Gy after systemic treatment.
Bachmayer, S; Fastner, G; Vaszi, A; Iglseder, W; Kopp, P; Holzinger, J; Dinnewitzer, A; Rinnerthaler, G; Gampenrieder, SP; Emmanuel, K; Greil, R; Sedlmayer, F; Zehentmayr, F;
Strahlenther Onkol. 2018; 194(7): 627-637.
Originalarbeiten (Zeitschrift)
Distribution of Curcumin and THC in Peripheral Blood Mononuclear Cells Isolated from Healthy Individuals and Patients with Chronic Lymphocytic Leukemia.
Bolger, GT; Licollari, A; Tan, A; Greil, R; Pleyer, L; Vcelar, B; Majeed, M; Sordillo, P;
Anticancer Res. 2018; 38(1): 12-130.
Originalarbeiten (Zeitschrift)
PET-guided treatment in patients with advanced-stage Hodgkins lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group.
Borchmann, P; Goergen, H; Kobe, C; Lohri, A; Greil, R; Eichenauer, DA; Zijlstra, JM; Markova, J; Meissner, J; Feuring-Buske, M; Hüttmann, A; Dierlamm, J; Soekler, M; Beck, HJ; Willenbacher, W; Ludwig, WD; Pabst, T; Topp, MS; Hitz, F; Bentz, M; Keller, UB; Kühnhardt, D; Ostermann, H; Schmitz, N; Hertenstein, B; Aulitzky, W; Maschmeyer, G; Vieler, T; Eich, H; Baues, C; Stein, H; Fuchs, M; Kuhnert, G; Diehl, V; Dietlein, M; Engert, A;
Lancet. 2018; 390(10114): 2790-2802.
Originalarbeiten (Zeitschrift)
A phase I study of lenalidomide in patients with chronic myelomonocytic leukemia (CMML) - AGMT_CMML-1.
Burgstaller, S; Stauder, R; Kuehr, T; Lang, A; Machherndl-Spandl, S; Mayrbaeurl, B; Noesslinger, T; Petzer, A; Valent, P; Greil, R; Thaler, J;
Leuk Lymphoma. 2018; 59(5):1121-1126
Originalarbeiten (Zeitschrift)
The multiple myeloma treatment landscape: international guideline recommendations and clinical practice in Europe.
Cavo, M; Terpos, E; Bargay, J; Einsele, H; Cavet, J; Greil, R; de Wit, E
EXPERT REV HEMATOL. 2018; 11(3): 219-237.
Übersichtsarbeiten
Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes.
Domenyuk, V; Gatalica, Z; Santhanam, R; Wei, XX; Stark, A; Kennedy, P; Toussaint, B; Levenberg, S; Wang, J; Xiao, NQ; Greil, R; Rinnerthaler, G; Gampenrieder, SP; Heimberger, AB; Berry, DA; Barker, A; Quackenbush, J; Marshall, JL; Poste, G; Vacirca, JL; Vidal, GA; Schwartzberg, LS; Halbert, DD; Voss, A; Magee, D; Miglarese, MR; Famulok, M; Mayer, G; Spetzler, D
NAT COMMUN. 2018; 9(1): 1219
Originalarbeiten (Zeitschrift)
Remission maintenance treatment options in chronic lymphocytic leukemia.
Egle, A; Pleyer, L; Melchardt, T; Hartmann, TN; Greil, R;
Cancer Treat Rev. 2018; 70:56-66
Übersichtsarbeiten
Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.
Egle, A; Steurer, M; Melchardt, T; Weiss, L; Gassner, FJ; Zaborsky, N; Geisberger, R; Catakovic, K; Hartmann, TN; Pleyer, L; Voskova, D; Thaler, J; Lang, A; Girschikofsky, M; Petzer, A; Greil, R;
Ann Hematol. 2018; 97(10): 1825-1839.
Originalarbeiten (Zeitschrift)
Correction to: Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.
Egle, A; Steurer, M; Melchardt, T; Weiss, L; Gassner, FJ; Zaborsky, N; Geisberger, R; Catakovic, K; Hartmann, TN; Pleyer, L; Voskova, D; Thaler, J; Lang, A; Girschikofsky, M; Petzer, A; Greil, R;
Ann Hematol. 2018; 97(9):1745
Korrekturen
Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+).
Falantes, J; Pleyer, L; Thépot, S; Almeida, AM; Maurillo, L; Martínez-Robles, V; Stauder, R; Itzykson, R; Pinto, R; Venditti, A; Bargay, J; Burgstaller, S; Martínez, MP; Seegers, V; Cortesão, E; Foncillas, MÁ; Gardin, C; Montesinos, P; Musto, P; Fenaux, P; Greil, R; Sanz, MA; Ramos, F;
Leuk Lymphoma. 2018; 59(5):1113-1120
Originalarbeiten (Zeitschrift)
Impact of Breast Surgery in Primary Metastasized Breast Cancer: Outcomes of the Prospective Randomized Phase III ABCSG-28 POSYTIVE Trial.
Fitzal, F; Bjelic-Radisic, V; Knauer, M; Steger, G; Hubalek, M; Balic, M; Singer, C; Bartsch, R; Schrenk, P; Soelkner, L; Greil, R; Gnant, M;
Ann Surg. 2018;
Originalarbeiten (Zeitschrift)
DNA Methylation Signatures Predicting Bevacizumab Efficacy in Metastatic Breast Cancer
Gampenrieder, SP; Rinnerthaler, G; Hackl, H; Pulverer, W; Weinhaeusel, A; Ilic, S; Hufnagl, C; Hauser-Kronberger, C; Egle, A; Risch, A; Greil, R
THERANOSTICS. 2018; 8(8): 2278-2288.
Originalarbeiten (Zeitschrift)
Imprecision and DNA Break Repair Biased towards Incompatible End Joining in Leukemia.
Gassner, FJ; Schubert, M; Rebhandl, S; Spandl, K; Zaborsky, N; Catakovic, K; Blaimer, S; Hebenstreit, D; Greil, R; Geisberger, R;
Mol Cancer Res. 2018; 16(3):428-438
Originalarbeiten (Zeitschrift)
A phase 1 dose-escalation study on the safety, tolerability and activity of liposomal curcumin (Lipocurc
Greil, R; Greil-Ressler, S; Weiss, L; Schönlieb, C; Magnes, T; Radl, B; Bolger, GT; Vcelar, B; Sordillo, PP;
Cancer Chemother Pharmacol. 2018; 82(4): 695-706.
Originalarbeiten (Zeitschrift)
Sequential immunotherapy in a patient with primary refractory Hodgkin lymphoma and novel mutations.
Greil, R; Pleyer, L; Jansko, B; Feierabend, C; Rettenbacher, L; Stiefel, O; Rass, C; Morre, P; Neureiter, D; Greil-Ressler, S;
Oncotarget. 2018; 9(29): 20928-20940.
Originalarbeiten (Zeitschrift)
Microenvironment-induced CD44v6 promotes early disease progression in chronic lymphocytic leukemia.
Gutjahr, JC; Szenes, E; Tschech, L; Asslaber, D; Schlederer, M; Roos, S; Yu, X; Girbl, T; Sternberg, C; Egle, A; Aberger, F; Alon, R; Kenner, L; Greil, R; Orian-Rousseau, V; Hartmann, TN;
Blood. 2018; 131(12): 1337-1349.
Originalarbeiten (Zeitschrift)
Impact of antibiotic treatment on immune-checkpoint blockade efficacy in advanced non-squamous non-small cell lung cancer.
Huemer, F; Rinnerthaler, G; Westphal, T; Hackl, H; Hutarew, G; Gampenrieder, SP; Weiss, L; Greil, R;
Oncotarget. 2018; 9(23):-16520
Originalarbeiten (Zeitschrift)
Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie).
Huemer, F; Thaler, J; Piringer, G; Hackl, H; Pleyer, L; Hufnagl, C; Weiss, L; Greil, R;
BMC Cancer. 2018; 18(1): 11
Originalarbeiten (Zeitschrift)
Establishment and validation of a novel risk model for estimating time to first treatment in 120 patients with chronic myelomonocytic leukaemia.
Huemer, F; Weiss, L; Faber, V; Neureiter, D; Egle, A; Geissler, K; Voskova, D; Zebisch, A; Burgstaller, S; Pichler, A; Stauder, R; Sperr, W; Lang, A; Pfeilstöcker, M; Machherndl-Spandl, S; Stampfl, M; Greil, R; Pleyer, L;
Wien Klin Wochenschr. 2018; 130(3-4): 115-125.
Originalarbeiten (Zeitschrift)
Intensified preoperative chemoradiation by adding oxaliplatin in locally advanced, primary operable (cT3NxM0) rectal cancer : Impact on long-term outcome. Results of the phase II TAKO 05/ABCSG R‑02 trial.
Kogler, P; DeVries, AF; Eisterer, W; Thaler, J; Sölkner, L; Öfner, D;
Strahlenther Onkol. 2018; 194(1): 41-49.
Originalarbeiten (Zeitschrift)
The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab.
Magnes, T; Melchardt, T; Hufnagl, C; Weiss, L; Mittermair, C; Neureiter, D; Klieser, E; Rinnerthaler, G; Roesch, S; Gaggl, A; Greil, R; Egle, A;
Pharmacogenomics J. 2018; 18(3):-479
Originalarbeiten (Zeitschrift)
Clonal evolution and heterogeneity in metastatic head and neck cancer-An analysis of the Austrian Study Group of Medical Tumour Therapy study group.
Melchardt, T; Magnes, T; Hufnagl, C; Thorner, AR; Ducar, M; Neureiter, D; Tränkenschuh, W; Klieser, E; Gaggl, A; Rösch, S; Rasp, G; Hartmann, TN; Pleyer, L; Rinnerthaler, G; Weiss, L; Greil, R; Egle, A;
Eur J Cancer. 2018; 93:69-78
Originalarbeiten (Zeitschrift)
Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial
Paschka, P; Schlenk, RF; Weber, D; Benner, A; Bullinger, L; Heuser, M; Gaidzik, VI; Thol, F; Agrawal, M; Teleanu, V; Lubbert, M; Fiedler, W; Radsak, M; Krauter, J; Horst, HA; Greil, R; Mayer, K; Kundgen, A; Martens, U; Heil, G; Salih, HR; Hertenstein, B; Schwanen, C; Wulf, G; Lange, E; Pfreundschuh, M; Ringhoffer, M; Girschikofsky, M; Heinicke, T; Kraemer, D; Gohring, G; Ganser, A; Dohner, K; Dohner, H
LEUKEMIA. 2018; 32(7): 1621-1630.
Originalarbeiten (Zeitschrift)
A prospective, multicenter pilot study to investigate the feasibility and safety of a 1-year controlled exercise training after adjuvant chemotherapy in colorectal cancer patients.
Piringer, G; Fridrik, M; Fridrik, A; Leiherer, A; Zabernigg, A; Greil, R; Eisterer, W; Tschmelitsch, J; Lang, A; Frantal, S; Burgstaller, S; Gnant, M; Thaler, J;
Support Care Cancer. 2018; 26(4):1345-1352
Originalarbeiten (Zeitschrift)
ASCO 2018 highlights: metastatic breast cancer
Rinnerthaler, G; Gampenrieder, SP; Greil, R
MEMO-MAG EUR MED ONC. 2018; 11(4): 276-279.
Übersichtsarbeiten
SABCS 2017: lifestyle factors, hormone receptor-positive advanced disease, liquid biopsies, and prognosis.
Rinnerthaler, G; Gampenrieder, SP; Greil, R
MEMO-MAG EUR MED ONC. 2018; 11(3): 208-212.
Übersichtsarbeiten
Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial).
Rinnerthaler, G; Gampenrieder, SP; Petzer, A; Burgstaller, S; Fuchs, D; Rossmann, D; Balic, M; Egle, D; Rumpold, H; Singer, CF; Bartsch, R; Petru, E; Melchardt, T; Ulmer, H; Mlineritsch, B; Greil, R;
BMC Cancer. 2018; 18(1): 1074
Originalarbeiten (Zeitschrift)
Outcome of Patients With Early-Stage Infradiaphragmatic Hodgkin Lymphoma: A Comprehensive Analysis From the German Hodgkin Study Group.
Sasse, S; Goergen, H; Plütschow, A; Böll, B; Eichenauer, DA; Fuchs, M; Behringer, K; Zijlstra, JM; Greil, R; Markova, J; Topp, MS; Meissner, J; Neubauer, A; Baues, C; Engert, A; Borchmann, P; von Tresckow, B;
J Clin Oncol. 2018; 36(25): 2603-2611.
Originalarbeiten (Zeitschrift)
Novel models for prediction of benefit and toxicity with FOLFIRINOX treatment of pancreatic cancer using clinically available parameters.
Schlick, K; Magnes, T; Ratzinger, L; Jaud, B; Weiss, L; Melchardt, T; Greil, R; Egle, A;
PLoS One. 2018; 13(11): e0206688
Originalarbeiten (Zeitschrift)
Risks and chances of aberrant DNA repair in cancer.
Schubert, M; Greil, R; Geisberger, R;
Oncoscience. 2018; 5(9-10): 256-257.
Editorials
Investigating epigenetic effects of activation-induced deaminase in chronic lymphocytic leukemia.
Schubert, M; Hackl, H; Gassner, FJ; Greil, R; Geisberger, R;
PLoS One. 2018; 13(12): e0208753
Originalarbeiten (Zeitschrift)
Extensive Leptomeningeal Intracranial and Spinal Metastases in a Patient with a Supratentorial Glioblastoma Multiforme, IDH-Wildtype.
Schwartz, C; Romagna, A; Machegger, L; Weiss, L; Huemer, F; Fastner, G; Kleindienst, W; Serge, W; Greil, R; Winkler, PA;
World Neurosurg. 2018; 120:442-447
Fallberichte
Cure in metastatic breast cancer.
Westphal, T; Gampenrieder, SP; Rinnerthaler, G; Greil, R;
Memo. 2018; 11(3):172-179
Übersichtsarbeiten
Supervised versus autonomous exercise training in breast cancer patients: A multicenter randomized clinical trial.
Westphal, T; Rinnerthaler, G; Gampenrieder, SP; Niebauer, J; Thaler, J; Pfob, M; Fuchs, D; Riedmann, M; Mayr, B; Reich, B; Melchardt, T; Mlineritsch, B; Pleyer, L; Greil, R;
Cancer Med. 2018; 7(12):596-5972
Originalarbeiten (Zeitschrift)

Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen

KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)
Burtness, B; Harrington, KJ; Greil, R; Soulieres, D; Tahara, M; De Castro, G; Psyrri, A; Rotllan, NB; Neupane, PC; Bratland, A; Fuereder, T; Hughes, BGM; Mesia, R; Ngamphaiboon, N; Rordorf, T; Ishak, WZW; Roy, A; Cheng, J; Jin, F; Rischin, D
ANN ONCOL. 2018; 29:
Abstracts (Zeitschrift)
Polyligand profiling differentiates cancer patients according to their benefit of treatment
Domenyuk, V; Gatalica, Z; Santhanam, R; Wei, XX; Stark, A; Kennedy, P; Toussaint, B; Levenberg, S; Wang, R; Xiao, N; Greil, R; Rinnerthaler, G; Gampenrieder, S; Heimberger, AB; Berry, DJ; Barker, A; Demetri, GD; Quackenbush, J; Marshall, JL; Poste, G; Vacirca, JL; Vidal, GA; Schwartzberg, LS; Halbert, DD; Voss, A; Miglarese, MR; Famulok, M; Mayer, G; Spetzler, D
CANCER RES. 2018; 78(4):
Abstracts (Zeitschrift)
The EndoPredict score predicts residual cancer burden after neoadjuvant chemotherapy and after neoendocrince therapy in HR+/HER2-breast cancer patients from ABCSG 34
Dubsky, PC; Fesl, C; Singer, CF; Pfeiler, G; Kronenwett, R; Hubalek, M; Bartsch, R; Stoeger, H; Pichler, A; Petru, E; Bjelic-Radisic, V; Greil, R; Rudas, M; Tea, MKM; Wette, V; Petzner, AL; Sevelda, P; Egle, D; Fitzal, F; Exner, R; Jakesz, R; Balic, M; Tinchon, C; Bago-Horvath, Z; Lax, S; Regitnig, P; Gnant, M; Filipits, M
CANCER RES. 2018; 78(4):
Abstracts (Zeitschrift)
Exome sequencing of tumors from the TCL1 mouse model for CLL reveals genetic heterogeneity and dynamics during disease development
Egle, A; Gassner, FJ; Hopner, JP; Hebenstreit, D; Stark, R; Asslaber, D; Steiner, M; Geisberger, R; Greil, R; Zaborsky, N
ONCOL RES TREAT. 2018; 41: 31-31.
Abstracts (Zeitschrift)
mRNA expression of ER, PR, HER2 and Ki67 are concordant to central ihc and predict clinical outcome: A validation study from the ABCSG-6 biomarker cohort
Filipits, M; Rudas, M; Singer, C; Bago-Horvath, Z; Greil, R; Balic, M; Lax, SF; Wu, N; Zhao, S; Weidler, J; Bates, M; Hlauschek, D; Gnant, M; Dubsky, P
ANN ONCOL. 2018; 29: 480-480.
Abstracts (Zeitschrift)
PET-Guided Treatment of Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase 3 Trial HD16 By the German Hodgkin Study Group
Fuchs, M; Goergen, H; Kobe, C; Eich, H; Baues, C; Greil, R; Sasse, S; Zijlstra, JM; Lohri, A; Rosenwald, A; von Tresckow, B; Diehl, V; Kuhnert, G; Dietlein, M; Borchmann, P; Engert, A
BLOOD. 2018; 132:
Abstracts (Zeitschrift)
Contrast-enhanced MRI does not accurately predict pathologic complete response (pCR) after neoadjuvant chemotherapy in early or locally advanced breast cancer
Gampenrieder, SP; Peer, A; Weismann, C; Meissnitzer, M; Rinnerthaler, G; Webhofer, J; Westphal, T; Popovscaia, M; Meissnitzer, T; Reitsamer, R; Hauser-Kronberger, C; Egger, H; Hergan, K; Mlineritsch, B; Greil, R
CANCER RES. 2018; 78(4):
Abstracts (Zeitschrift)
RNA editing in CLL
Gassner, FJ; Zaborsky, N; Sychikow, I; Levanon, E; Greil, R; Geisberger, R
ONCOL RES TREAT. 2018; 41: 169-169.
Abstracts (Zeitschrift)
Long-Term Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Polycythemia Vera - Final Phase I/II Peginvera Study Results
Gisslinger, H; Buxhofer-Ausch, V; Thaler, J; Forjan, E; Willenbacher, E; Wolf, D; Kralovics, R; Gisslinger, B; Stampfl-Mattersberger, M; Egle, A; Melchardt, T; Burgstaller, S; Schalling, M; Krauth, MT; Greil, R; Kadlecova, P; Zoerer, M; Empson, V; Grohmann-Izay, B; Klade, C
BLOOD. 2018; 132:
Abstracts (Zeitschrift)
A prospective randomized multi-center phase-III trial of additional 2 versus additional 5 years of anastrozole after initial 5 years of adjuvant endocrine therapy - results from 3,484 postmenopausal women in the ABCSG-16 trial
Gnant, M; Steger, G; Greil, R; Fitzal, F; Mlineritsch, B; Manfreda, D; Tausch, C; Balic, M; Dubsky, P; Moik, M; Thaler, J; Egle, D; Bjelic-Radisic, V; Selim, U; Exner, R; Singer, C; Melbinger-Zeinitzer, E; Haslbauer, F; Stoger, H; Helfgott, R; Sevelda, P; Trapl, H; Wette, V; Solkner, L; Jakesz, R
CANCER RES. 2018; 78(4):
Abstracts (Zeitschrift)
Efficacy and Safety of Ibrutinib (IBR) after Venetoclax (VEN) Treatment in IBR-Naive Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Follow-up of Patients from the MURANO Study
Greil, R; Fraser, G; Leber, B; Marks, R; Quaresmini, G; Middeke, JM; Semenzato, G; Schary, W; Boyer, M; Breuleux, M; Crompton, N; Humphrey, K; Marlton, P
BLOOD. 2018; 132:
Abstracts (Zeitschrift)
Prospective observational study to evaluate the persistence of treatment with denosumab (dmab) in patients (pts) with bone metastases (BM) from solid tumors (ST) in routine clinical practice: Final analysis
Haslbauer, F; Petzer, AL; Safanda, M; Tomova, A; Porubska, M; Bajory, Z; Niepel, D; Jager, C; Kalinin, D; Greil, R
ANN ONCOL. 2018; 29:
Abstracts (Zeitschrift)
Evaluation of circulating cell-free DNA as a molecular monitoring tool in patients with metastatic cancer
Hufnagl, C; Leisch, M; Weiss, L; Melchardt, T; Moik, M; Geisberger, R; Asslaber, D; Steininger, P; Meissnitzer, T; Neureiter, D; Greil, R; Egle, A
ONCOL RES TREAT. 2018; 41: 307-307.
Abstracts (Zeitschrift)
Prognostic Value of Circulating Bcl-2/Igh Levels before and after Treatment in 415 Patients with Advanced Follicular Lymphoma Receiveing First-Line Immuno-Chemotherapy in 2 Prospective StiL Trails - the Effects of Riruximab Maintenance
Kobbe, G; Pechtel, S; Zohren, F; Barth, J; Burchardt, AC; Buske, C; Dienst, A; Germing, U; Greil, R; Hertenstein, B; Kauff, F; Koenigsmann, M; Lerchenmuller, C; Schroeder, TM; Haas, R; Rummel, MJ
BLOOD. 2018; 132:
Abstracts (Zeitschrift)
Ixazomib in Combination with Thalidomide and Dexamethasone for Induction and Ixazomib Maintenance Therapy Overcomes High-Risk Cytogenetics (but not of 1q21 Gain) in Relapsed/Refractory Multiple Myeloma - AGMT_MM1
Ludwig, H; Ponisch, W; Knop, S; Schreder, M; Lechner, D; Hajek, R; Gunsilius, E; Krenosz, KJ; Petzer, A; Weisel, K; Einsele, H; Greil, R; Zojer, N
BLOOD. 2018; 132:
Abstracts (Zeitschrift)
Spatial heterogeneity in diffuse large B-cell lymphoma
Magnes, T; Melchardt, T; Thorner, A; Neureiter, D; Klieser, E; Greil, R; Egle, A
ONCOL RES TREAT. 2018; 41: 243-244.
Abstracts (Zeitschrift)
Ibrutinib plus Obinutuzumab Versus Chlorambucil plus Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results from Phase 3 iLLUMINATE
Moreno, C; Greil, R; Demirkan, F; Tedeschi, A; Anz, B; Larratt, L; Simkovic, M; Samoilova, O; Novak, J; Ben-Yehuda, D; Strugov, V; Gill, D; Gribben, JG; Hsu, E; Zhou, C; Clow, F; James, DF; Styles, L; Flinn, IW
BLOOD. 2018; 132:
Abstracts (Zeitschrift)
Fracture Risk after Stopping Adjuvant Denosumab in Hormone Receptor Positive Breast Cancer Patients on Aromatase Inhibitor Therapy - an Analysis of 3,425 Postmenopausal Patients in the Phase III ABCSG-18 trial
Pfeiler, G; Steger, GG; Egle, D; Greil, R; Fitzal, F; Wette, V; Balic, M; Haslbauer, F; Melbinger-Zeinitzer, E; Bjelic-Radisic, V; Bergh, J; Jakesz, R; Marth, C; Sevelda, P; Mlineritsch, B; Exner, R; Fesl, C; Frantal, S; Singer, CF; Gnant, M
J BONE MINER RES. 2018; 33: 55-55.
Abstracts (Zeitschrift)
Ixazomib in combination with carboplatin in pretreated women with advanced triple negative breast cancer, a phase I/II trial (AGMT MBC-10 trial)
Rinnerthaler, G; Gampenrieder, SP; Petzer, A; Pusch, R; Fridrik, M; Rossmann, D; Balic, M; Egle, D; Rumpold, H; Singer, C; Bartsch, R; Melchardt, T; Ulmer, H; Mlineritsch, B; Greil, R
CANCER RES. 2018; 78(4):
Abstracts (Zeitschrift)
Ixazomib in combination with carboplatin in pretreated women with advanced triple negative breast cancer, an ongoing phase I/II trial (AGMT MBC-10 trial)
Rinnerthaler, G; Gampenrieder, SP; Petzer, A; Pusch, R; Voskova, D; Rossmann, D; Balic, M; Egle, D; Rumpold, H; Singer, CF; Melchardt, T; Ulmer, H; Mlineritsch, B; Greil, R
CANCER RES. 2018; 78(13):
Abstracts (Zeitschrift)
Four versus two years of Rituximab maintenance (R-maintenance) following Bendamustine plus Rituximab (B-R): initial results of a prospective, randomized multicenter phase 3 study in first-line follicular lymphoma (the StiL NHL7-2008 MAINTAIN study)
Rummel, M; Buske, C; Hertenstein, B; Lerchenmuller, CA; Koenigsmann, M; Lange, E; Reeb, M; Kaiser, U; Balser, C; Behringer, D; Durig, J; Gaska, T; Maschmeyer, G; Schliesser, G; Burchardt, A; Barth, J; Kauff, F; Hinke, A; Greil, R
ONCOL RES TREAT. 2018; 41: 251-251.
Abstracts (Zeitschrift)
Two years Rituximab maintenance vs. observation after first line treatment with bendamustine plus rituximab (B-R) in patients with marginal zone lymphoma (MZL): results of a prospective, randomized, multicenter phase 2 study (the StiL NHL7-2008 MAINTAIN trial)
Rummel, M; Koenigsmann, M; Chow, KU; Knauf, W; Lerchenmuller, CA; Losem, C; Gorner, M; Hertenstein, B; Decker, T; Ganser, A; Gaska, T; Heike, M; Lange, E; Weide, R; Willenbacher, W; Burchardt, A; Kauff, F; Barth, J; Hinke, A; Greil, R
ONCOL RES TREAT. 2018; 41: 253-253.
Abstracts (Zeitschrift)
Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia (AML): Results from the Prospective Randomized AMLSG 09-09 Phase-III Study
Schlenk, RF; Paschka, P; Krzykalla, J; Weber, D; Kapp-Schwoerer, S; Gaidzik, VI; Leis, C; Fiedler, W; Kindler, T; Schroeder, T; Mayer, K; Lubbert, M; Wattad, MA; Gotze, KS; Horst, HA; Koller, E; Wulf, G; Schleicher, J; Bentz, M; Greil, R; Hertenstein, B; Krauter, J; Martens, U; Nachbaur, D; Abu Samra, M; Girschikofsky, M; Benner, A; Thol, F; Heuser, M; Ganser, A; Dohner, K
BLOOD. 2018; 132:
Abstracts (Zeitschrift)
Elucidating the contribution of AID to the clonal evolution of chronic lymphocytic leukemia
Schubert, M; Zaborsky, N; Huemer, M; Hopner, JP; Gassner, FJ; Arzt, C; Greil, R; Geisberger, R
ONCOL RES TREAT. 2018; 41: 169-169.
Abstracts (Zeitschrift)
Panitumumab-Associated Encephalopathy after Accidental Intra-Arterial Application through Dislocated Central Venous Access Device
Sellner, J; Pilz, G; Gschwandtner, G; Rosler, C; Schlick, K; Greil, R; Pikija, S
ANN NEUROL. 2018; 84: S45-S45.
Abstracts (Zeitschrift)
Real-World multicenter Austrian analysis of the safety and effectiveness of nab-paclitaxel in young and elderly patients with metastatic breast cancer
Steger, G; Petru, E; Haslbauer, F; Marth, C; Egle, D; Galid, A; Sliwa, T; Lang, A; Kuehr, T; Petzer, A; Ruckser, R; Greil, R; Mlineritsch, B; Singer, C; Seifert, M; Andel, J; Kwasny, W; Pichler, P; Tinchon, C; Bartsch, R
EUR J CANCER. 2018; 92: S97-S97.
Abstracts (Zeitschrift)
Efficacy and safety of dabrafenib plus trametinib in patients with BRAF V600E-mutated biliary tract cancer and adenocarcinoma of the small intestine
Wainberg, Z; Lassen, U; Elez, E; Italiano, A; Curigliano, G; DeBraud, F; Prager, G; Greil, R; Stein, A; Angelica, F; Schellens, JHM; Wen, PY; Boran, AD; Mookerjee, B; Burgess, P; Rangwala, F; Subbiah, V
EUR J CANCER. 2018; 103: E3-E4.
Abstracts (Zeitschrift)
Screening for human epidermal growth factor receptor 2 (HER2) positivity in patients with inoperable locally advanced or metastatic gastric or gastro-esophageal junction (GEJ) cancer. AGMT Gastric-5
Woll, E; Regitnig, P; Winder, T; Thaler, J; Hockl, P; Eisterer, W; Ganzer, H; Wustner, A; Andel, J; Greil, R
ONCOL RES TREAT. 2018; 41: 255-255.
Abstracts (Zeitschrift)

2017

Beiträge in Fachzeitschriften

Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study
Almeida, AM; Prebet, T; Itzykson, R; Ramos, F; Al-Ali, H; Shammo, J; Pinto, R; Maurillo, L; Wetzel, J; Musto, P; Van De Loosdrecht, AA; Costa, MJ; Esteves, S; Burgstaller, S; Stauder, R; Autzinger, EM; Lang, A; Krippl, P; Geissler, D; Falantes, JF; Pedro, C; Bargay, J; Deben, G; Garrido, A; Bonanad, S; Diez-Campelo, M; Thepot, S; Ades, L; Sperr, WR; Valent, P; Fenaux, P; Sekeres, MA; Greil, R; Pleyer, L
INT J MOL SCI. 2017; 18(4): 837
Originalarbeiten (Zeitschrift)
Distribution and Metabolism of Lipocurc™ (Liposomal Curcumin) in Dog and Human Blood Cells: Species Selectivity and Pharmacokinetic Relevance.
Bolger, GT; Licollari, A; Tan, A; Greil, R; Vcelar, B; Majeed, M; Helson, L;
Anticancer Res. 2017; 37(7):348-3492
Originalarbeiten (Zeitschrift)
Progression-free survival of early interim PET-positive patients with advanced stage Hodgkins lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group.
Borchmann, P; Haverkamp, H; Lohri, A; Mey, U; Kreissl, S; Greil, R; Markova, J; Feuring-Buske, M; Meissner, J; Dührsen, U; Ostermann, H; Keller, U; Maschmeyer, G; Kuhnert, G; Dietlein, M; Kobe, C; Eich, H; Baues, C; Stein, H; Fuchs, M; Diehl, V; Engert, A;
Lancet Oncol. 2017; 18(4): 454-463.
Originalarbeiten (Zeitschrift)
TIGIT expressing CD4+T cells represent a tumor-supportive T cell subset in chronic lymphocytic leukemia.
Catakovic, K; Gassner, FJ; Ratswohl, C; Zaborsky, N; Rebhandl, S; Schubert, M; Steiner, M; Gutjahr, JC; Pleyer, L; Egle, A; Hartmann, TN; Greil, R; Geisberger, R;
Oncoimmunology. 2017; 7(1):e1371399
Originalarbeiten (Zeitschrift)
Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab Followed by Concomitant Chemoradiation and Surgical Resection in Locally Advanced Rectal Cancer with High Risk of Recurrence - A Phase II Study.
Eisterer, W; Piringer, G; DE Vries, A; Öfner, D; Greil, R; Tschmelitsch, J; Samonigg, H; Sölkner, L; Gnant, M; Thaler, J;
Anticancer Res. 2017; 37(5):2683-2691
Originalarbeiten (Zeitschrift)
Endothelin-1 genetic polymorphism as predictive marker for bevacizumab in metastatic breast cancer.
Gampenrieder, SP; Hufnagl, C; Brechelmacher, S; Huemer, F; Hackl, H; Rinnerthaler, G; Romeder, F; Monzo Fuentes, C; Morre, P; Hauser-Kronberger, C; Mlineritsch, B; Greil, R;
Pharmacogenomics J. 2017; 17(4):344-350
Originalarbeiten (Zeitschrift)
SABCS 2016: systemic therapy for metastatic breast cancer
Gampenrieder, SP; Rinnerthaler, G; Greil, R
MEMO-MAG EUR MED ONC. 2017; 10(2): 86-89.
Übersichtsarbeiten
Antiangiogenic therapy in breast cancer.
Gampenrieder, SP; Westphal, T; Greil, R;
Memo. 2017; 10(4):194-201
Übersichtsarbeiten
Reactivation of dormant anti-tumor immunity - a clinical perspective of therapeutic immune checkpoint modulation.
Greil, R; Hutterer, E; Hartmann, TN; Pleyer, L;
Cell Commun Signal. 2017; 15(1):5
Übersichtsarbeiten
Intermittent low-dose bevacizumab in hereditary hemorrhagic telangiectasia : A case report.
Huemer, F; Dejaco, M; Grabmer, C; Melchardt, T; Neureiter, D; Mayer, G; Egle, A; Greil, R; Weiss, L;
Wien Klin Wochenschr. 2017; 129(3-4):-144
Fallberichte
A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma.
Kiesewetter, B; Willenbacher, E; Willenbacher, W; Egle, A; Neumeister, P; Voskova, D; Mayerhoefer, ME; Simonitsch-Klupp, I; Melchardt, T; Greil, R; Raderer, M;
Blood. 2017; 129(3):-385
Originalarbeiten (Zeitschrift)
Red blood cell alloimmunization in 184 patients with myeloid neoplasms treated with azacitidine - A retrospective single center experience.
Leisch, M; Weiss, L; Lindlbauer, N; Jungbauer, C; Egle, A; Rohde, E; Greil, R; Grabmer, C; Pleyer, L;
Leuk Res. 2017; 59:12-19
Originalarbeiten (Zeitschrift)
Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib-dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study.
Ludwig, H; Weisel, K; Petrucci, MT; Leleu, X; Cafro, AM; Garderet, L; Leitgeb, C; Foa, R; Greil, R; Yakoub-Agha, I; Zboralski, D; Vauléon, S; Dümmler, T; Beyer, D; Kruschinski, A; Riecke, K; Baumann, M; Engelhardt, M;
Leukemia. 2017; 31(4):997-1000
Letter
Update on squamous cell carcinoma of the head and neck: ASCO annual meeting 2017.
Magnes, T; Egle, A; Greil, R; Melchardt, T;
MEMO-MAG EUR MED ONC. 2017; 10(4): 220-223.
Übersichtsarbeiten
Prognostic score in patients with recurrent or metastatic carcinoma of the head and neck treated with cetuximab and chemotherapy.
Magnes, T; Melchardt, T; Weiss, L; Mittermair, C; Neureiter, D; Klieser, E; Gampenrieder, S; Moser, G; Gaggl, A; Greil, R; Egle, A;
PLoS One. 2017; 12(7):e0180995
Originalarbeiten (Zeitschrift)
Transient congenital dilated cardiomyopathy after maternal R-CHOP chemotherapy during pregnancy.
Padberg, S; Mick, I; Frenzel, C; Greil, R; Hilberath, J; Schaefer, C;
Reprod Toxicol. 2017; 71: 146-149.
Fallberichte
Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group
Pleyer, L; Dohner, H; Dombret, H; Seymour, JF; Schuh, AC; Beach, CL; Swern, AS; Burgstaller, S; Stauder, R; Girschikofsky, M; Sill, H; Schlick, K; Thaler, J; Halter, B; Spandl, SM; Zebisch, A; Pichler, A; Pfeilstocker, M; Autzinger, EM; Lang, A; Geissler, K; Voskova, D; Sperr, WR; Hojas, S; Rogulj, IM; Andel, J; Greil, R
INT J MOL SCI. 2017; 18(2): 415
Originalarbeiten (Zeitschrift)
Improvement of quality of life and psychological distress after inpatient cancer rehabilitation
Riedl, D; Giesinger, JM; Wintner, LM; Loth, FL; Rumpold, G; Greil, R; Nickels, A; Licht, T; Holzner, B
WIEN KLIN WOCHENSCHR. 2017; 129(19-20): 692-701.
Originalarbeiten (Zeitschrift)
The first meeting of the Austrian Expert Panel for Molecular Cancer Profiling
Seeber, A; Gastl, G; Eisterer, W; Gampenrieder, SP; Gerger, A; Kieler, M; Pichler, M; Prager, GW; Untergasser, G; Weltermann, A; Greil, R
MEMO-MAG EUR MED ONC. 2017; 10(4): 255-258.
Originalarbeiten (Zeitschrift)
Hemeoxygenase-1 as a Novel Driver in Ritonavir-Induced Insulin Resistance in HIV-1-Infected Patients.
Taylor, N; Kremser, I; Auer, S; Hoermann, G; Greil, R; Haschke-Becher, E; Esterbauer, H; Kenner, L; Oberkofler, H;
J Acquir Immune Defic Syndr. 2017; 75(1):e13-e20
Originalarbeiten (Zeitschrift)
Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.
Thieblemont, C; Tilly, H; Gomes da Silva, M; Casasnovas, RO; Fruchart, C; Morschhauser, F; Haioun, C; Lazarovici, J; Grosicka, A; Perrot, A; Trotman, J; Sebban, C; Caballero, D; Greil, R; van Eygen, K; Cohen, AM; Gonzalez, H; Bouabdallah, R; Oberic, L; Corront, B; Choufi, B; Lopez-Guillermo, A; Catalano, J; Van Hoof, A; Briere, J; Cabeçadas, J; Salles, G; Gaulard, P; Bosly, A; Coiffier, B;
J CLIN ONCOL. 2017; 35(22): 2473-2481.
Originalarbeiten (Zeitschrift)
ASCO-update: gastrointestinal tumors.
Weiss, L; Huemer, F; Greil, R;
Memo. 2017; 10(4): 240-243.
Übersichtsarbeiten
Influence of body mass index on survival in indolent and mantle cell lymphomas: analysis of the StiL NHL1 trial.
Weiss, L; Melchardt, T; Egle, A; Hopfinger, G; Hackl, H; Greil, R; Barth, J; Rummel, M;
Ann Hematol. 2017; 96(7): 1155-1162.
Originalarbeiten (Zeitschrift)
The double-edged sword of (re)expression of genes by hypomethylating agents: from viral mimicry to exploitation as priming agents for targeted immune checkpoint modulation.
Wolff, F; Leisch, M; Greil, R; Risch, A; Pleyer, L;
CELL COMMUN SIGNAL. 2017; 15(1): 13
Übersichtsarbeiten
Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients - AGMT_GASTRIC-3.
Wöll, E; Thaler, J; Keil, F; Gruenberger, B; Hejna, M; Eisterer, W; Fridrik, MA; Ulmer, H; Trommet, V; Huemer, F; Weiss, L; Greil, R;
Anticancer Res. 2017; 37(10): 5553-5558.
Originalarbeiten (Zeitschrift)

Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen

Quality-of-life results from a randomized, phase-II-study of the therapeutic cancer vaccine L-BLP25 (Stimuvax (R)) in the preoperative treatment of women with primary breast cancer (ABCSG-34)
Bjelic-Radisic, V; Singer, CF; Pfeiler, G; Hubalek, M; Bartsch, R; Stoger, H; Pichler, A; Petru, E; Greil, R; Wette, V; Petzer, A; Sevelda, P; Egle, D; Dubsky, P; Fitzal, F; Jakesz, R; Balic, M; Frantal, S; Solkner, L; Gnant, M
ANN ONCOL. 2017; 28:
Abstracts (Zeitschrift)
CTCA toxicity scoring and EORTC quality of life questionnaire: A comparison of physiciansxxx and patientsxxx scoring of toxicity in the "Panther trial"
Brandberg, Y; Loibl, S; Foukakis, T; Johansson, H; Gnant, M; Singer, CF; von Minckwitz, G; Bengtsson, NO; Karlsson, E; Mlineritsch, B; Hellstrom, M; Steger, G; Carlsson, L; Egle, D; Greil, R; Bergh, J
ANN ONCOL. 2017; 28:
Abstracts (Zeitschrift)
SUCCESSFUL LONG-TERM MAINTENANCE OF PV PATIENTS WITH A MONTHLY SCHEDULE OF ROPEGINTERFERON ALFA-2B-AN UPDATE FROM THE PEGINVERA STUDY
Buxhofer-Ausch, V; Grohmann-Izay, B; Thaler, J; Schloegl, E; Gastl, G; Wolf, D; Kralovics, R; Gisslinger, B; Ban, S; Egle, A; Melchardt, T; Burgstaller, S; Willenbacher, E; Schalling, M; Krauth, MT; Greil, R; Zoerer, M; Kadlecova, P; Klade, C; Gisslinger, H
HAEMATOLOGICA. 2017; 102: 284-284.
Abstracts (Zeitschrift)
TIGIT as a new target for checkpoint inhibition for chronic lymphocytic leukemia
Catakovic, K; Gassner, F; Rathswohl, C; Greil, R; Hartmann, T; Geisberger, R
LEUKEMIA LYMPHOMA. 2017; 58: 53-54.
Abstracts (Zeitschrift)
Low expression of miR-20a-5p predicts benefit to bevacizumab in metastatic breast cancer patients treated within the TANIA trial
Gampenrieder, SP; Rinnerthaler, G; Hackl, H; Steiner, M; Fuentes, CM; Hufnagl, C; Hauser-Kronberger, C; Egle, A; Greil, R
ANN ONCOL. 2017; 28:
Abstracts (Zeitschrift)
DNA methylation signature predicting bevacizumab efficacy in metastatic breast cancer
Gampenrieder, SP; Rinnerthaler, G; Pulverer, W; Weinhusel, A; Hufnagl, C; Hackl, H; Hauser-Kronberger, C; Mlineritsch, B; Greil, R
CANCER RES. 2017; 77:
Abstracts (Zeitschrift)
Real life registry data of primary localisation of a well-defined colon cancer population of western Austria (Salzburg, Tyrol and Vorarlberg), eastern Switzerland (St. Gallen and Graubunden) and Liechtenstein
Hartmann, BL; Oberaigner, W; Frick, H; Weiss, L; Winder, T; Philipp-Abbrederis, K; Herrmann, C; Huynh, MQ; Spizzo, G; Lang, CM; Seeber, A; Schneider, J; Woll, E; Mosler, P; Greil, R; Rossle, M; Rumpold, H; Gastl, G; von Moos, R; Lang, AH
ANN ONCOL. 2017; 28:
Abstracts (Zeitschrift)
ALL ORAL COMBINATION OF IXAZOMIB PLUS THALIDOMIDE AND DEXAMETHASONE FOR RELAPSED OR REFRACTORY MULTIPLE MYELOMA: INTERIM DATA OF AN ONGOING PHASE II TRIAL
Ludwig, H; Poenisch, W; Knop, S; Schreder, M; Lechner, D; Hajek, R; Gunsilius, E; Fridrik, M; Petzer, A; Weisel, K; Rauch, E; Greil, R; Zojer, N
HAEMATOLOGICA. 2017; 102: 110-110.
Abstracts (Zeitschrift)
R-EFECT: A multicenter, retrospective evaluation of CML therapy in Austria assessing the impact of early treatment response on patient outcomes in a real-life setting
Petzer, A; Herndlhofer, S; Weltertnann, A; Sliwa, T; Schmidt, S; Greil, R; Wolfler, A; Wiesholzer, M; Dormann, C; Thaler, J; Tinchon, C; Ruckser, R; Lang, A; Hanig, J; Winiger, I; Muenchmeier, N; Sperr, WR
ONCOL RES TREAT. 2017; 40: 58-58.
Abstracts (Zeitschrift)
NGS ANALYSIS OF 474 BONE MARROW SAMPLES FROM 157 AML PATIENTS TREATED WITH AZACITIDINE-IMPACT OF AGE ON MUTATIONAL LOAD
Pleyer, L; Gassner, FJ; Burgstaller, S; Wedler, H; Hartmann, TN; Jansko, B; Neureiter, D; Thaler, J; Greil, R
HAEMATOLOGICA. 2017; 102: 215-216.
Abstracts (Zeitschrift)
Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: Final PFS results of a phase II trial (AGMT MBC-6)
Rinnerthaler, G; Gampenrieder, SP; Voskova, D; Petzer, A; Hubalek, M; Petru, E; Hartmann, B; Andel, J; Balic, M; Melchardt, T; Ulmer, H; Mlineritsch, B; Greil, R
CANCER RES. 2017; 77:
Abstracts (Zeitschrift)
CLL cells residing in spleen and bone marrow microenvironments differ in their CD44 variant usage for migration and proliferation
Roos, S; Schlederer, M; Hartmann, T; Gutjahr, JC; Szenes, E; Tschech, L; Girbl, T; Greil, R; Kenner, L; Orian-Rousseau, V; Ronen, A
LEUKEMIA LYMPHOMA. 2017; 58: 41-42.
Abstracts (Zeitschrift)
Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomized, neoadjuvant phase-II study (ABCSG-34)
Singer, CF; Pfeiler, G; Hubalek, M; Bartsch, R; Stoeger, H; Pichler, A; Petru, E; Greil, R; Rudas, M; Tea, MK; Wette, V; Petzer, AL; Sevelda, P; Egle, D; Dubsky, PC; Balic, M; Tinchon, C; Bago-Horvath, Z; Frantal, S; Michael, G
CANCER RES. 2017; 77:
Abstracts (Zeitschrift)

2016

Beiträge in Fachzeitschriften

Cancer-Related Fatigue in Patients With and Survivors of Hodgkin Lymphoma: The Impact on Treatment Outcome and Social Reintegration.
Behringer, K; Goergen, H; Müller, H; Thielen, I; Brillant, C; Kreissl, S; Halbsguth, TV; Meissner, J; Greil, R; Moosmann, P; Shonukan, O; Rueffer, JU; Flechtner, HH; Fuchs, M; Diehl, V; Engert, A; Borchmann, P;
J Clin Oncol. 2016; 34(36):4329-4337
Originalarbeiten (Zeitschrift)
DPYD Genotyping to Predict Adverse Events Following Treatment With Fluorouracil-Based Adjuvant Chemotherapy in Patients With Stage III Colon Cancer: A Secondary Analysis of the PETACC-8 Randomized Clinical Trial.
Boige, V; Vincent, M; Alexandre, P; Tejpar, S; Landolfi, S; Le Malicot, K; Greil, R; Cuyle, PJ; Yilmaz, M; Faroux, R; Matzdorff, A; Salazar, R; Lepage, C; Taieb, J; Laurent-Puig, P;
JAMA Oncol. 2016; 2(5):655-662
Originalarbeiten (Zeitschrift)
Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials.
Böll, B; Goergen, H; Behringer, K; Bröckelmann, PJ; Hitz, F; Kerkhoff, A; Greil, R; von Tresckow, B; Eichenauer, DA; Bürkle, C; Borchmann, S; Fuchs, M; Diehl, V; Engert, A; Borchmann, P;
Blood. 2016; 127(18):218-292
Originalarbeiten (Zeitschrift)
Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial.
Foukakis, T; von Minckwitz, G; Bengtsson, NO; Brandberg, Y; Wallberg, B; Fornander, T; Mlineritsch, B; Schmatloch, S; Singer, CF; Steger, G; Egle, D; Karlsson, E; Carlsson, L; Loibl, S; Untch, M; Hellström, M; Johansson, H; Anderson, H; Malmström, P; Gnant, M; Greil, R; Möbus, V; Bergh, J;
JAMA. 2016; 316(18):-1896
Originalarbeiten (Zeitschrift)
Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: A randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikamentöse Tumortherapie AGMT](NHL-14).
Fridrik, MA; Jaeger, U; Petzer, A; Willenbacher, W; Keil, F; Lang, A; Andel, J; Burgstaller, S; Krieger, O; Oberaigner, W; Sihorsch, K; Greil, R;
Eur J Cancer. 2016; 58:-21
Originalarbeiten (Zeitschrift)
CDK4/6 inhibition in luminal breast cancer.
Gampenrieder, SP; Rinnerthaler, G; Greil, R;
Memo. 2016; 9:76-81
Übersichtsarbeiten
Combined CXCR3/CXCR4 measurements are of high prognostic value in chronic lymphocytic leukemia due to negative co-operativity of the receptors.
Ganghammer, S; Gutjahr, J; Hutterer, E; Krenn, PW; Pucher, S; Zelle-Rieser, C; Jöhrer, K; Wijtmans, M; Leurs, R; Smit, MJ; Gattei, V; Greil, R; Hartmann, TN;
Haematologica. 2016; 101(3):e99-102
Letter
Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial.
Greil, R; Obrtlíková, P; Smolej, L; Kozák, T; Steurer, M; Andel, J; Burgstaller, S; Mikušková, E; Gercheva, L; Nösslinger, T; Papajík, T; Ladická, M; Girschikofsky, M; Hrubiško, M; Jäger, U; Fridrik, M; Pecherstorfer, M; Králiková, E; Burcoveanu, C; Spasov, E; Petzer, A; Mihaylov, G; Raynov, J; Oexle, H; Zabernigg, A; Flochová, E; Palášthy, S; Stehlíková, O; Doubek, M; Altenhofer, P; Pleyer, L; Melchardt, T; Klingler, A; Mayer, J; Egle, A;
Lancet Haematol. 2016; 3(7):e317-e329
Originalarbeiten (Zeitschrift)
The AKT1 isoform plays a dominant role in the survival and chemoresistance of chronic lymphocytic leukaemia cells.
Hofbauer, SW; Krenn, PW; Piñόn Hofbauer, J; Pucher, S; Asslaber, D; Egle, A; Hartmann, TN; Greil, R;
Br J Haematol. 2016; 172(5):815-819
Letter
Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancer.
Karthaus, M; Hofheinz, RD; Mineur, L; Letocha, H; Greil, R; Thaler, J; Fernebro, E; Oliner, KS; Boedigheimer, M; Twomey, B; Zhang, Y; Demonty, G; Köhne, CH;
Br J Cancer. 2016; 115(10):1215-1222
Originalarbeiten (Zeitschrift)
CD4+ T cells, but not non-classical monocytes, are dispensable for the development of chronic lymphocytic leukemia in the TCL1-tg murine model.
Kocher, T; Asslaber, D; Zaborsky, N; Flenady, S; Denk, U; Reinthaler, P; Ablinger, M; Geisberger, R; Bauer, JW; Seiffert, M; Hartmann, TN; Greil, R; Egle, A; Piñón Hofbauer, J;
Leukemia. 2016; 30(6):1409-1413
Letter
ILK Induction in Lymphoid Organs by a TNFα-NF-κB-Regulated Pathway Promotes the Development of Chronic Lymphocytic Leukemia.
Krenn, PW; Hofbauer, SW; Pucher, S; Hutterer, E; Hinterseer, E; Denk, U; Asslaber, D; Ganghammer, S; Sternberg, C; Neureiter, D; Aberger, F; Wickström, SA; Egle, A; Greil, R; Hartmann, TN;
Cancer Res. 2016; 76(8):218-296
Originalarbeiten (Zeitschrift)
An international, multicenter, prospective, observational study of neutropenia in patients being treated with lenalidomide + dexamethasone for relapsed or relapsed/refractory multiple myeloma (RR-MM).
Leleu, X; Terpos, E; Sanz, RG; Cooney, J; OGorman, P; Minarik, J; Greil, R; Williams, C; Gray, D; Szabo, Z;
Am J Hematol. 2016; 91(8):806-811
Originalarbeiten (Zeitschrift)
Fluorouracil and Dihydropyrimidine Dehydrogenase Genotyping.
Magnes, T; Melchardt, T; Weiss, L; Hufnagl, C; Greil, R; Egle, A;
J Clin Oncol. 2016; 34(20):2433-2434
Letter
Clonal evolution in relapsed and refractory diffuse large B-cell lymphoma is characterized by high dynamics of subclones.
Melchardt, T; Hufnagl, C; Weinstock, DM; Kopp, N; Neureiter, D; Tränkenschuh, W; Hackl, H; Weiss, L; Rinnerthaler, G; Hartmann, TN; Greil, R; Weigert, O; Egle, A;
Oncotarget. 2016; 7(32):51494-51502
Originalarbeiten (Zeitschrift)
Panitumumab-Associated Encephalopathy after Accidental Intra-arterial Application through Dislocated Central Venous Access Device.
Pikija, S; Pilz, G; Gschwandtner, G; Rösler, C; Schlick, K; Greil, R; Sellner, J;
Front Neurol. 2016; 7:196
Fallberichte
Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications.
Pleyer, L; Burgstaller, S; Stauder, R; Girschikofsky, M; Sill, H; Schlick, K; Thaler, J; Halter, B; Machherndl-Spandl, S; Zebisch, A; Pichler, A; Pfeilstöcker, M; Autzinger, EM; Lang, A; Geissler, K; Voskova, D; Geissler, D; Sperr, WR; Hojas, S; Rogulj, IM; Andel, J; Greil, R;
J Hematol Oncol. 2016; 9:39
Originalarbeiten (Zeitschrift)
Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis-Masters of Survival and Clonality?
Pleyer, L; Valent, P; Greil, R;
Int J Mol Sci. 2016; 17(7):
Übersichtsarbeiten
NCCN-IPI score-independent prognostic potential of pretreatment uric acid levels for clinical outcome of diffuse large B-cell lymphoma patients.
Prochazka, KT; Melchardt, T; Posch, F; Schlick, K; Deutsch, A; Beham-Schmid, C; Weiss, L; Gary, T; Neureiter, D; Klieser, E; Greil, R; Neumeister, P; Egle, A; Pichler, M;
Br J Cancer. 2016; 115(10):1264-1272
Originalarbeiten (Zeitschrift)
Assessment of Pharmacokinetic Interaction Between Capecitabine and Cetuximab in Metastatic Colorectal Cancer Patients.
Rachar, V; Czejka, M; Kitzmueller, M; Buchner, P; Lichtneckert, M; Greil, R; Geiler, H; Dittrich, C;
Anticancer Res. 2016; 36(9):4715-4723
Originalarbeiten (Zeitschrift)
miR-16-5p Is a Stably-Expressed Housekeeping MicroRNA in Breast Cancer Tissues from Primary Tumors and from Metastatic Sites.
Rinnerthaler, G; Hackl, H; Gampenrieder, SP; Hamacher, F; Hufnagl, C; Hauser-Kronberger, C; Zehentmayr, F; Fastner, G; Sedlmayer, F; Mlineritsch, B; Greil, R;
Int J Mol Sci. 2016; 17(2):
Originalarbeiten (Zeitschrift)
CCR10/CCL27 crosstalk contributes to failure of proteasome-inhibitors in multiple myeloma.
Thangavadivel, S; Zelle-Rieser, C; Olivier, A; Postert, B; Untergasser, G; Kern, J; Brunner, A; Gunsilius, E; Biedermann, R; Hajek, R; Pour, L; Willenbacher, W; Greil, R; Jöhrer, K;
Oncotarget. 2016; 7(48):78605-78618
Originalarbeiten (Zeitschrift)
The clinical significance of fibrinogen plasma levels in patients with diffuse large B cell lymphoma.
Troppan, KT; Melchardt, T; Wenzl, K; Schlick, K; Deutsch, A; Bullock, MD; Reitz, D; Beham-Schmid, C; Weiss, L; Neureiter, D; Tränkenschuh, W; Greil, R; Neumeister, P; Egle, A; Pichler, M;
J Clin Pathol. 2016; 69(4):326-330
Originalarbeiten (Zeitschrift)
Immune checkpoint blockade in ovarian cancer.
Weiss, L; Huemer, F; Mlineritsch, B; Greil, R;
Memo. 2016; 9:82-84
Übersichtsarbeiten
Low Beclin-1 expression predicts improved overall survival in patients treated with immunomodulatory drugs for multiple myeloma and identifies autophagy inhibition as a promising potentially druggable new therapeutic target: an analysis from The Austrian Myeloma Registry (AMR).
Willenbacher, W; Thangavadivel, S; Greil, R; Willenbacher, E; Weger, R; Manzl, C; Jöhrer, K; Brunner, A;
Leuk Lymphoma. 2016; 57(10):2330-2341
Originalarbeiten (Zeitschrift)
CD1d expression on chronic lymphocytic leukemia B cells affects disease progression and induces T cell skewing in CD8 positive and CD4CD8 double negative T cells.
Zaborsky, N; Gassner, FJ; Asslaber, D; Reinthaler, P; Denk, U; Flenady, S; Hofbauer, JP; Danner, B; Rebhandl, S; Harrer, A; Geisberger, R; Greil, R; Egle, A;
Oncotarget. 2016; 7(31):4945-49469
Originalarbeiten (Zeitschrift)
T cells in multiple myeloma display features of exhaustion and senescence at the tumor site.
Zelle-Rieser, C; Thangavadivel, S; Biedermann, R; Brunner, A; Stoitzner, P; Willenbacher, E; Greil, R; Jöhrer, K;
J Hematol Oncol. 2016; 9(1):116
Originalarbeiten (Zeitschrift)
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial.
Zielinski, C; Láng, I; Inbar, M; Kahán, Z; Greil, R; Beslija, S; Stemmer, SM; Zvirbule, Z; Steger, GG; Melichar, B; Pienkowski, T; Sirbu, D; Petruzelka, L; Eniu, A; Nisenbaum, B; Dank, M; Anghel, R; Messinger, D; Brodowicz, T;
Lancet Oncol. 2016; 17(9):1230-1239
Originalarbeiten (Zeitschrift)

Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen

Tissue microRNAs predicting the pattern of breast cancer metastases
Gampenrieder, SP; Hackl, H; Rinnerthaler, G; Steiner, M; Hufnagl, C; Hauser-Kronberger, C; Mlineritsch, B; Greil, R
EUR J CANCER. 2016; 57: S111-S111.
Abstracts (Zeitschrift)
DNA methylation patterns correlating with outcome in patients treated with first-line bevacizumab for metastatic breast cancer
Gampenrieder, SP; Rinnerthaler, G; Weinhausel, A; Pulverer, W; Hugnagl, C; Hackl, H; Romeder, F; Fuentes, CM; Hauser-Kronberger, C; Mlineritsch, B; Greil, R
CANCER RES. 2016; 76:
Abstracts (Zeitschrift)
The impact of adjuvant denosumab on disease-free survival: Results from 3,425 postmenopausal patients of the ABCSG-18 trial
Gnant, M; Pfeiler, G; Dubsky, PC; Hubalek, M; Greil, R; Jakesz, R; Wette, V; Balic, M; Haslbauer, F; Melbinger-Zeinitzer, E; Bjelic-Radisic, V; Artner-Matuschek, S; Fitzal, F; Marth, C; Sevelda, P; Mlineritsch, B; Steger, GG; Manfreda, D; Exner, R; Egle, D; Bergh, J; Kainberger, F; Talbot, S; Warner, D; Fesl, C; Singer, CF
CANCER RES. 2016; 76:
Abstracts (Zeitschrift)
CXCL12 ANTAGONISM BY THE L-RNA APTAMER OLAPTESED PEGOL IS EFFECTIVE AS A MOBILIZING AND THERAPEUTIC AGENT IN A MURINE CHRONIC LYMPHOCYTIC LEUKEMIA MODEL
Hinterseer, E; Hutterer, E; Krenn, PW; Reinthaler, P; Hopner, J; Hopfinger, M; Eulberg, D; Maasch, C; Kruschinski, A; Vater, A; Egle, A; Greil, R; Hartmann, TN
HAEMATOLOGICA. 2016; 101: 45-46.
Abstracts (Zeitschrift)
Tumor response as important parameter during first-line treatment of metastatic colorectal carcinoma (mCRC) with panitumumab plus FOLFIRI
Karthaus, M; Hofheinz, R; Mineur, L; Letocha, H; Greil, R; Thaler, J; Fernebro, E; Zhang, Y; Demonty, G; Kohne, CH
ONCOL RES TREAT. 2016; 39: 73-73.
Abstracts (Zeitschrift)
OUTCOME OF PATIENTS WITH REFRACTORY OR RELAPSED AML WITH IDH1 AND IDH2 MUTATIONS AFTER CONVENTIONAL SALVAGE THERAPY: A STUDY OF THE GERMAN-AUSTRIAN AML STUDY GROUP (AMLSG)
Paschka, P; Schlenk, R; Weber, D; Horst, HA; Ringhoffer, M; Khone, CH; Held, G; Kundgen, A; Gotze, K; Brossart, P; Greil, R; Lubbert, M; Wattad, M; Rummel, MJ; Heuser, M; Gaidzik, VI; Teleanu, V; Thol, F; Gohring, G; Ganser, A; Dohner, K; Dohner, H
HAEMATOLOGICA. 2016; 101: 326-326.
Abstracts (Zeitschrift)
R-EFECT: A multicenter, retrospective evaluation of CML therapy in Austria assessing the impact of early treatment response on patient outcomes in a real-life setting
Petzer, A; Herndlhofer, S; Weltermann, A; Sliwa, T; Schmidt, S; Greil, R; Molfler, A; Wiesholzer, M; Dormann, C; Thaler, J; Tinchon, C; Ruckser, R; Lang, A; Hanig, J; Winiger, I; Muenchmeier, N; Sperr, WR
ONCOL RES TREAT. 2016; 39: 58-58.
Abstracts (Zeitschrift)
Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: Stage 1 results of a phase II trial (AGMT MBC-6)
Rinnerthaler, G; Gampenrieder, SP; Fridrik, M; Petzer, A; Hubalek, M; Petru, E; Jager, T; Andel, J; Balic, M; Ulmer, H; Mlineritsch, B; Greil, R
CANCER RES. 2016; 76:
Abstracts (Zeitschrift)
Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: Updated safety results of a phase II trial (AGMT MBC-6)
Rinnerthaler, G; Gampenrieder, SP; Voskova, D; Petzer, A; Hubalek, M; Petru, E; Hartmann, B; Andel, J; Balic, M; Melchardt, T; Mlineritsch, B; Greil, R
ANN ONCOL. 2016; 27:
Abstracts (Zeitschrift)
Secondary resectability rates observed in a multicenter randomized phase II study of modified capecitabine/ irinotecan (mXELIRI) plus bevacizumab (bev) followed by capecitabine/oxaliplatin (XELOX) plus bev or the reverse sequence in patients with metastatic colorectal cancer (mCRC)
Scheithauer, W; Prager, G; Greil, R; Mlineritsch, B; Schaberl-Moser, R; Gerger, A; Langle, F; Viragos-Toth, I; Andel, J; Pichler, A; Pecherstorfer, M; Kretschmer, A; Seebacher, A; Jagdt, B; Eisterer, W; Krippl, P
ANN ONCOL. 2016; 27:
Abstracts (Zeitschrift)
Stromel co-expression of urokinase-type plasminogen activator (uPA) and plasminogen activator Inhibitor (PAI-1) protein by IHC predicts poor disease outcome in endocrine-treated postmenopausal patients with receptor-positive early breast cancer
Singer, CF; Filipits, M; Jahn, S; Abete, L; Jakesz, R; Greil, R; Bauernhofer, T; Kwasny, W; Seifert, M; Fitzal, F; Schmitt, M; Moinfar, F; Gnant, M
CANCER RES. 2016; 76:
Abstracts (Zeitschrift)
Safety and effectiveness of nab-paclitaxel in young and elderly patients with metastatic breast cancer: a prospective, multicenter non-interventional study
Steger, G; Petru, E; Haslbauer, F; Egle, D; Galid, A; Sliwa, T; Lang, A; Kuhr, T; Petzer, A; Ruckser, R; Mlineritsch, B; Greil, R; Seifert, M; Singer, C; Andel, J; Kwasny, W; Marth, C; Pichler, P; Tinchon, C; Bartsch, R
ANN ONCOL. 2016; 27:
Abstracts (Zeitschrift)
An elevated fibrinogen/CRP ratio predicts a remarkable survival advantage in patients with metastatic pancreatic cancer
Winder, T; Posch, F; Asamer, E; Stotz, M; Siebenhuner, A; Schlick, K; Magnes, T; Samaras, P; Szkandera, J; Clavien, PA; Neureiter, D; Greil, R; Pestalozzi, BC; Stoeger, H; Gerger, A; Egle, A; Pichler, M
ANN ONCOL. 2016; 27:
Abstracts (Zeitschrift)

Nichtpublizierte (nicht zitierfähige) Beiträge für wissenschaftliche Veranstaltungen

Impact of Red Blood Cell Alloimmunization in Patients with MDS, AML and CMML
Leisch M, Weiß L, Lindlbauer N, Rohde E, Greil R, Grabmer C, Pleyer L
Jahrestagung der Deutschen Gesellschaft für Transfusionsmedizin und Immunhämatologie; 07.-10.09.2016; Nürnberg. 2016.

2015

Beiträge in Fachzeitschriften

Treatment of Patients With Myelodysplastic Syndrome With Lenalidomide in Clinical Routine in Austria.
Aschauer, G; Greil, R; Linkesch, W; Nösslinger, T; Stauder, R; Burgstaller, S; Fiegl, M; Fridrik, M; Girschikofsky, M; Keil, F; Petzer, A;
Clin Lymphoma Myeloma Leuk. 2015; 15(11):e143-e149
Originalarbeiten (Zeitschrift)
Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin"s lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial.
Behringer, K; Goergen, H; Hitz, F; Zijlstra, JM; Greil, R; Markova, J; Sasse, S; Fuchs, M; Topp, MS; Soekler, M; Mathas, S; Meissner, J; Wilhelm, M; Koch, P; Lindemann, HW; Schalk, E; Semrau, R; Kriz, J; Vieler, T; Bentz, M; Lange, E; Mahlberg, R; Hassler, A; Vogelhuber, M; Hahn, D; Mezger, J; Krause, SW; Skoetz, N; Böll, B; von Tresckow, B; Diehl, V; Hallek, M; Borchmann, P; Stein, H; Eich, H; Engert, A;
Lancet. 2015; 385(9976):1418-1427
Originalarbeiten (Zeitschrift)
Cost-effectiveness analysis of prognostic gene expression signature-based stratification of early breast cancer patients.
Blank, PR; Filipits, M; Dubsky, P; Gutzwiller, F; Lux, MP; Brase, JC; Weber, KE; Rudas, M; Greil, R; Loibl, S; Szucs, TD; Kronenwett, R; Schwenkglenks, M; Gnant, M;
Pharmacoeconomics. 2015; 33(2):17-90
Originalarbeiten (Zeitschrift)
A phase 1 dose escalation study of BI 831266, an inhibitor of Aurora kinase B, in patients with advanced solid tumors.
Dittrich, C; Fridrik, MA; Koenigsberg, R; Lee, C; Goeldner, RG; Hilbert, J; Greil, R;
Invest New Drugs. 2015; 33(2):409-422
Originalarbeiten (Zeitschrift)
IOERT as anticipated tumor bed boost during breast-conserving surgery after neoadjuvant chemotherapy in locally advanced breast cancer--results of a case series after 5-year follow-up.
Fastner, G; Reitsamer, R; Ziegler, I; Zehentmayr, F; Fussl, C; Kopp, P; Peintinger, F; Greil, R; Fischer, T; Deutschmann, H; Sedlmayer, F;
Int J Cancer. 2015; 136(5):1193-1201
Originalarbeiten (Zeitschrift)
The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial.
Fitzal, F; Filipits, M; Rudas, M; Greil, R; Dietze, O; Samonigg, H; Lax, S; Herz, W; Dubsky, P; Bartsch, R; Kronenwett, R; Gnant, M;
Br J Cancer. 2015; 112(8):1405-1410
Originalarbeiten (Zeitschrift)
CXCL12-induced VLA-4 activation is impaired in trisomy 12 chronic lymphocytic leukemia cells: a role for CCL21.
Ganghammer, S; Hutterer, E; Hinterseer, E; Brachtl, G; Asslaber, D; Krenn, PW; Girbl, T; Berghammer, P; Geisberger, R; Egle, A; Zucchetto, A; Kruschinski, A; Gattei, V; Chigaev, A; Greil, R; Hartmann, TN;
Oncotarget. 2015; 6(14):12048-12060
Originalarbeiten (Zeitschrift)
Chronic lymphocytic leukaemia induces an exhausted T cell phenotype in the TCL1 transgenic mouse model.
Gassner, FJ; Zaborsky, N; Catakovic, K; Rebhandl, S; Huemer, M; Egle, A; Hartmann, TN; Greil, R; Geisberger, R;
Br J Haematol. 2015; 170(4):515-522
Originalarbeiten (Zeitschrift)
Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera.
Gisslinger, H; Zagrijtschuk, O; Buxhofer-Ausch, V; Thaler, J; Schloegl, E; Gastl, GA; Wolf, D; Kralovics, R; Gisslinger, B; Strecker, K; Egle, A; Melchardt, T; Burgstaller, S; Willenbacher, E; Schalling, M; Them, NC; Kadlecova, P; Klade, C; Greil, R;
Blood. 2015; 126(15):1762-1769
Originalarbeiten (Zeitschrift)
Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12.
Gnant, M; Mlineritsch, B; Stoeger, H; Luschin-Ebengreuth, G; Knauer, M; Moik, M; Jakesz, R; Seifert, M; Taucher, S; Bjelic-Radisic, V; Balic, M; Eidtmann, H; Eiermann, W; Steger, G; Kwasny, W; Dubsky, P; Selim, U; Fitzal, F; Hochreiner, G; Wette, V; Sevelda, P; Ploner, F; Bartsch, R; Fesl, C; Greil, R;
Ann Oncol. 2015; 26(2):313-320
Originalarbeiten (Zeitschrift)
Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial.
Gnant, M; Pfeiler, G; Dubsky, PC; Hubalek, M; Greil, R; Jakesz, R; Wette, V; Balic, M; Haslbauer, F; Melbinger, E; Bjelic-Radisic, V; Artner-Matuschek, S; Fitzal, F; Marth, C; Sevelda, P; Mlineritsch, B; Steger, GG; Manfreda, D; Exner, R; Egle, D; Bergh, J; Kainberger, F; Talbot, S; Warner, D; Fesl, C; Singer, CF;
Lancet. 2015; 386(9992):433-443
Originalarbeiten (Zeitschrift)
Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype.
Gnant, M; Sestak, I; Filipits, M; Dowsett, M; Balic, M; Lopez-Knowles, E; Greil, R; Dubsky, P; Stoeger, H; Rudas, M; Jakesz, R; Ferree, S; Cowens, JW; Nielsen, T; Schaper, C; Fesl, C; Cuzick, J;
Ann Oncol. 2015; 26(8):1685-1691
Originalarbeiten (Zeitschrift)
The Role of CD44 in the Pathophysiology of Chronic Lymphocytic Leukemia.
Gutjahr, JC; Greil, R; Hartmann, TN;
Front Immunol. 2015; 6:177
Übersichtsarbeiten
VLA-4 and CXCR4 overexpression in bone marrow of an aleukemic B-cell acute lymphoblastic leukemia presenting with osteolytic bone lesions.
Hinterseer, E; Stiefel, O; Neureiter, D; Kandler, G; Vogt, S; Hutter, J; Strasser, G; Greil, R; Hartmann, TN; Hopfinger, G;
Leuk Lymphoma. 2015; 56(8):2465-2467
Letter
Anti-Hu Antibody Associated Paraneoplastic Cerebellar Degeneration in Head and Neck Cancer.
Huemer, F; Melchardt, T; Tränkenschuh, W; Neureiter, D; Moser, G; Magnes, T; Weiss, L; Schlattau, A; Hufnagl, C; Ricken, G; Höftberger, R; Greil, R; Egle, A;
BMC Cancer. 2015; 15:996
Fallberichte
CD18 (ITGB2) expression in chronic lymphocytic leukaemia is regulated by DNA methylation-dependent and -independent mechanisms.
Hutterer, E; Asslaber, D; Caldana, C; Krenn, PW; Zucchetto, A; Gattei, V; Greil, R; Hartmann, TN;
Br J Haematol. 2015; 169(2):286-289
Letter
Response to comment by P. Vassilakopoulos and colleagues.
Jaeger, U; Praxmarer, M; Greil, R;
Haematologica. 2015; 100(11):e482
Author reply
Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial.
Jaeger, U; Trneny, M; Melzer, H; Praxmarer, M; Nawarawong, W; Ben Yehuda, D; Goldstein, D; Mihaljevic, B; Ilhan, O; Ballova, V; Hedenus, M; Hsiao, LT; Au, WY; Burgstaller, S; Weidinger, G; Keil, F; Dittrich, C; Skrabs, C; Klingler, A; Chott, A; Fridrik, MA; Greil, R;
Haematologica. 2015; 100(7):955-963
Originalarbeiten (Zeitschrift)
Adipocyte-derived players in hematologic tumors: useful novel targets?
Jöhrer, K; Ploner, C; Thangavadivel, S; Wuggenig, P; Greil, R;
Expert Opin Biol Ther. 2015; 15(1):61-77
Originalarbeiten (Zeitschrift)
Hedgehog/GLI and PI3K signaling in the initiation and maintenance of chronic lymphocytic leukemia.
Kern, D; Regl, G; Hofbauer, SW; Altenhofer, P; Achatz, G; Dlugosz, A; Schnidar, H; Greil, R; Hartmann, TN; Aberger, F;
Oncogene. 2015; 34(42):534-551
Originalarbeiten (Zeitschrift)
Longitudinal analysis of 2293 NSCLC patients: a comprehensive study from the TYROL registry.
Kocher, F; Hilbe, W; Seeber, A; Pircher, A; Schmid, T; Greil, R; Auberger, J; Nevinny-Stickel, M; Sterlacci, W; Tzankov, A; Jamnig, H; Kohler, K; Zabernigg, A; Frötscher, J; Oberaigner, W; Fiegl, M;
Lung Cancer. 2015; 87(2):193-200
Originalarbeiten (Zeitschrift)
Factors Associated with Low-Level Viraemia and Virological Failure: Results from the Austrian HIV Cohort Study
Leierer, G; Grabmeier-Pfistershammer, K; Steuer, A; Geit, M; Sarcletti, M; Haas, B; Kanatschnig, M; Rappold, M; Zangerle, R; Ledergerber, B; Taylor, N
PLOS ONE. 2015; 10(11):
Originalarbeiten (Zeitschrift)
Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up.
Ludwig, H; Greil, R; Masszi, T; Spicka, I; Shpilberg, O; Hajek, R; Dmoszynska, A; Paiva, B; Vidriales, MB; Esteves, G; Stoppa, AM; Robinson, D; Chaturvedi, S; Ataman, O; Enny, C; Feng, H; van de Velde, H; Viterbo, L;
Br J Haematol. 2015; 171(3):3-54
Originalarbeiten (Zeitschrift)
Lenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II study.
Ludwig, H; Rauch, E; Kuehr, T; Adam, Z; Weißmann, A; Kasparu, H; Autzinger, EM; Heintel, D; Greil, R; Poenisch, W; Müldür, E; Zojer, N;
Haematologica. 2015; 100(3):385-391
Originalarbeiten (Zeitschrift)
CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancer.
Melchardt, T; Hufnagl, C; Magnes, T; Weiss, L; Hutarew, G; Neureiter, D; Schlattau, A; Moser, G; Gaggl, A; Tränkenschuh, W; Greil, R; Egle, A;
BMC Cancer. 2015; 15:725
Originalarbeiten (Zeitschrift)
A modified scoring of the NCCN-IPI is more accurate in the elderly and is improved by albumin and β2 -microglobulin.
Melchardt, T; Troppan, K; Weiss, L; Hufnagl, C; Neureiter, D; Tränkenschuh, W; Hopfinger, G; Magnes, T; Deutsch, A; Neumeister, P; Hackl, H; Greil, R; Pichler, M; Egle, A;
Br J Haematol. 2015; 168(2):239-245
Originalarbeiten (Zeitschrift)
Independent Prognostic Value of Serum Markers in Diffuse Large B-Cell Lymphoma in the Era of the NCCN-IPI.
Melchardt, T; Troppan, K; Weiss, L; Hufnagl, C; Neureiter, D; Tränkenschuh, W; Schlick, K; Huemer, F; Deutsch, A; Neumeister, P; Greil, R; Pichler, M; Egle, A;
J Natl Compr Canc Netw. 2015; 13(12):1501-1508
Originalarbeiten (Zeitschrift)
Treatment of aggressive B-cell lymphoma in elderly patients: influence of single nucleotide polymorphisms affecting pharmacodynamics of chemotherapeutics.
Melchardt, T; Weiss, L; Hufnagl, C; Neureiter, D; Kemmerling, R; Morre, P; Boekstegers, A; Hopfinger, G; Auberger, J; Steinkirchner, S; Pleyer, L; Greil, R; Egle, A;
Leuk Lymphoma. 2015; 56(2):353-360
Originalarbeiten (Zeitschrift)
Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation.
Merkel, O; Hamacher, F; Griessl, R; Grabner, L; Schiefer, AI; Prutsch, N; Baer, C; Egger, G; Schlederer, M; Krenn, PW; Hartmann, TN; Simonitsch-Klupp, I; Plass, C; Staber, PB; Moriggl, R; Turner, SD; Greil, R; Kenner, L;
J Pathol. 2015; 236(4):445-456
Originalarbeiten (Zeitschrift)
Lapatinib-plus-pegylated liposomal doxorubicin in advanced HER2-positive breast cancer following trastuzumab: a phase II trial.
Pircher, M; Mlineritsch, B; Fridrik, MA; Dittrich, C; Lang, A; Petru, E; Weltermann, A; Thaler, J; Hufnagl, C; Gampenrieder, SP; Rinnerthaler, G; Ressler, S; Ulmer, H; Greil, R;
Anticancer Res. 2015; 35(1):517-521
Originalarbeiten (Zeitschrift)
Digging deep into "dirty" drugs - modulation of the methylation machinery.
Pleyer, L; Greil, R;
Drug Metab Rev. 2015; 47(2):252-279
Originalarbeiten (Zeitschrift)
Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome prediction.
Ramos, F; Thépot, S; Pleyer, L; Maurillo, L; Itzykson, R; Bargay, J; Stauder, R; Venditti, A; Seegers, V; Martínez-Robles, V; Burgstaller, S; Récher, C; Debén, G; Gaidano, G; Gardin, C; Musto, P; Greil, R; Sánchez-Guijo, F; Fenaux, P;
Leuk Res. 2015; 39(3):296-306
Originalarbeiten (Zeitschrift)
AID/APOBEC deaminases and cancer.
Rebhandl, S; Huemer, M; Greil, R; Geisberger, R;
Oncoscience. 2015; 2(4):320-333
Übersichtsarbeiten
Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma.
Robak, T; Huang, H; Jin, J; Zhu, J; Liu, T; Samoilova, O; Pylypenko, H; Verhoef, G; Siritanaratkul, N; Osmanov, E; Alexeeva, J; Pereira, J; Drach, J; Mayer, J; Hong, X; Okamoto, R; Pei, L; Rooney, B; van de Velde, H; Cavalli, F;
N Engl J Med. 2015; 372(10): 944-953.
Originalarbeiten (Zeitschrift)
Cytomegalovirus reactivation and its clinical impact in patients with solid tumors.
Schlick, K; Grundbichler, M; Auberger, J; Kern, JM; Hell, M; Hohla, F; Hopfinger, G; Greil, R;
Infect Agent Cancer. 2015; 10:45
Originalarbeiten (Zeitschrift)
A patient diagnosed with BRAF-mutated non-small cell lung cancer and hairy cell leukemia: at last, which entity is really carrying the BRAF mutation?
Schlick, K; Troch, M; Placher-Sorko, G; Faber, V; Neureiter, D; Berghoff, AS; Preusser, M; Greil, R; Hopfinger, G;
Ann Hematol. 2015; 94(2):345-346
Letter
Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b.
Them, NC; Bagienski, K; Berg, T; Gisslinger, B; Schalling, M; Chen, D; Buxhofer-Ausch, V; Thaler, J; Schloegl, E; Gastl, GA; Wolf, D; Strecker, K; Egle, A; Melchardt, T; Burgstaller, S; Willenbacher, E; Zagrijtschuk, O; Klade, C; Greil, R; Gisslinger, H; Kralovics, R;
Am J Hematol. 2015; 90(4):288-294
Originalarbeiten (Zeitschrift)
Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study.
Tiede, A; Klamroth, R; Scharf, RE; Trappe, RU; Holstein, K; Huth-Kühne, A; Gottstein, S; Geisen, U; Schenk, J; Scholz, U; Schilling, K; Neumeister, P; Miesbach, W; Manner, D; Greil, R; von Auer, C; Krause, M; Leimkühler, K; Kalus, U; Blumtritt, JM; Werwitzke, S; Budde, E; Koch, A; Knöbl, P;
Blood. 2015; 125(7):1091-1097
Originalarbeiten (Zeitschrift)
The significance of pretreatment anemia in the era of R-IPI and NCCN-IPI prognostic risk assessment tools: a dual-center study in diffuse large B-cell lymphoma patients.
Troppan, KT; Melchardt, T; Deutsch, A; Schlick, K; Stojakovic, T; Bullock, MD; Reitz, D; Beham-Schmid, C; Weiss, L; Neureiter, D; Wenzl, K; Greil, R; Neumeister, P; Egle, A; Pichler, M;
Eur J Haematol. 2015; 95(6):538-544
Originalarbeiten (Zeitschrift)
B-cell receptor usage correlates with the sensitivity to CD40 stimulation and the occurrence of CD4+ T-cell clonality in chronic lymphocytic leukemia.
Zaborsky, N; Holler, C; Geisberger, R; Asslaber, D; Gassner, FJ; Egger, V; Piñón-Hofbauer, J; Kocher, T; Hartmann, TN; Greil, R; Egle, A;
Haematologica. 2015; 100(8):e307-e310
Letter

Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen

Molecular Characterization of Relapsed Core-Binding Factor (CBF) Acute Myeloid Leukemia (AML)
Agrawal, M; Corbacioglu, A; Jahn, N; Bullinger, L; Teleanu, MV; Gaidzik, VI; Weber, D; Gohring, G; Luebbert, M; Fiedler, W; Brossart, P; Kindler, T; Radsak, M; Ringhoffer, M; Gotze, KS; Greil, R; Thol, F; Heuser, M; Ganser, A; Schlenk, RF; Dohner, H; Paschka, P; Dohner, K
BLOOD. 2015; 126(23):
Abstracts (Zeitschrift)
CLINICAL OUTCOMES OF ACUTE ERYTHROLEUKEMIA TREATED WITH AZACITIDINE: A RETROSPECTIVE MULTICENTER STUDY
Almeida, A; Prebet, T; Itzykson, R; Ramos, F; Al Ali, HK; Shammo, J; Pinto, R; Maurillo, L; WetzeI, J; Musto, P; van de Loosdrecht, A; Costa, MJ; Burgstaller, S; Stauder, R; Auzinger, G; Lang, A; Krippl, P; Geissler, D; Falantes, JF; Pedro, C; Bargay, J; Deben, G; Garrido, A; Bonanad, S; Diez-Campelo, M; Fenaux, P; Thepot, S; Ades, L; Sekeres, M; Greil, R; Pleyer, L
HAEMATOLOGICA. 2015; 100: 384-384.
Abstracts (Zeitschrift)
DYPD genotyping to predict toxicity in patients with stage III colon cancer treated with 5-fluorouracil-based adjuvant chemotherapy in the PETACC-8 phase III trial
Boige, V; Vincent, M; Alexandre, P; Stoehlmacher, J; Tejpar, S; Landolfi, S; Le Malicot, K; Greil, R; Cuyle, PJAR; Yilmaz, MKN; Faroux, R; Matzdorff, A; Salazar, R; Sanches, E; Mineur, L; Lepage, C; Taieb, J; Laurent-Puig, P
J CLIN ONCOL. 2015; 33(15):
Abstracts (Zeitschrift)
Four Weeks Administration Schedule of Ropeginterferon Alfa-2b (AOP2014/P1101) in Polycythemia Very Patients Allows Maintaining of Efficacy with Favorable Toxicity Profile in the Phase I/II Peginvera Stud
Buxhofer-Ausch, V; Gisslinger, H; Thaler, J; Schlogl, E; Gastl, G; Wolf, D; Kralovics, R; Gisslinger, B; Ban, S; Egle, A; Melchardt, T; Burgstaller, S; Willenbacher, E; Schalling, M; Krauth, MT; Them, NCC; Zorer, M; Ammann-Mwathi, O; Kadlecova, P; Zagrijtschuk, O; Klade, C; Greil, R
BLOOD. 2015; 126(23):
Abstracts (Zeitschrift)
MRD dynamics after chemoimmunotherapy induction treatment of CLL independently predict outcome: first analysis of a secondary endpoint from the international randomized AGMT-CLL8/a Mabtenance trial
Egle, A; Doubek, M; Stehlikova, O; Pleyer, L; Altenhofer, P; Melchardt, T; Smolej, L; Mihaylov, GG; Mikuskova, E; Mayer, J; Greil, R
LEUKEMIA LYMPHOMA. 2015; 56: 123-124.
Abstracts (Zeitschrift)
Azacitidine in Older Patients with Acute Myeloid Leukemia (AML). Results from the Expanded International E-Alma Series (E-ALMA plus ) According to the MRC Risk Index Score
Falantes, J; Thepot, S; Pleyer, L; Maurillo, L; Martinez-Robles, V; Itzykson, R; Bargay, J; Stauder, R; Venditti, A; Martinez, MP; Seegers, V; Foncillas, MA; Burgstaller, S; Gardin, C; Montesinos, P; Musto, P; Greil, R; Sanz, M; Fenaux, P; Ramos, F
BLOOD. 2015; 126(23):
Abstracts (Zeitschrift)
Clinical results of triple negative breast cancer patients treated by IOERT-boost during breast conserving surgery
Fastner, G; Hauser-Kronberger, C; Moder, A; Reitsamer, R; Zehentmayr, F; Kopp, P; Greil, R; Fischer, T; Dietze, O; Sedlmayer, F;
Radiotherapy and Oncology. 2015; 115(Supplement 1):235-235.-ESTRO 2015; 24.-28.04.2015; Barcelona.
Abstracts (Zeitschrift)
MicroRNAs correlating with outcome in patients treated with first-line bevacizumab for metastatic breast cancer
Gampenrieder, SP; Hamacher, F; Rinnerthaler, G; Hufnagl, C; Hackl, H; Romeder, F; Muss, C; Hauser-Kronbeger, C; Mlineritsch, B; Greil, R
CANCER RES. 2015; 75(9):
Abstracts (Zeitschrift)
Long Term Efficacy and Safety Results and Analysis of Dose Correlations from the Phase I/II Peginvera Study of Ropeginterferon Alfa-2b, a Novel IFNa-2b, in Polycythemia Vera Patient
Gisslinger, H; Buxhofer-Ausch, V; Thaler, J; Schlogl, E; Gastl, G; Wolf, D; Schalling, M; Gisslinger, B; Ban, S; Egle, A; Melchardt, T; Burgstaller, S; Willenbacher, E; Krauth, MT; Them, NCC; Kralovics, R; Zorer, M; Ammann-Mwathi, O; Kadlecova, P; Zagrijtschuk, O; Klade, C; Greil, R
BLOOD. 2015; 126(23):
Abstracts (Zeitschrift)
Adjuvant denosumab in breast cancer: Results from 3,425 postmenopausal patients of the ABCSG-18 trial.
Gnant, M; Pfeiler, G; Dubsky, PC; Hubalek, M; Greil, R; Jakesz, R; Wette, V; Balic, M; Haslbauer, F; Melbinger-Zeinitzer, E; Radisic, VB; Bergh, JCS; Fitzal, F; Egle, D; Mlineritsch, B; Steger, GG; Talbot, S; Warner, DJ; Fesl, C; Singer, CF
J CLIN ONCOL. 2015; 33(15):
Abstracts (Zeitschrift)
Tumour response outcomes during the first-line treatment of metastatic colorectal carcinoma (mCRC) with panitumumab plus FOLFIRI
Karthaus, M; Hofheinz, R; Mineur, L; Letocha, H; Greil, R; Thaler, J; Fernebro, E; Zhang, Y; Oliner, KS; Demonty, G; Kohne, CH
EUR J CANCER. 2015; 51: S375-S376.
Abstracts (Zeitschrift)
PGDFR blockade as a novel therapy for NPM-ALK(+) anaplastic large cell lymphoma
Kenner, L; Kuroll, M; Hartmann, T; Krenn, P; Schlederer, M; Prutsch, N; Greil, R; Turner, S; Merkel, O
BRIT J HAEMATOL. 2015; 171: 28-28.
Abstracts (Zeitschrift)
Phase 3 trial of pembrolizumab as a first-line treatment in subjects with recurrent/metastatic head and neck squamous cell carcinoma: KEYNOTE-048
Klochikhin, A; Greil, R; Cohen, E; Vermorken, J; Harrington, K; Tahara, M; Ge, JY; Geib, J; Jin, F; Burtness, B
ANN ONCOL. 2015; 26: 5-5.
Abstracts (Zeitschrift)
Survival advantage of anastrozol compared to tamoxifen for lobular breast cancer in the ABCSG-8 study
Knauer, M; Gruber, C; Dietze, O; Greil, R; Stoger, H; Rudas, M; Bago-Horvath, Z; Mlineritsch, B; Kwasny, W; Singer, C; Dubsky, P; Jakesz, R; Fitzal, F; Steger, G; Bartsch, R; Filipits, M; Fesl, C; Gnant, M
CANCER RES. 2015; 75(9):
Abstracts (Zeitschrift)
Amphiregulin (AREG) expression and response to first-line panitumumab (pmab) plus FOLFIRI in metastatic colorectal cancer (mCRC).
Kohne, CH; Hofheinz, R; Mineur, L; Letocha, H; Greil, R; Thaler, J; Twomey, B; Oliner, KS; Boedigheimer, M; Terwey, JH; Karthaus, M
J CLIN ONCOL. 2015; 33(3):
Abstracts (Zeitschrift)
Expression of amphiregulin (AREG) and response to first-line panitumumab (pmab) plus FOLFIRI in metastatic colorectal cancer (mCRC).
Kohne, CH; Hofheinz, RD; Mineur, L; Letocha, H; Greil, R; Thaler, J; Twomey, B; Oliner, KS; Boedigheimer, M; Terwey, JH; Karthaus, M
J CLIN ONCOL. 2015; 33(15):
Abstracts (Zeitschrift)
Primary Progressive Disease in Hodgkin Lymphoma Patients: A Retrospective Analysis from the German Hodgkin Study Group
Kreissl, S; Goergen, H; von Tresckow, B; Behringer, K; Markova, J; Lohri, A; Meissner, J; Zijlstra, JM; Greil, R; Topp, MS; Sokler, M; Dohner, H; Diehl, V; Engert, A; Borchmann, P
BLOOD. 2015; 126(23):
Abstracts (Zeitschrift)
Integrin-linked kinase is induced by TNF alpha-NF-kappa B signals and required for centrosome clustering and mitotic spindle organization during chronic lymphocytic leukemia cell cycle progression
Krenn, P; Hofbauer, S; Pucher, S; Hutterer, E; Hinterseer, E; Asslaber, D; Sternberg, C; Neureiter, D; Aberger, F; Wickstroem, S; Greil, R; Hartmann, TN
ONCOL RES TREAT. 2015; 38: 200-201.
Abstracts (Zeitschrift)
Integrin-linked kinase is induced by TNF alpha- NF-kappa B signals and required for centrosome clustering and mitotic spindle organization during chronic lymphocytic leukemia cell cycle progression
Krenn, PW; Hofbauer, SW; Pucher, S; Hutterer, E; Hinterseer, E; Asslaber, D; Sternberg, C; Neureiter, D; Aberger, F; Wickstrom, SA; Greil, R; Hartmann, TN
LEUKEMIA LYMPHOMA. 2015; 56: 65-67.
Abstracts (Zeitschrift)
DASATINIB (DAS) IN COMBINATION WITH CHEMOTHERAPY AND AS MAINTENANCE IN CORE-BINDING FACTOR (CBF) ACUTE MYELOID LEUKEMIA (AML): A PHASE IB/IIA STUDY OF THE GERMAN-AUSTRIAN AML STUDY GROUP (AMLSG)
Paschka, P; Schlenk, RF; Weber, D; Fiedler, W; Lubbert, M; Theobald, M; Greil, R; Horst, HA; Krauter, J; Salih, HR; Heil, G; Martens, U; Kundgen, A; Brossart, P; Heuser, M; Gaidzik, VI; Thol, F; Gohring, G; Ganser, A; Dohner, K; Dohner, H
HAEMATOLOGICA. 2015; 100: 194-195.
Abstracts (Zeitschrift)
Is It Time to Redefine Response in Elderly Patients with WHO-Acute Myeloid Leukemia (AML) Unfit for Intensive Chemotherapy?
Pleyer, L; Burgstaller, S; Stauder, R; Girschikofsky, M; Sill, H; Schlick, K; Thaler, J; Halter, B; Machherndl-Spandl, S; Zebisch, A; Pichler, A; Pfeilstocker, M; Autzinger, EM; Lang, A; Geissler, K; Voskova, D; Geissler, D; Sperr, WR; Hojas, S; Rogulj, IM; Andel, J; Greil, R
BLOOD. 2015; 126(23):
Abstracts (Zeitschrift)
Azacitidine in Acute Myeloid Leukemia with > 30% Bone Marrow Blasts and < 15 G/L White Blood Cell Count: Results from the Austrian Azacitidine Registry of the AGMT Study Group Versus Randomized Controlled Phase III Clinical Trial Data
Pleyer, L; Burgstaller, S; Stauder, R; Girschikofsky, M; Sill, H; Schlick, K; Thaler, J; Halter, B; Machherndl-Spandl, S; Zebisch, A; Pichler, A; Pfeilstocker, M; Autzinger, EM; Lang, A; Geissler, K; Voskova, D; Geissler, D; Sperr, WR; Hojas, S; Rogulj, IM; Andel, J; Greil, R
BLOOD. 2015; 126(23):
Abstracts (Zeitschrift)
Androgen receptor expression in pre-menopausal early breast cancer patients treated with endocrine therapy within the ABCSG-12 trial - a single center pilot analysis
Rinnerthaler, G; Knopp, AM; Hauser-Kronberger, C; Gampenrieder, SP; Morro, P; Mlineritsch, B; Fesl, C; Gnant, M; Greil, R
CANCER RES. 2015; 75(9):
Abstracts (Zeitschrift)
UPDATED REPORT OF THE AUSTRIAN CML-REGISTRY
Schmidt, S; Wolfler, A; Greil, R; Burgstaller, S; Sliwa, T; Petzer, A; Lang, A; Weltermann, A; Voskova, D; Mitterer, M; Valent, P; Eberhard, N; Walder, A; Geissler, K; Andel, J; Hausler, C; Ludescher, C; Oexle, H; Korger, M; Schnallinger, M; Schreieck, S; Krippl, P; Pober, M; Woll, E; Geissler, D; Rochau, U; Siebert, U; Thaler, J; Gastl, G
HAEMATOLOGICA. 2015; 100: 693-693.
Abstracts (Zeitschrift)
Tyrosin kinase inhibitors usage and response analysis in the Austrian CML registry cohort
Schmidt, S; Wolfler, A; Greil, R; Burgstaller, S; Sliwa, T; Petzer, A; Lang, A; Weltermann, A; Voskova, D; Mitterer, M; Valent, P; Eberhard, N; Walder, A; Geissler, K; Andel, J; Hausler, C; Ludescher, C; Oexle, H; Korger, M; Schnallinger, M; Schreieck, S; Krippl, P; Wiesholzer, M; Woll, E; Geissler, D; Rochau, U; Siebert, U; Thaler, J; Gastl, G
ONCOL RES TREAT. 2015; 38: 133-133.
Abstracts (Zeitschrift)
Assessment of pharmacokinetic (PK) interaction between cetuximab (CTX) and capecitabine (CCB) or oxaliplatin (OX) in metastatic colorectal cancer (mCRC) patients (pts) (AGMT_CAPECET_PK)
Schreiber, V; Kitzmueller, M; Buchner, P; Weissenboeck, N; Lichtneckert, M; Greil, R; Geiler, H; Czejka, M; Dittrich, C
EUR J CANCER. 2015; 51: S361-S361.
Abstracts (Zeitschrift)
Influence of immunohistological detection of intratumoral urokinase-type plasminogen activator (uPA) on disease outcome in endocrine-treated postmenopausal patients with hormone receptor-positive early breast cancer.
Singer, CF; Filipits, M; Jahn, S; Abete, L; Jakesz, R; Greil, R; Bauernhofer, T; Kwasny, W; Seifert, M; Fitzal, F; Schmitt, M; Moinfar, F; Gnant, M
J CLIN ONCOL. 2015; 33(15):
Abstracts (Zeitschrift)
Bevacizumab in combination with docetaxel plus trastuzumab +/- non-pegylated liposomal doxorubicin: Final results of ABCSG-32, a prospective, randomized phase II-study
Steger, GG; Greil, R; Hubalek, M; Fridrik, MA; Singer, CF; Bartsch, R; Balic, M; Dubsky, P; Egle, D; Gampenrieder, SP; Pfeiler, G; Mayr, D; Czech, T; Rinnerthaler, G; Exner, R; Petzer, AL; Sevelda, P; Lang, A; Rudas, M; Krause, B; Seifert, M; Frantal, S; Zielinski, CC; Gnant, M
CANCER RES. 2015; 75(9):
Abstracts (Zeitschrift)
Immunotherapy of ovarian cancer
Weiss, L; Mlineritsch, B; Greil, R
ONCOL RES TREAT. 2015; 38: 6-6.
Abstracts (Zeitschrift)
Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV-capecitabine (CAP) for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)
Zielinski, CC; Lang, I; Inbar, M; Kahan, Z; Greil, R; Beslija, S; Stemmer, SM; Zvirbule, Z; Steger, GG; Melichar, B; Pienkowski, T; Sirbu, D; Petruzelka, L; Eniu, A; Nisenbaum, B; Dank, M; Anghel, R; Messinger, D; Brodowicz, T
EUR J CANCER. 2015; 51: S263-S264.
Abstracts (Zeitschrift)

2014

Beiträge in Fachzeitschriften

A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia.
Awan, FT; Hillmen, P; Hellmann, A; Robak, T; Hughes, SG; Trone, D; Shannon, M; Flinn, IW; Byrd, JC;
Br J Haematol. 2014; 167(4): 466-477.
Originalarbeiten (Zeitschrift)
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
Benboubker, L; Dimopoulos, MA; Dispenzieri, A; Catalano, J; Belch, AR; Cavo, M; Pinto, A; Weisel, K; Ludwig, H; Bahlis, N; Banos, A; Tiab, M; Delforge, M; Cavenagh, J; Geraldes, C; Lee, JJ; Chen, C; Oriol, A; de la Rubia, J; Qiu, L; White, DJ; Binder, D; Anderson, K; Fermand, JP; Moreau, P; Attal, M; Knight, R; Chen, G; Van Oostendorp, J; Jacques, C; Ervin-Haynes, A; Avet-Loiseau, H; Hulin, C; Facon, T;
N Engl J Med. 2014; 371(10): 906-917.
Originalarbeiten (Zeitschrift)
MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysis.
Benner, A; Mansouri, L; Rossi, D; Majid, A; Willander, K; Parker, A; Bond, G; Pavlova, S; Nückel, H; Merkel, O; Ghia, P; Montserrat, E; Kaderi, MA; Rosenquist, R; Gaidano, G; Dyer, MJ; Söderkvist, P; Linderholm, M; Oscier, D; Tvaruzkova, Z; Pospisilova, S; Dührsen, U; Greil, R; Döhner, H; Stilgenbauer, S; Zenz, T;
Haematologica. 2014; 99(8): 1285-1291.
Originalarbeiten (Zeitschrift)
The pathogenic relevance of the prognostic markers CD38 and CD49d in chronic lymphocytic leukemia.
Brachtl, G; Piñón Hofbauer, J; Greil, R; Hartmann, TN;
Ann Hematol. 2014; 93(3): 361-374.
Übersichtsarbeiten
Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses.
Brodowicz, T; Lang, I; Kahan, Z; Greil, R; Beslija, S; Stemmer, SM; Kaufman, B; Petruzelka, L; Eniu, A; Anghel, R; Koynov, K; Vrbanec, D; Pienkowski, T; Melichar, B; Spanik, S; Ahlers, S; Messinger, D; Inbar, MJ; Zielinski, C;
Br J Cancer. 2014; 111(11): 2051-2057.
Originalarbeiten (Zeitschrift)
Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.
Butts, C; Socinski, MA; Mitchell, PL; Thatcher, N; Havel, L; Krzakowski, M; Nawrocki, S; Ciuleanu, TE; Bosquée, L; Trigo, JM; Spira, A; Tremblay, L; Nyman, J; Ramlau, R; Wickart-Johansson, G; Ellis, P; Gladkov, O; Pereira, JR; Eberhardt, WE; Helwig, C; Schröder, A; Shepherd, FA;
Lancet Oncol. 2014; 15(1): 59-68.
Originalarbeiten (Zeitschrift)
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Byrd, JC; Brown, JR; O"Brien, S; Barrientos, JC; Kay, NE; Reddy, NM; Coutre, S; Tam, CS; Mulligan, SP; Jaeger, U; Devereux, S; Barr, PM; Furman, RR; Kipps, TJ; Cymbalista, F; Pocock, C; Thornton, P; Caligaris-Cappio, F; Robak, T; Delgado, J; Schuster, SJ; Montillo, M; Schuh, A; de Vos, S; Gill, D; Bloor, A; Dearden, C; Moreno, C; Jones, JJ; Chu, AD; Fardis, M; McGreivy, J; Clow, F; James, DF; Hillmen, P;
N Engl J Med. 2014; 371(3): 213-223.
Originalarbeiten (Zeitschrift)
Preoperative treatment with capecitabine, cetuximab and radiotherapy for primary locally advanced rectal cancer--a phase II clinical trial.
Eisterer, W; De Vries, A; Öfner, D; Rabl, H; Koplmüller, R; Greil, R; Tschmelitsch, J; Schmid, R; Kapp, K; Lukas, P; Sedlmayer, F; Höfler, G; Gnant, M; Thaler, J;
Anticancer Res. 2014; 34(11):676-673
Originalarbeiten (Zeitschrift)
Alemtuzumab in chronic lymphocytic leukemia: final results of a large observational multicenter study in mostly pretreated patients.
Fiegl, M; Stauder, R; Steurer, M; Mian, M; Hopfinger, G; Brychtova, Y; Skrabs, C; Zabernigg, A; Schmid, F; Haslbaur, F; Winder, G; Walder, A; Lang, A; Voskova, D; Greil, R; Mayer, J; Gastl, G;
Ann Hematol. 2014; 93(2):26-77
Originalarbeiten (Zeitschrift)
The PAM50 Risk-of-Recurrence Score Predicts Risk for Late Distant Recurrence after Endocrine Therapy in Postmenopausal Women with Endocrine-Responsive Early Breast Cancer.
Filipits, M; Nielsen, TO; Rudas, M; Greil, R; Stoger, H; Jakesz, R; Bago-Horvath, Z; Dietze, O; Regitnig, P; Gruber-Rossipal, C; Muller-Holzner, E; Singer, CF; Mlineritsch, B; Dubsky, P; Bauernhofer, T; Hubalek, M; Knauer, M; Trapl, H; Fesl, C; Schaper, C; Ferree, S; Liu, SZ; Cowens, JW; Gnant, M
CLIN CANCER RES. 2014; 20(5): 1298-1305.
Originalarbeiten (Zeitschrift)
Erratum to: Randomized open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkin"s lymphoma (NHL). A multicenter trial by the Austrian Working Group For Medical Tumor Therapy.
Fridrik, MA; Greil, R; Hausmaninger, H; Krieger, O; Oppitz, P; Stöger, M; Klocker, J; Neubauer, M; Helm, W; Pont, J; Fazeny, B; Hudec, M; Simonitsch, I; Radaszkiewicz, T;
Ann Hematol. 2014; 93(3): 539-540.
Korrekturen
Bone-Targeted Therapy in Metastatic Breast Cancer - All Well-Established Knowledge?
Gampenrieder, SP; Rinnerthaler, G; Greil, R
BREAST CARE. 2014; 9(5): 323-330.
Übersichtsarbeiten
Multi-gene signatures in breast cancer: actual clinical impact
GAMPENRIEDER, SP; RINNERTHALER, G; GREIL, R
memo - Magazine of European Medical Oncology. 2014; Volume 7, Issue 1: 16-21.
Originalarbeiten (Zeitschrift)
Hypertension as a predictive marker for bevacizumab in metastatic breast cancer: results from a retrospective matched-pair analysis.
Gampenrieder, SP; Romeder, F; Muß, C; Pircher, M; Ressler, S; Rinnerthaler, G; Bartsch, R; Sattlberger, C; Mlineritsch, B; Greil, R;
Anticancer Res. 2014; 34(1): 227-233.
Originalarbeiten (Zeitschrift)
Chemotherapy-induced augmentation of T cells expressing inhibitory receptors is reversed by treatment with lenalidomide in chronic lymphocytic leukemia.
Gassner, FJ; Zaborsky, N; Neureiter, D; Huemer, M; Melchardt, T; Egle, A; Rebhandl, S; Catakovic, K; Hartmann, TN; Greil, R; Geisberger, R;
Haematologica. 2014; 99(5):67-69
Letter
Sensitive testing of plasma HIV-1 RNA and Sanger sequencing of cellular HIV-1 DNA for the detection of drug resistance prior to starting first-line antiretroviral therapy with etravirine or efavirenz.
Geretti, AM; Conibear, T; Hill, A; Johnson, JA; Tambuyzer, L; Thys, K; Vingerhoets, J; Van Delft, Y;
J Antimicrob Chemother. 2014; 69(4): 1090-1097.
Originalarbeiten (Zeitschrift)
The CXCR4 and adhesion molecule expression of CD34+ hematopoietic cells mobilized by "on-demand" addition of plerixafor to granulocyte-colony-stimulating factor.
Girbl, T; Lunzer, V; Greil, R; Namberger, K; Hartmann, TN
TRANSFUSION. 2014; 54(9): 2325-2335.
Originalarbeiten (Zeitschrift)
Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone.
Gnant, M; Filipits, M; Greil, R; Stoeger, H; Rudas, M; Bago-Horvath, Z; Mlineritsch, B; Kwasny, W; Knauer, M; Singer, C; Jakesz, R; Dubsky, P; Fitzal, F; Bartsch, R; Steger, G; Balic, M; Ressler, S; Cowens, JW; Storhoff, J; Ferree, S; Schaper, C; Liu, S; Fesl, C; Nielsen, TO;
Ann Oncol. 2014; 25(2): 339-345.
Originalarbeiten (Zeitschrift)
Targeting proliferation of chronic lymphocytic leukemia (CLL) cells through KCa3.1 blockade.
Grössinger, EM; Weiss, L; Zierler, S; Rebhandl, S; Krenn, PW; Hinterseer, E; Schmölzer, J; Asslaber, D; Hainzl, S; Neureiter, D; Egle, A; Piñón-Hofbauer, J; Hartmann, TN; Greil, R; Kerschbaum, HH;
Leukemia. 2014; 28(4):954-958
Letter
Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study.
Guglielmelli, P; Biamonte, F; Rotunno, G; Artusi, V; Artuso, L; Bernardis, I; Tenedini, E; Pieri, L; Paoli, C; Mannarelli, C; Fjerza, R; Rumi, E; Stalbovskaya, V; Squires, M; Cazzola, M; Manfredini, R; Harrison, C; Tagliafico, E; Vannucchi, AM;
Blood. 2014; 123(14): 2157-2160.
Originalarbeiten (Zeitschrift)
Kasabach-Merritt phenomenon in hepatic angiosarcoma.
Habringer, S; Boekstegers, A; Weiss, L; Hopfinger, G; Meissnitzer, T; Melchardt, T; Egle, A; Greil, R;
Br J Haematol. 2014; 167(5):716-718
Letter
Differential survival trends of stage II colorectal cancer patients relate to promoter methylation status of PCDH10, SPARC, and UCHL1.
Heitzer, E; Artl, M; Filipits, M; Resel, M; Graf, R; Weißenbacher, B; Lax, S; Gnant, M; Wrba, F; Greil, R; Dietze, O; Hofbauer, F; Böhm, G; Höfler, G; Samonigg, H; Schaberl-Moser, R; Balic, M; Dandachi, N;
Mod Pathol. 2014; 27(6): 906-915.
Originalarbeiten (Zeitschrift)
Tiam1/Rac1 signals contribute to the proliferation and chemoresistance, but not motility, of chronic lymphocytic leukemia cells.
Hofbauer, SW; Krenn, PW; Ganghammer, S; Asslaber, D; Pichler, U; Oberascher, K; Henschler, R; Wallner, M; Kerschbaum, H; Greil, R; Hartmann, TN;
Blood. 2014; 123(14):2181-2188
Originalarbeiten (Zeitschrift)
Female gender may predict response to FOLFIRINOX in patients with unresectable pancreatic cancer: a single institution retrospective review.
Hohla, F; Hopfinger, G; Romeder, F; Rinnerthaler, G; Bezan, A; Stättner, S; Hauser-Kronberger, C; Ulmer, H; Greil, R;
Int J Oncol. 2014; 44(1):319-326
Originalarbeiten (Zeitschrift)
Targeted therapy in advanced metastatic colorectal cancer: Current concepts and perspectives
Hohla, F; Winder, T; Greil, R; Rick, FG; Block, NL; Schally, AV
WORLD J GASTROENTERO. 2014; 20(20): 6102-6112.
Originalarbeiten (Zeitschrift)
Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial.
Hopfinger, G; Nösslinger, T; Lang, A; Linkesch, W; Melchardt, T; Weiss, L; Egle, A; Greil, R;
Ann Hematol. 2014; 93(3):459-462
Originalarbeiten (Zeitschrift)
Overcoming resistance against HER2-targeting agents in fifth-line therapy: is there still a place for bevacizumab in HER2+ breast cancer?
Huemer, F; Gampenrieder, SP; Schlattau, A; Greil, R;
Clin Breast Cancer. 2014; 14(1):e17-e20
Fallberichte
AID induces intraclonal diversity and genomic damage in CD86(+) chronic lymphocytic leukemia cells.
Huemer, M; Rebhandl, S; Zaborsky, N; Gassner, FJ; Hainzl, S; Weiss, L; Hebenstreit, D; Greil, R; Geisberger, R;
Eur J Immunol. 2014; 44(12):3747-3757
Originalarbeiten (Zeitschrift)
Multicenter phase II study evaluating docetaxel and cisplatin as neoadjuvant induction regimen prior to surgery or radiochemotherapy with docetaxel, followed by adjuvant docetaxel therapy in chemonaive patients with NSCLC stage II, IIIA and IIIB (TAX-AT 1.203 Trial).
Kocher, F; Pircher, A; Mohn-Staudner, A; Romeder, F; Duller, W; Steinmaurer, M; Eckmayr, J; Schmid, T; Hilbe, W; Fiegl, M; Greil, R
LUNG CANCER. 2014; 85(3): 395-400.
Originalarbeiten (Zeitschrift)
Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma.
Ludwig, H; Kasparu, H; Leitgeb, C; Rauch, E; Linkesch, W; Zojer, N; Greil, R; Seebacher, A; Pour, L; Weißmann, A; Adam, Z;
Blood. 2014; 123(7):985-991
Originalarbeiten (Zeitschrift)
Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials.
McGale, P; Taylor, C; Correa, C; Cutter, D; Duane, F; Ewertz, M; Gray, R; Mannu, G; Peto, R; Whelan, T; Wang, Y; Wang, Z; Darby, S;
Lancet. 2014; 383(9935): 2127-2135.
Originalarbeiten (Zeitschrift)
Liver toxicity during temozolomide chemotherapy caused by Chinese herbs.
Melchardt, T; Magnes, T; Weiss, L; Grundbichler, M; Strasser, M; Hufnagl, C; Moik, M; Greil, R; Egle, A;
BMC COMPLEM ALTERN M. 2014; 14: 115
Fallberichte
Pleural decortication of a marginal zone lymphoma.
Melchardt, T; Weiss, L; Namberger, K; Pretsch, I; Hutter, J; Rettenbacher, L; Neureiter, D; Troch, M; Greil, R; Egle, A;
Ann Hematol. 2014; 93(7):1253-1254
Letter
Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group.
Pleyer, L; Burgstaller, S; Girschikofsky, M; Linkesch, W; Stauder, R; Pfeilstocker, M; Schreder, M; Tinchon, C; Sliwa, T; Lang, A; Sperr, WR; Krippl, P; Geissler, D; Voskova, D; Schlick, K; Thaler, J; Machherndl-Spandl, S; Theiler, G; Eckmüllner, O; Greil, R;
ANN HEMATOL. 2014; 93(11): 1825-1838.
Originalarbeiten (Zeitschrift)
Azacitidine in CMML: matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival.
Pleyer, L; Germing, U; Sperr, WR; Linkesch, W; Burgstaller, S; Stauder, R; Girschikofsky, M; Schreder, M; Pfeilstocker, M; Lang, A; Sliwa, T; Geissler, D; Schlick, K; Placher-Sorko, G; Theiler, G; Thaler, J; Mitrovic, M; Neureiter, D; Valent, P; Greil, R;
Leuk Res. 2014; 38(4):475-483
Originalarbeiten (Zeitschrift)
APOBEC3 signature mutations in chronic lymphocytic leukemia.
Rebhandl, S; Huemer, M; Gassner, FJ; Zaborsky, N; Hebenstreit, D; Catakovic, K; Grössinger, E; Greil, R; Geisberger, R;
Leukemia. 2014; 28(9): 1929-1932.
Originalarbeiten (Zeitschrift)
Alternative splice variants of AID are not stoichiometrically present at the protein level in chronic lymphocytic leukemia.
Rebhandl, S; Huemer, M; Zaborsky, N; Gassner, FJ; Catakovic, K; Felder, TK; Greil, R; Geisberger, R;
Eur J Immunol. 2014; 44(7):2175-2187
Originalarbeiten (Zeitschrift)
Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24).
Steger, GG; Greil, R; Lang, A; Rudas, M; Fitzal, F; Mlineritsch, B; Hartmann, BL; Bartsch, R; Melbinger, E; Hubalek, M; Stoeger, H; Dubsky, P; Ressler, S; Petzer, AL; Singer, CF; Muss, C; Jakesz, R; Gampenrieder, SP; Zielinski, CC; Fesl, C; Gnant, M;
Ann Oncol. 2014; 25(2):366-371
Originalarbeiten (Zeitschrift)
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Taieb, J; Tabernero, J; Mini, E; Subtil, F; Folprecht, G; Van Laethem, JL; Thaler, J; Bridgewater, J; Petersen, LN; Blons, H; Collette, L; Van Cutsem, E; Rougier, P; Salazar, R; Bedenne, L; Emile, JF; Laurent-Puig, P; Lepage, C;
Lancet Oncol. 2014; 15(8): 862-873.
Originalarbeiten (Zeitschrift)
Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients.
Tassara, M; Döhner, K; Brossart, P; Held, G; Götze, K; Horst, HA; Ringhoffer, M; Köhne, CH; Kremers, S; Raghavachar, A; Wulf, G; Kirchen, H; Nachbaur, D; Derigs, HG; Wattad, M; Koller, E; Brugger, W; Matzdorff, A; Greil, R; Heil, G; Paschka, P; Gaidzik, VI; Göttlicher, M; Döhner, H; Schlenk, RF;
Blood. 2014; 123(26): 4027-4036.
Originalarbeiten (Zeitschrift)
Performance characteristics of the COBAS Ampliprep/COBAS TaqMan v2.0 and the Abbott RealTime hepatitis C assays - implications for response-guided therapy in genotype 1 infections.
Taylor, N; Haschke-Becher, E; Greil, R; Strasser, M; Oberkofler, H;
Antivir Ther. 2014; 19(5): 449-454.
Originalarbeiten (Zeitschrift)
Human immunodeficiency virus type 2 infections in Austria.
Taylor, N; Kern, JM; Prammer, W; Lang, A; Haas, B; Gisinger, M; Zangerle, R; Egle, A; Greil, R; Oberkofler, H; Eberle, J;
Wien Klin Wochenschr. 2014; 126(7-8):212-216
Originalarbeiten (Zeitschrift)
Assessment of TP53 functionality in chronic lymphocytic leukaemia by different assays; an ERIC-wide approach.
Te Raa, GD; Malčiková, J; Mraz, M; Trbusek, M; Le Garff-Tavernier, M; Merle-Béral, H; Greil, R; Merkel, O; Pospíšilová, S; Lin, K; Pettitt, AR; Stankovic, T; van Oers, MH; Eldering, E; Stilgenbauer, S; Zenz, T; Kater, AP;
Br J Haematol. 2014; 167(4): 565-569.
Letter
C-reactive protein level is a prognostic indicator for survival and improves the predictive ability of the R-IPI score in diffuse large B-cell lymphoma patients.
Troppan, KT; Schlick, K; Deutsch, A; Melchardt, T; Egle, A; Stojakovic, T; Beham-Schmid, C; Weiss, L; Neureiter, D; Wenzl, K; Greil, R; Neumeister, P; Pichler, M;
Br J Cancer. 2014; 111(1):55-60
Originalarbeiten (Zeitschrift)
Increased body mass index is associated with improved overall survival in diffuse large B-cell lymphoma.
Weiss, L; Melchardt, T; Habringer, S; Boekstegers, A; Hufnagl, C; Neureiter, D; Hopfinger, G; Greil, R; Egle, A;
Ann Oncol. 2014; 25(1):171-176
Originalarbeiten (Zeitschrift)

Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen

The Transcription Factor IRF4 Is Crucial for CLL Progression and Regulates Survival and Proliferation in a Microenvironment Related Manner
Asslaber, D; Hofbauer, JP; Zaborsky, N; Flenady, S; Hartmann, TN; Greil, R; Egle, A
BLOOD. 2014; 124(21):
Abstracts (Zeitschrift)
The integrin VLA-4 shows impaired CXCL12-induced inside-out activation in trisomy12 harboring chronic lymphocytic leukemia (CLL) cells
Ganghammer, S; Hutterer, E; Hinterseer, E; Brachtl, G; Asslaber, D; Krenn, PW; Girbl, T; Berghammer, P; Geisberger, R; Egle, A; Zucchetto, A; Gattei, V; Chigaev, A; Greil, R; Hartmann, TN
ONCOL RES TREAT. 2014; 37: 222-222.
Abstracts (Zeitschrift)
Switch from Every Two Weeks to Every Four Weeks Administration Schedule of AOP2014, an Innovative Pegylated Interferon Alpha, in Polycythemia Very Patients Allows Maintaining of Efficacy with Improved Toxicity Profile in Phase I/II Study
Gisslinger, H; Buxhofer-Ausch, V; Thaler, J; Schloegl, E; Gastl, GA; Wolf, D; Kralovics, R; Gisslinger, B; Strecker, K; Egle, A; Melchardt, T; Burgstaller, S; Willenbacher, E; Zoerer, M; Kadlecova, P; Zagrijtschuk, O; Klade, C; Greil, R
BLOOD. 2014; 124(21):
Abstracts (Zeitschrift)
Rituximab Maintenance after Chemoimmunotherapy Induction in 1st and 2st Line Improves Progression Free Survival: Planned Interim Analysis of the International Randomized AGMT-CLL8/a Mabtenance Trial
Greil, R; Obrtlikova, P; Smolej, L; Kozak, T; Steurer, M; Andel, J; Thaler, J; Mikuskova, E; Gercheva, L; Nosslinger, T; Ladicka, M; Girschikofsky, M; Hrubiko, M; Jager, U; Fridrik, MA; Pecherstorfer, M; Kralikova, E; Burcoveanu, C; Goranov, S; Jurkovikova, J; Petzer, AL; Mihaylov, GG; Raynov, J; Oexle, H; Zabernigg, A; Flochova, E; Palasthy, S; Melchardt, T; Mayer, J; Egle, A
BLOOD. 2014; 124(21):
Abstracts (Zeitschrift)
Malignant Lymphoblasts in T Cell Acute Lymphoblastic Leukemia Express High Levels of Kv1.3
Groessinger, E; Weiss, L; Chen, MY; Wulff, H; Greil, R; Kerschbaum, H
BIOPHYS J. 2014; 106(2): 551A-551A.
Abstracts (Zeitschrift)
The Spiegelmer (R) NOX-A12 Mobilizes CLL Cells from Lymphoid Organs and Prevents Their Recirculation
Hinterseer, E; Girbl, T; Hutterer, E; Berghammer, P; Ganghammer, S; Sifft, EA; Pinon-Hofbauer, J; Egle, A; Kruschinski, A; Greil, R; Hartmann, TN
SCAND J IMMUNOL. 2014; 79(6): 468-469.
Abstracts (Zeitschrift)
Chronic Lymphocytic Leukaemia Cells with Trisomy 12 Home to the Bone Marrow in a CXCR4-Independent Manner
Hutterer, E; Ganghammer, S; Hinterseer, E; Brachtl, G; Asslaber, D; Krenn, P; Girbl, T; Berghammer, P; Geisberger, R; Egle, A; Zucchetto, A; Gattei, V; Chigaev, A; Greil, R; Hartmann, T
SCAND J IMMUNOL. 2014; 79(6): 468-468.
Abstracts (Zeitschrift)
Chronic Lymphocytic Leukaemia Cells with Trisomy 12 Home to the Bone Marrow in a CXCR4-Independent Manner
Hutterer, E; Ganghammer, S; Hinterseer, E; Brachtl, G; Asslaber, D; Krenn, P; Girbl, T; Berghammer, P; Geisberger, R; Egle, A; Zucchetto, A; Gattei, V; Chigaev, A; Greil, R; Hartmann, T
Chronic Lymphocytic Leukaemia Cells with Trisomy 12 Home to the Bone Marrow in a CXCR4-Independent Manner. 2014; 79(6): 424-478.-Scandinavian Society for Immunology 42nd Annual Meeting; 11.-14.06.2014; Reykjavik.
Abstracts (Zeitschrift)
Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced squamous cell carcinoma of the head and neck
Keil, F; Selzer, E; Berghold, A; Reinisch, S; de Vries, A; Greil, R; Bachtiary, B; Tinchon, C; Anderhuber, W; Burian, M; Kasparek, AK; Elsasser, W; Kainz, H; Riedl, R; Kapp, K; Kopp, M; Kornek, G
ONCOL RES TREAT. 2014; 37: 273-273.
Abstracts (Zeitschrift)
Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first disease progression (PD) in patients with metastatic colorectal cancer (mCRC) previously treated with BEV-based therapy: Outcomes according to KRAS status and first-line CT backbone in the ML18147 study.
Kubicka, S; Greil, R; Andre, T; Bennouna, J; Sastre, J; Van Cutsem, E; Von Moos, R; Osterlund, PJ; Hegde, P; Sersch, MA; Osborne, S; Hermann, F; Arnold, D
J CLIN ONCOL. 2014; 32(3):
Abstracts (Zeitschrift)
Impact of Donor Type on Outcome after Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia Patients: Analysis of the German-Austrian Acute Myeloid Leukemia Study Group (AMLSG)
Kuchenbauer, F; Bunjes, DW; Herr, W; Heuser, M; Spath, D; Casper, J; Horst, HA; Brossart, P; Held, G; Kobbe, G; Ringhoffer, M; Wattad, M; Salih, HR; Gotze, K; Wulf, G; Theobald, M; Rummel, MJ; Fiedler, W; Westermann, J; Salwender, H; Petzer, AL; Hartmann, F; Lubbert, M; Martens, U; Greil, R; Kirchner, HH; Paschka, P; Gaidzik, VI; Teleanu, V; Thol, F; Gohring, G; Dohner, K; Ganserxxx, A; Dohner, H; Schlenk, RF
BLOOD. 2014; 124(21):
Abstracts (Zeitschrift)
AN INTERNATIONAL, MULTICENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF NEUTROPENIA IN PATIENTS BEING TREATED WITH LENALIDOMIDE plus DEXAMETHASONE FOR RELAPSED OR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RR-MM)
Leleu, X; Terpos, E; Sanz, RG; Cooney, J; OxxxGorman, P; Minarik, J; Greil, R; Williams, C; Gray, D; Szabo, Z
HAEMATOLOGICA. 2014; 99: 368-368.
Abstracts (Zeitschrift)
INTERIM RESULTS FROM A PHASE IIA STUDY OF THE ANTI-CXCL12 SPIEGELMER OLAPTESED PEGOL (NOX-A12) IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA
Ludwig, H; Weisel, K; Petrucci, MT; Leleu, X; Cafro, AM; Kropff, M; Greil, R; Zojer, N; Dummler, T; Kruschinski, A; Riecke, K; Foa, R; Yakoub-Agha, I; Engelhardt, M
HAEMATOLOGICA. 2014; 99: 115-116.
Abstracts (Zeitschrift)
Clonal Evolution in Relapsed or Refractory Diffuse Large B Cell Lymphoma
Melchardt, T; Hufnagl, C; Weigert, O; Weinstock, DM; Kopp, N; Weiss, L; Neureiter, D; Trankenschuh, W; Hackl, H; Greil, R; Egle, A
BLOOD. 2014; 124(21):
Abstracts (Zeitschrift)
Azacitidine in Patients with Acute Myeloid Leukemia: Impact of Intermediate-Risk Vs High-Risk Cytogenetics on Patient Outcomes
Pleyer, L; Burgstaller, S; Stauder, R; Girschikofsky, M; Linkesch, W; Pfeilstocker, M; Autzinger, EM; Tinchon, C; Sliwa, T; Lang, A; Sperr, WR; Geissler, D; Krippl, P; Voskova, D; Rossmann, DH; Schlick, K; Thaler, J; Halter, B; Machherndl-Spandl, S; Theiler, G; Valent, P; Eckmullner, O; Greil, R
BLOOD. 2014; 124(21):
Abstracts (Zeitschrift)
Azacitidine in Acute Myeloid Leukemia: Comparison of Patients with AML-MRF Vs AML-NOS Enrolled in the Austrian Azacitidine Registry
Pleyer, L; Burgstaller, S; Stauder, R; Girschikofsky, M; Linkesch, W; Pfeilstocker, M; Autzinger, EM; Tinchon, C; Sliwa, T; Lang, A; Sperr, WR; Geissler, D; Krippl, P; Voskova, D; Rossmann, DH; Schlick, K; Thaler, J; Halter, B; Machherndl-Spandl, S; Theiler, G; Valent, P; Eckmullner, O; Greil, R
BLOOD. 2014; 124(21):
Abstracts (Zeitschrift)
Azacitidine in Patients with Acute Myeloid Leukemia: Assessing the Potential Negative Impact of Elevated Baseline White Blood Cell Count on Outcome
Pleyer, L; Burgstaller, S; Stauder, R; Girschikofsky, M; Linkesch, W; Pfeilstocker, M; Autzinger, EM; Tinchon, C; Sliwa, T; Lang, A; Sperr, WR; Geissler, D; Krippl, P; Voskova, D; Rossmann, DH; Schlick, K; Thaler, J; Halter, B; Machherndl-Spandl, S; Theiler, G; Valent, P; Eckmullner, O; Greil, R
BLOOD. 2014; 124(21):
Abstracts (Zeitschrift)
Azacitidine in Patients with Relapsed/Refractory Acute Myeloid Leukemia : Retrospective Analysis of the Austrian Azacitidine Registry
Pleyer, L; Burgstaller, S; Stauder, R; Girschikofsky, M; Linkesch, W; Pfeilstocker, M; Autzinger, EM; Tinchon, C; Sliwa, T; Lang, A; Sperr, WR; Geissler, D; Krippl, P; Voskova, D; Rossmann, DH; Schlick, K; Thaler, J; Halter, B; Machherndl-Spandl, S; Theiler, G; Valent, P; Eckmullner, O; Greil, R
BLOOD. 2014; 124(21):
Abstracts (Zeitschrift)
Azacitidine in Patients with Treatment-Related Acute Myeloid Leukemia: Retrospective Analysis of the Austrian Azacitidine Registry
Pleyer, L; Burgstaller, S; Stauder, R; Girschikofsky, M; Linkesch, W; Pfeilstoker, M; Autzinger, EM; Tinchon, C; Sliwa, T; Lang, A; Sperr, WR; Geissler, D; Krippl, P; Voskova, D; Rossmann, DH; Schlick, K; Thaler, J; Halter, B; Machherndl-Spandl, S; Theiler, G; Valent, P; Eckmullner, O; Greil, R
BLOOD. 2014; 124(21):
Abstracts (Zeitschrift)
Excellent response of lupus hepatitis to mycophenolate mofetil: a case report
Psenak, O; Studnicka-Benke, A; Greil, R
WIEN KLIN WOCHENSCHR. 2014; 126:
Abstracts (Zeitschrift)
A PHASE II STUDY OF RITUXIMAB PLUS LENALIDOMIDE IN PATIENTS WITH EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF THE MUCOSA-ASSOCIATED LYMPHOID TISSUE (MALT LYMPHOMA)
Raderer, M; Kiesewetter, B; Willenbacher, W; Neumeister, P; Fridrik, M; Greil, R
HAEMATOLOGICA. 2014; 99: 226-226.
Abstracts (Zeitschrift)
UPDATED REPORT OF THE AUSTRIAN CML REGISTRY
Schmidt, S; Sill, H; Greil, R; Burgstaller, S; Schlogl, E; Petzer, A
HAEMATOLOGICA. 2014; 99: 341-341.
Abstracts (Zeitschrift)
Updated report of the Austrian CML registry
Schmidt, S; Sill, H; Greil, R; Burgstaller, S; Sliwa, T; Petzer, A; Lang, A; Weltermann, A; Voskova, D; Mitterer, M; Valent, P; Eberhard, N; Walder, A; Geissler, K; Andel, J; Hausler, C; Ludescher, C; Oexle, H; Korger, M; Schnallinger, M; Schreieck, S; Krippl, P; Pober, M; Woell, E; Geissler, D; Rochau, U; Siebert, U; Thaler, J; Gastl, G
ONCOL RES TREAT. 2014; 37: 57-58.
Abstracts (Zeitschrift)
Spliceosome Mediated RNA Trans-Splicing for Targeting Kappa(+) B-Cell Neoplasms
Weiss, L; Gruber, C; Koller, U; Pinon-Hofbauer, J; Hainzl, S; Hufnagl, C; Melchardt, T; Brachtl, G; Greil, R; Bauer, J; Egle, A
BLOOD. 2014; 124(21):
Abstracts (Zeitschrift)

Beiträge in Sonstigen Zeitschriften

T-DM1
GAMPENRIEDER, SP; GREIL, R; MARTH, C; PETRU, E; RINNERTHALER, G; STEGER, GG
ArzneimittelPROFIL T-DM1, Juli 2014. 2014.

2013

Beiträge in Fachzeitschriften

Mimicking the microenvironment in chronic lymphocytic leukaemia - where does the journey go?
Asslaber, D; Grössinger, EM; Girbl, T; Hofbauer, SW; Egle, A; Weiss, L; Greil, R; Hartmann, TN;
Br J Haematol. 2013; 160(5):711-714
Letter
Topical evening primrose oil for reduction of bortezomib-induced skin reactions.
Auberger, J; Vogt, S; Hopfinger, G; Clausen, J; Greil, R;
Ann Hematol. 2013; 92(7):995-996
Letter
Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer.
Baselga, J; Gómez, P; Greil, R; Braga, S; Climent, MA; Wardley, AM; Kaufman, B; Stemmer, SM; Pêgo, A; Chan, A; Goeminne, JC; Graas, MP; Kennedy, MJ; Ciruelos Gil, EM; Schneeweiss, A; Zubel, A; Groos, J; Melezínková, H; Awada, A;
J Clin Oncol. 2013; 31(20):2586-2592
Originalarbeiten (Zeitschrift)
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.
Bennouna, J; Sastre, J; Arnold, D; Osterlund, P; Greil, R; Van Cutsem, E; von Moos, R; Viéitez, JM; Bouché, O; Borg, C; Steffens, CC; Alonso-Orduña, V; Schlichting, C; Reyes-Rivera, I; Bendahmane, B; André, T; Kubicka, S;
Lancet Oncol. 2013; 14(1):29-37
Originalarbeiten (Zeitschrift)
Systemic effect of catumaxomab in a patient with metastasized colorectal cancer: a case report.
Bezan, A; Hohla, F; Meissnitzer, T; Greil, R;
BMC Cancer. 2013; 13(1): 618
Fallberichte
ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials.
Böll, B; Görgen, H; Fuchs, M; Pluetschow, A; Eich, HT; Bargetzi, MJ; Weidmann, E; Junghanß, C; Greil, R; Scherpe, A; Schmalz, O; Eichenauer, DA; von Tresckow, B; Rothe, A; Diehl, V; Engert, A; Borchmann, P;
J Clin Oncol. 2013; 31(12):1522-1529
Originalarbeiten (Zeitschrift)
Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer.
Crown, JP; Diéras, V; Staroslawska, E; Yardley, DA; Bachelot, T; Davidson, N; Wildiers, H; Fasching, PA; Capitain, O; Ramos, M; Greil, R; Cognetti, F; Fountzilas, G; Blasinska-Morawiec, M; Liedtke, C; Kreienberg, R; Miller, WH; Tassell, V; Huang, X; Paolini, J; Kern, KA; Romieu, G;
J Clin Oncol. 2013; 31(23):2870-2878
Originalarbeiten (Zeitschrift)
The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients.
Dubsky, P; Brase, JC; Jakesz, R; Rudas, M; Singer, CF; Greil, R; Dietze, O; Luisser, I; Klug, E; Sedivy, R; Bachner, M; Mayr, D; Schmidt, M; Gehrmann, MC; Petry, C; Weber, KE; Fisch, K; Kronenwett, R; Gnant, M; Filipits, M;
Br J Cancer. 2013; 109(12):2959-2964
Originalarbeiten (Zeitschrift)
EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer.
Dubsky, P; Filipits, M; Jakesz, R; Rudas, M; Singer, CF; Greil, R; Dietze, O; Luisser, I; Klug, E; Sedivy, R; Bachner, M; Mayr, D; Schmidt, M; Gehrmann, MC; Petry, C; Weber, KE; Kronenwett, R; Brase, JC; Gnant, M;
Ann Oncol. 2013; 24(3): 640-647.
Originalarbeiten (Zeitschrift)
Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG).
Gaidzik, VI; Schlenk, RF; Paschka, P; Stölzle, A; Späth, D; Kuendgen, A; von Lilienfeld-Toal, M; Brugger, W; Derigs, HG; Kremers, S; Greil, R; Raghavachar, A; Ringhoffer, M; Salih, HR; Wattad, M; Kirchen, HG; Runde, V; Heil, G; Petzer, AL; Girschikofsky, M; Heuser, M; Kayser, S; Goehring, G; Teleanu, MV; Schlegelberger, B; Ganser, A; Krauter, J; Bullinger, L; Döhner, H; Döhner, K;
Blood. 2013; 121(23):4769-4777
Originalarbeiten (Zeitschrift)
Neoadjuvant chemotherapy and targeted therapy in breast cancer: past, present, and future.
Gampenrieder, SP; Rinnerthaler, G; Greil, R;
J Oncol. 2013; 2013: 732047
Übersichtsarbeiten
AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
Gianni, L; Romieu, GH; Lichinitser, M; Serrano, SV; Mansutti, M; Pivot, X; Mariani, P; Andre, F; Chan, A; Lipatov, O; Chan, S; Wardley, A; Greil, R; Moore, N; Prot, S; Pallaud, C; Semiglazov, V;
J Clin Oncol. 2013; 31(14):1719-1725
Originalarbeiten (Zeitschrift)
CD40-mediated activation of chronic lymphocytic leukemia cells promotes their CD44-dependent adhesion to hyaluronan and restricts CCL21-induced motility.
Girbl, T; Hinterseer, E; Grössinger, EM; Asslaber, D; Oberascher, K; Weiss, L; Hauser-Kronberger, C; Neureiter, D; Kerschbaum, H; Naor, D; Alon, R; Greil, R; Hartmann, TN;
Cancer Res. 2013; 73(2): 561-570.
Originalarbeiten (Zeitschrift)
Everolimus in Postmenopausal, Hormone Receptor-Positive Advanced Breast Cancer: Summary and Results of an Austrian Expert Panel Discussion
Gnant, M; Greil, R; Hubalek, M; Steger, G
BREAST CARE. 2013; 8(4): 293-299.
Übersichtsarbeiten
The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial.
Gnant, M; Pfeiler, G; Stöger, H; Mlineritsch, B; Fitzal, F; Balic, M; Kwasny, W; Seifert, M; Stierer, M; Dubsky, P; Greil, R; Steger, G; Samonigg, H; Fesl, C; Jakesz, R;
Br J Cancer. 2013; 109(3): 58-96.
Originalarbeiten (Zeitschrift)
CYP2D6 Metabolism and Patient Outcome in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSG) 8.
Goetz, MP; Suman, VJ; Hoskin, TL; Gnant, M; Filipits, M; Safgren, SL; Kuffel, M; Jakesz, R; Rudas, M; Greil, R; Dietze, O; Lang, A; Offner, F; Reynolds, CA; Weinshilboum, RM; Ames, MM; Ingle, JN;
Clin Cancer Res. 2013; 19(2): 500-507.
Originalarbeiten (Zeitschrift)
[Successful cancer therapy: chance and challenges.]
Greil, R; Hiddemann, W;
Dtsch Med Wochenschr. 2013; 138(41): 2083
Editorials
A modified Phenol-chloroform extraction method for isolating circulating cell free DNA of tumor patients.
Hufnagl, C; Stöcher, M; Moik, M; Geisberger, R; Greil, R;
Journal of nucleic acids investigation. 2013; Vol 4, No 1 (2013): 1-3.
Originalarbeiten (Zeitschrift)
Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced squamous cell carcinoma of the head and neck.
Keil, F; Selzer, E; Berghold, A; Reinisch, S; Kapp, KS; De Vries, A; Greil, R; Bachtiary, B; Tinchon, C; Anderhuber, W; Burian, M; Kasparek, AK; Elsäßer, W; Kainz, H; Riedl, R; Kopp, M; Kornek, G;
Eur J Cancer. 2013; 49(2):352-359
Originalarbeiten (Zeitschrift)
Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings.
Kubicka, S; Greil, R; André, T; Bennouna, J; Sastre, J; Van Cutsem, E; von Moos, R; Osterlund, P; Reyes-Rivera, I; Müller, T; Makrutzki, M; Arnold, D;
Ann Oncol. 2013; 24(9):2342-2349
Originalarbeiten (Zeitschrift)
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.
Lang, I; Brodowicz, T; Ryvo, L; Kahan, Z; Greil, R; Beslija, S; Stemmer, SM; Kaufman, B; Zvirbule, Z; Steger, GG; Melichar, B; Pienkowski, T; Sirbu, D; Messinger, D; Zielinski, C;
Lancet Oncol. 2013; 14(2):125-133
Originalarbeiten (Zeitschrift)
Utility of PCR in diagnosis of invasive fungal infections: real-life data from a multicenter study.
Lass-Flörl, C; Mutschlechner, W; Aigner, M; Grif, K; Marth, C; Girschikofsky, M; Grander, W; Greil, R; Russ, G; Cerkl, P; Eller, M; Kropshofer, G; Eschertzhuber, S; Kathrein, H; Schmid, S; Beer, R; Lorenz, I; Theurl, I; Nachbaur, D;
J Clin Microbiol. 2013; 51(3):863-868
Originalarbeiten (Zeitschrift)
Randomized Phase II Study of Bortezomib, Thalidomide, and Dexamethasone With or Without Cyclophosphamide As Induction Therapy in Previously Untreated Multiple Myeloma.
Ludwig, H; Viterbo, L; Greil, R; Masszi, T; Spicka, I; Shpilberg, O; Hajek, R; Dmoszynska, A; Paiva, B; Vidriales, MB; Esteves, G; Stoppa, AM; Robinson, D; Ricci, D; Cakana, A; Enny, C; Feng, H; van de Velde, H; Harousseau, JL;
J Clin Oncol. 2013; 31(2):247-255
Originalarbeiten (Zeitschrift)
What’s new in Hodgkin’s lymphoma: ASH 2012 and more
Melchardt, T; Weiss, L; Greil, R; Egle, A;
Magazine of European Medical Oncology. 2013; Volume 6, Issue 3: 193-196.
Übersichtsarbeiten
Viral infections and their management in patients with chronic lymphocytic leukemia.
Melchardt, T; Weiss, L; Greil, R; Egle, A;
Leuk Lymphoma. 2013; 54(8):1602-1613
Übersichtsarbeiten
Complications of 5-azacytidine: Three cases of severe ischemic colitis in elderly patients with myelodysplastic syndrome.
Melchardt, T; Weiss, L; Pleyer, L; Steinkirchner, S; Auberger, J; Hopfinger, G; Greil, R; Egle, A;
Oncol Lett. 2013; 6(6):1756-1758
Originalarbeiten (Zeitschrift)
A case of long-term remission with ofatumumab maintenance therapy in multiply relapsed and rituximab-refractory chronic lymphocytic leukaemia with deletion 17p.
Namberger, K; Weiss, L; Krause, B; Melchardt, T; Greil, R;
Eur J Haematol. 2013; 90(4):349-350
Letter
Efficacy of tamoxifen ± aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trial.
Pfeiler, G; Stöger, H; Dubsky, P; Mlineritsch, B; Singer, C; Balic, M; Fitzal, F; Moik, M; Kwasny, W; Selim, U; Renner, K; Ploner, F; Steger, GG; Seifert, M; Hofbauer, F; Sandbichler, P; Samonigg, H; Jakesz, R; Greil, R; Fesl, C; Gnant, M;
Br J Cancer. 2013; 108(7):1408-1414
Originalarbeiten (Zeitschrift)
Azacitidine in patients with WHO-defined AML - results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group.
Pleyer, L; Stauder, R; Burgstaller, S; Schreder, M; Tinchon, C; Pfeilstocker, M; Steinkirchner, S; Melchardt, T; Mitrovic, M; Girschikofsky, M; Lang, A; Krippl, P; Sliwa, T; Egle, A; Linkesch, W; Voskova, D; Angermann, H; Greil, R;
J Hematol Oncol. 2013; 6:32
Editorials
Mycophenolatmofetil und Azathioprin in der Schwangerschaft bei einer Patientin mit systemischem Lupus erythematodes.
Psenak, O; Studnicka-Benke, A; Greil, R
Rheuma plus. 2013; 12: 18-20.
Fallberichte
[71-year old woman with neutropenic fever during chemotherapy].
Schlick, K; Datz, L; Hohla, F; Greil, R; Hopfinger, G;
Dtsch Med Wochenschr. 2013; 138(41):2091-2092
Fallberichte
The clinical potential of temsirolimus in second or later lines of treatment for metastatic renal cell carcinoma.
Stenner-Liewen, F; Grünwald, V; Greil, R; Porta, C;
Expert Rev Anticancer Ther. 2013; 13(9): 1021-1033.
Originalarbeiten (Zeitschrift)
Cobas ampliprep/cobas TaqMan HIV-1 v2.0 assay: consequences at the cohort level.
Taylor, N; Grabmeier-Pfistershammer, K; Egle, A; Greil, R; Rieger, A; Ledergerber, B; Oberkofler, H;
PLoS One. 2013; 8(8):e74024
Originalarbeiten (Zeitschrift)
Use of romiplostim allows for hepatitis C therapy in a HIV/HCV coinfected patient.
Taylor, N; Melchardt, T; Grundbichler, M; Strasser, M; Egle, A; Greil, R;
Ann Hematol. 2013; 92(7):1001-1002
Letter
Rituximab plus subcutaneous cladribine in patients with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: a phase II study by the Arbeitsgemeinschaft Medikamentose Tumortherapie.
Troch, M; Kiesewetter, B; Willenbacher, W; Willenbacher, E; Zebisch, A; Linkesch, W; Fridrik, M; Müllauer, L; Greil, R; Raderer, M;
Haematologica. 2013; 98(2): 264-268.
Originalarbeiten (Zeitschrift)
Circulating tumor DNA to monitor metastatic breast cancer.
Weiss, L; Hufnagl, C; Greil, R;
N Engl J Med. 2013; 369(1): 93
Letter
ASH 2012 update chronic lymphocytic leukemia—the best is yet to come
Weiss, L; Melchardt, T; Greil, R; Hopfinger, G;
Magazine of European Medical Oncology. 2013; Volume 6, Issue 3: 177-180.
Übersichtsarbeiten

Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen

The transcription factor IRF-4 is related to prognosis in Chronic Lymphocytic Leukemia (CLL) and involved in proliferation and survival
Asslaber, D; Hofbauer, JP; Zaborsky, N; Kocher, T; Hartmann, TN; Greil, R; Egle, A
ONKOLOGIE. 2013; 36: 222-223.
Abstracts (Zeitschrift)
Hypertension as a predictive marker for bevacizumab in metastatic breast cancer: updated results from a retrospective matched-pair analysis
Gampenrieder, SP; Romeder, F; Muss, C; Pircher, M; Ressler, S; Rinnerthaler, G; Bartsch, R; Sattlberger, C; Mlineritsch, B; Greil, R
EUR J CANCER. 2013; 49: S417-S418.
Abstracts (Zeitschrift)
CXCR3 modulates CXCL12-mediated cellular responses in chronic lymphocytic leukemia
Ganghammer, S; Hinterseer, E; Johrer, K; Greil, R; Hartmann, TN
CYTOKINE. 2013; 63(3): 264-264.
Abstracts (Zeitschrift)
Blockade of the Potassium Channel KCa3.1 inhibits proliferation in Chronic Lymphocytic Leukemia
Grossinger, EM; Weiss, L; Zierler, S; Hinterseer, E; Schmolzer, J; Asslaber, D; Hainzl, S; Egle, A; Pinon, JD; Hartmann, TN; Greil, R; Kerschbaum, HH
ONKOLOGIE. 2013; 36: 191-192.
Abstracts (Zeitschrift)
Tiam1/Rac1 signals contribute to CLL cell proliferation and chemoresistance
Hofbauer, SW; Krenn, PW; Ganghammer, S; Asslaber, D; Pichler, U; Wallner, M; Henschler, R; Greil, R; Hartmann, TN
ONKOLOGIE. 2013; 36: 56-56.
Abstracts (Zeitschrift)
Lapatinib plus Caelyx in patients with advanced or metastatic Her 2 positive breast cancer following failure of Trastuzumab therapy - A Phase II study of the Arbeitsgemeinschaft Medikamentose Tumortherapie
Pircher, M; Mlineritsch, B; Fridrik, M; Dittrich, C; Lang, A; Petru, E; Weltermann, A; Thaler, J; Hufnagl, C; Gampenrieder, SP; Ressler, S; Rinnerthaler, G; Ulmer, H; Greil, R
ONKOLOGIE. 2013; 36: 159-159.
Abstracts (Zeitschrift)
"ABCSG C-07 EXERCISE - Pilot study": Endurance exercise to reduce the recurrence rate after adjuvant chemotherapy for colorectal cancer
Piringer, G; Fridrik, M; Fridrik, A; Zabernigg, A; Greil, R; Eisterer, W; Tschmelitsch, J; Lang, A; Gnant, M; Thaler, J
ONKOLOGIE. 2013; 36: 72-72.
Abstracts (Zeitschrift)
MESENCHYMAL STEM CELLS RETAIN THEIR PRO-OLIGODENDROGENIC ACTIVITY DURING AGING: A RATIONALE FOR AUTOLOGOUS TRANSPLANTATION IN MULTIPLE SCLEROSIS
Rivera, FJ; Wodnar, R; Feichtner, M; Oberbauer, E; Brachtl, G; Greil, R; Rohde, E; Franklin, RJM; Aigner, L
GLIA. 2013; 61: S52-S52.
Abstracts (Zeitschrift)
Two patients diagnosed with coexisting hematologic and oncologic BRAF V600E mutated malignancies. Which entity is really carrying the BRAF (V600E) mutation?
Schlick, K; Troch, M; Placher-Sorko, G; Faber, V; Neureiter, D; Greil, R; Hopfinger, G
ONKOLOGIE. 2013; 36: 168-169.
Abstracts (Zeitschrift)
Updated report of the Austrian CML registry
Schmidt, S; Burgstaller, S; Linkesch, W; Greil, R; Schlogl, E; Fridrik, M; Krieger, O; Petzer, A; Lang, A; Mitterer, M; Valent, P; Walder, A; Sliwa, T; Keil, F; Korger, M; Hausler, C; Woll, E; Oexle, H; Schnallinger, M; Pober, M; Rochau, U; Siebert, U; Thaler, J; Gastl, G
ONKOLOGIE. 2013; 36: 63-63.
Abstracts (Zeitschrift)
Antiapoptotic effects of p21 regarding its subcellular localization in arsenic trioxide induced apoptosis in CLL
Sifft, E; Hofbauer, JP; Asslaber, D; Hartmann, TN; Merkel, O; Greil, R
ONKOLOGIE. 2013; 36: 222-222.
Abstracts (Zeitschrift)
Influence of Body Mass Index on survival in indolent and Mantle-cell Lymphomas: Analysis of the StiL1 trial
Weiss, L; Melchardt, T; Egle, A; Hopfinger, G; Greil, R; Barth, J; Rummel, M
ONKOLOGIE. 2013; 36: 31-32.
Abstracts (Zeitschrift)

Herausgeberschaft von Sammelwerken

Aktuelle Diagnostik und Therapieoptionen bei aggressiven Lymphomen.

Hopfinger, G; Greil, R. (editor(s)). Bremen, London, Boston: UniMed Verlag; 2013. (ISBN: 978-3-8374-1407-3)

Beiträge in Sonstigen Zeitschriften

Management of immunosuppression in the treatment of chronic lymphocytic leukemia
Auberger, J; Greil, R
memo - Magazine of European Medical Oncology, 2013/1. 2013.
Lenalidomide/Rituximab Maintenance After Induction With Fludarabine/Rituximab In Combination With Escalating Doses Of Lenalidomide In Previously Untreated Chronic Lymphocytic Leukemia (CLL): The Revlirit CLL5 AGMT Phase I/II Study, Final Results
Egle, A; Steurer, M; Gassner, FJ; Geisberger, R; Melchardt, T; Pleyer, L; Weiss, L; Fridrik, MA; Thaler, J; Lang, A; Greil, R;
Blood (ASH Annual Meeting Abstracts). 2013. #4164:
Pertuzumab beim metastasierten HER2-positiven Mammakarzinom
GAMPENRIEDER, SP; GREIL, R; HUBALEK, M; RINNERTHALER, G; STEGER, GG
Journal of Medical Drug Reviews 2013. 2013. 3: 61-71.
Pertuzumab
GAMPENRIEDER, SP; GREIL, R; HUBALEK, M; RINNERTHALER, G; STEGER, GG
ArzneimittelPROFIL Pertuzumab, August 2013. 2013.
Bevacizumab Mammakarzinom.
GNANT, M; GAMPENRIEDER, SP; MARTH, C; PETRU, E; STEGER, G; RINNERTHALER, G; GREIL, R
ArzneimittelPROFIL Bevacizumab Mammakarzinom, April 2013. 2013.
Systemische Therapie des prämenopausalen Mammakarzinoms
Ressler, S; Greil, R;
Die Punkte. 2013.
Therapy with JAK 1/2 inhibitors for myelofibrosis
Romeder, F; Greil, R; Egle, A
memo - Magazine of European Medical Oncology, 2013/2. 2013.

2012

Beiträge in Fachzeitschriften

The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER).
Aapro, M; Molassiotis, A; Dicato, M; Peláez, I; Rodríguez-Lescure, Á; Pastorelli, D; Ma, L; Burke, T; Gu, A; Gascon, P; Roila, F;
Ann Oncol. 2012; 23(8):1986-1992
Originalarbeiten (Zeitschrift)
Canonical and noncanonical Hedgehog/GLI signaling in hematological malignancies.
Aberger, F; Kern, D; Greil, R; Hartmann, TN;
Vitam Horm. 2012; 88:2-54
Übersichtsarbeiten
What paths are open for tackling increasing azole resistance in Aspergillus in the clinic?
Auberger, J; Greil, R; Lass-Flörl, C;
Expert Rev Anti Infect Ther. 2012; 10(11):1229-1231
Editorials
First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study.
Bergh, J; Bondarenko, IM; Lichinitser, MR; Liljegren, A; Greil, R; Voytko, NL; Makhson, AN; Cortes, J; Lortholary, A; Bischoff, J; Chan, A; Delaloge, S; Huang, X; Kern, KA; Giorgetti, C;
J Clin Oncol. 2012; 30(9):921-929
Originalarbeiten (Zeitschrift)
Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group.
Dubsky, PC; Jakesz, R; Mlineritsch, B; Pöstlberger, S; Samonigg, H; Kwasny, W; Tausch, C; Stöger, H; Haider, K; Fitzal, F; Singer, CF; Stierer, M; Sevelda, P; Luschin-Ebengreuth, G; Taucher, S; Rudas, M; Bartsch, R; Steger, GG; Greil, R; Filipcic, L; Gnant, M;
J CLIN ONCOL. 2012; 30(7): 722-728.
Originalarbeiten (Zeitschrift)
Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkinxxxs lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial
Engert, A; Haverkamp, H; Kobe, C; Markova, J; Renner, C; Ho, A; Zijlstra, J; Kral, Z; Fuchs, M; Hallek, M; Kanz, L; Dohner, H; Dorken, B; Engel, N; Topp, M; Klutmann, S; Amthauer, H; Bockisch, A; Kluge, R; Kratochwil, C; Schober, O; Greil, R; Andreesen, R; Kneba, M; Pfreundschuh, M; Stein, H; Eich, HT; Muller, RP; Dietlein, M; Borchmann, P; Diehl, V
LANCET. 2012; 379(9828): 1791-1799.
Originalarbeiten (Zeitschrift)
Lipid profiles for etravirine versus efavirenz in treatment-naive patients in the randomized, double-blind SENSE trial.
Fätkenheuer, G; Duvivier, C; Rieger, A; Durant, J; Rey, D; Schmidt, W; Hill, A; van Delft, Y; Marks, S;
J Antimicrob Chemother. 2012; 67(3): 685-690.
Originalarbeiten (Zeitschrift)
Lysine residue at position 22 of the AID protein regulates its class switch activity.
Geisberger, R; Huemer, M; Gassner, FJ; Zaborsky, N; Egle, A; Greil, R;
PLoS One. 2012; 7(2):e30667
Originalarbeiten (Zeitschrift)
An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy.
Grünwald, V; Karakiewicz, PI; Bavbek, SE; Miller, K; Machiels, JP; Lee, SH; Larkin, J; Bono, P; Rha, SY; Castellano, D; Blank, CU; Knox, JJ; Hawkins, R; Anak, O; Rosamilia, M; Booth, J; Pirotta, N; Bodrogi, I;
Eur J Cancer. 2012; 48(3): 324-332.
Originalarbeiten (Zeitschrift)
A 55-year-old woman with locally advanced rectal cancer and a resectable synchronous hepatic metastasis: a case report.
Hohla, F; Mayer, P; Hutter, J; Meißnitzer, T; Greil, R;
memo - Magazine of European Medical Oncology. 2012; 5 (4): 273-276.
Fallberichte
Novel treatment avenues for peripheral T-cell lymphomas.
Hopfinger, G; Griessl, R; Sifft, E; Taylor, N; Kenner, L; Greil, R; Merkel, O;
Expert Opin Drug Discov. 2012; 7(12):1149-1163
Originalarbeiten (Zeitschrift)
Treating T-cell lymphoma: is there a light at the end of the tunnel?
Hopfinger, G; Merkel, O; Melchardt, T; Greil, R;
Magazine of European Medical Oncology. 2012; 5 (3): 174-177.
Originalarbeiten (Zeitschrift)
Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response.
Jäger, U; Fridrik, M; Zeitlinger, M; Heintel, D; Hopfinger, G; Burgstaller, S; Mannhalter, C; Oberaigner, W; Porpaczy, E; Skrabs, C; Einberger, C; Drach, J; Raderer, M; Gaiger, A; Putman, M; Greil, R;
Haematologica. 2012; 97(9):1431-1438
Originalarbeiten (Zeitschrift)
Chemokine-dependent B cell-T cell interactions in chronic lymphocytic leukemia and multiple myeloma - targets for therapeutic intervention?
Jöhrer, K; Hofbauer, SW; Zelle-Rieser, C; Greil, R; Hartmann, TN;
Expert Opin Biol Ther. 2012; 12(4):425-441
Originalarbeiten (Zeitschrift)
Antimyeloma activity of the sesquiterpene lactone cnicin: impact on Pim-2 kinase as a novel therapeutic target
Johrer, K; Obkircher, M; Neureiter, D; Parteli, J; Zelle-Rieser, C; Maizner, E; Kern, J; Hermann, M; Hamacher, F; Merkel, O; Wacht, N; Zidorn, C; Scheideler, M; Greil, R
J MOL MED. 2012; 90(6): 681-693.
Originalarbeiten (Zeitschrift)
First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer.
Köhne, CH; Hofheinz, R; Mineur, L; Letocha, H; Greil, R; Thaler, J; Fernebro, E; Gamelin, E; Decosta, L; Karthaus, M;
J Cancer Res Clin Oncol. 2012; 138(1):65-72
Originalarbeiten (Zeitschrift)
Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer.
Lang, I; Inbar, MJ; Kahán, Z; Greil, R; Beslija, S; Stemmer, SM; Kaufman, B; Zvirbule, Z; Steger, GG; Messinger, D; Brodowicz, T; Zielinski, C;
Eur J Cancer. 2012; 48(17):3140-3149
Originalarbeiten (Zeitschrift)
Actinomycin D induces p53-independent cell death and prolongs survival in high-risk chronic lymphocytic leukemia.
Merkel, O; Wacht, N; Sifft, E; Melchardt, T; Hamacher, F; Kocher, T; Denk, U; Hofbauer, JP; Egle, A; Scheideler, M; Schlederer, M; Steurer, M; Kenner, L; Greil, R;
Leukemia. 2012; 26(12):2508-2516
Originalarbeiten (Zeitschrift)
The role of biomarkers in the choice of therapy in triple negative breast cancer
Mlineritsch, B; Ressler, S; Greil, R
memo - Magazine of European Medical Oncology. 2012; 5: 101-104.
Übersichtsarbeiten
[Primary immune thrombocytopenia in adults: diagnostics and treatment consensus statement of the Austrian Society of Hematology and Oncology (ÖGHO)].
Pabinger, I; Gastl, G; Steurer, M; Sormann, S; Fillitz, M; Friedl, J; Geissler, D; Geissler, K; Greil, R; Knöbl, P; Kozek-Langenecker, S; Krippl, P; Kyrle, P; Lang, A; Linkesch, W; Ludwig, H; Müller, M; Panzer, S; Pittermann, E; Thaler, J; Weltermann, A;
WIEN KLIN WOCHENSCHR. 2012; 124(3-4): 111-123.
Originalarbeiten (Zeitschrift)
Continuous lenalidomide treatment for newly diagnosed multiple myeloma.
Palumbo, A; Hajek, R; Delforge, M; Kropff, M; Petrucci, MT; Catalano, J; Gisslinger, H; Wiktor-Jędrzejczak, W; Zodelava, M; Weisel, K; Cascavilla, N; Iosava, G; Cavo, M; Kloczko, J; Bladé, J; Beksac, M; Spicka, I; Plesner, T; Radke, J; Langer, C; Ben Yehuda, D; Corso, A; Herbein, L; Yu, Z; Mei, J; Jacques, C; Dimopoulos, MA;
N Engl J Med. 2012; 366(19):175-169
Originalarbeiten (Zeitschrift)
Influence of the American ODAC statement on Austrian bevacizumab prescribing practice for metastatic breast cancer.
Preusser, M; Fülöp, G; Berghoff, AS; Heinzl, H; Steger, GG; Greil, R; Zielinski, CC; Bartsch, R;
Oncologist. 2012; 17(7): e13-e17.
Originalarbeiten (Zeitschrift)
[Safety of immunosuppressants].
Psenak, O; Studnicka-Benke, A; Greil, R;
Z Rheumatol. 2012; 71(5):420-429
Originalarbeiten (Zeitschrift)
Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group
Reinacher-Schick, A; Schulmann, K; Modest, DP; Bruns, N; Graeven, U; Jaworska, M; Greil, R; Porschen, R; Arnold, D; Schmiegel, W; Tannapfel, A
BMC CANCER. 2012; 12: 349
Originalarbeiten (Zeitschrift)
LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases: a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial.
Schimanski, CC; Möhler, M; Schön, M; van Cutsem, E; Greil, R; Bechstein, WO; Hegewisch-Becker, S; von Wichert, G; Vöhringer, M; Heike, M; Heinemann, V; Peeters, M; Kanzler, S; Kasper, S; Overkamp, F; Schröder, J; Seehofer, D; Kullmann, F; Linz, B; Schmidtmann, I; Smith-Machnow, V; Gockel, I; Lang, H; Galle, PR;
BMC Cancer. 2012; 12:144
Originalarbeiten (Zeitschrift)
Prognostic Value of Number of Removed Lymph Nodes, Number of Involved Lymph Nodes, and Lymph Node Ratio in 7502 Breast Cancer Patients Enrolled onto Trials of the Austrian Breast and Colorectal Cancer Study Group (ABCSG)
Tausch, C; Taucher, S; Dubsky, P; Seifert, M; Reitsamer, R; Kwasny, W; Jakesz, R; Fitzal, F; Filipcic, L; Fridrik, M; Greil, R; Gnant, M
ANN SURG ONCOL. 2012; 19(6): 1808-1817.
Originalarbeiten (Zeitschrift)
Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study.
Thaler, J; Karthaus, M; Mineur, L; Greil, R; Letocha, H; Hofheinz, R; Fernebro, E; Gamelin, E; Baños, A; Köhne, CH;
BMC Cancer. 2012; 12: 438
Originalarbeiten (Zeitschrift)
Nilotinib as frontline and second-line therapy in chronic myeloid leukemia: open questions.
Valent, P; Gastl, G; Geissler, K; Greil, R; Hantschel, O; Lang, A; Linkesch, W; Lion, T; Petzer, AL; Pittermann, E; Pleyer, L; Thaler, J; Wolf, D;
Crit Rev Oncol Hematol. 2012; 82(3): 370-377.
Originalarbeiten (Zeitschrift)
Dose-Intensification in Early Unfavorable Hodgkinxxxs Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial
von Tresckow, B; Plutschow, A; Fuchs, M; Klimm, B; Markova, J; Lohri, A; Kral, Z; Greil, R; Topp, MS; Meissner, J; Zijlstra, JM; Soekler, M; Stein, H; Eich, HT; Mueller, RP; Diehl, V; Borchmann, P; Engert, A
J CLIN ONCOL. 2012; 30(9): 907-913.
Originalarbeiten (Zeitschrift)

Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen

Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: Results of a randomized phase III intergroup study (TML study).
Arnold, D; Andre, T; Bennouna, J; Sastre, J; Osterlund, PJ; Greil, R; Van Cutsem, E; Von Moos, R; Reyes-Rivera, I; Bendahmane, B; Kubicka, S
J CLIN ONCOL. 2012; 30(18):
Abstracts (Zeitschrift)
First Interim Efficacy and Safety Analysis of an International Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with Chemotherapy with or without Alemtuzumab and Consolidated by High Dose Therapy
d'Amore, F; Leppa, S; da Silva, MC; Relander, T; Brown, PD; Weidmann, E; Lauritzsen, GF; Pezzutto, A; Van Hoof, A; van Gelder, M; Doorduijn, JK; Wu, KL; Kluin-Nelemans, JC; Lugtenburg, PJ; Jankovska, M; Merup, M; Fagerli, UM; Walewski, J; Hagberg, H; Mariz, JM; Hansen, PB; Nosslinger, T; Janssens, A; Brandefors, L; Demuynck, H; Schaafsma, MR; Christiansen, I; Salek, D; Jyrkkio, S; Prochazka, V; Zijlstra, J; Bohmer, L; Greil, R; Stevens, W; Fijnheer, R; Kooy, MV; Grube, M; Hopfinger, G; Van den Neste, E; Jantunen, E; Trumper, L; Wulf, G; Altmann, B; Ziepert, M; Loeffler, M; Toldbod, H
BLOOD. 2012; 120(21):
Abstracts (Zeitschrift)
Abstract S4-3: The EndoPredict score identifies late distant metastases in ER+/HER2− breast cancer patients
Dubsky, P; Brase, JC; Fisch, K; Jakesz, R; Singer, CF; Greil, R; Dietze, O; Weber, KE; Petry, C; Kronenwett, R; Rudas, M; Knauer, M; Gnant, M; Filipits, M;
Cancer Research. 2012; 72(24 Suppl.):-Thirty-Fifth Annual CTRC‐AACR San Antonio Breast Cancer Symposium; 04.-08.12.2012; San Antonio, TX.
Abstracts (Zeitschrift)
T Cell Exhaustion Contributes to Immune Evasion in Chronic Lymphocytic Leukaemia
Gassner, FJ; Zaborsky, N; Neureiter, D; Huemer, M; Egle, A; Hartmann, TN; Greil, R; Geisberger, R
BLOOD. 2012; 120(21):
Abstracts (Zeitschrift)
BIOMARKER (BM) RESULTS FROM THE PHASE III AVEREL TRIAL OF 1ST-LINE BEVACIZUMAB (BV), TRASTUZUMAB (H) plus DOCETAXEL (T) FOR HER2-POSITIVE LOCALLY RECURRENT/METASTATIC BREAST CANCER (LR/MBC)
Gianni, L; Chan, A; Mansutti, M; Pivot, X; Greil, R; Provencher, L; Prot, S; Moore, N; Scherer, SJ; Pallaud, C
ANN ONCOL. 2012; 23: 531-532.
Abstracts (Zeitschrift)
AOP2014, a Novel Peg-Proline-Interferon Alpha-2b with Improved Pharmacokinetic Properties, Is Safe and Well Tolerated and Shows Promising Efficacy in Patients with Polycythemia Vera (PV)
Gisslinger, H; Kralovics, R; Gisslinger, B; Lechner, D; Buxhofer-Ausch, V; Strecker, K; Gastl, G; Willenbacher, E; Greil, R; Egle, A; Melchardt, T; Burgstaller, S; Schloegl, E; Tarmann, FJ; Zoerer, M; Klade, C; Zahriychuk, O; Thaler, J
BLOOD. 2012; 120(21):
Abstracts (Zeitschrift)
Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: results of a randomised phase III intergroup study initiated by the AIO and AGMT (ML18147)
Greil, R; Arnold, D; Hegewisch-Becker, S; Freier, W; Steffens, CC; Bertram, M; Schlichting, C; Andel, J; Taylor, M; Makrutzki, M; Kubicka, S
ONKOLOGIE. 2012; 35: 254-254.
Abstracts (Zeitschrift)
IMPACT OF NUMBER OF PREVIOUS TREATMENT LINES AND PRE-TREATMENT WITH BORTEZOMIB OR LENALIDOMIDE ON EFFICACY OF BORTEZOMIB-BENDAMUSTINE-DEXAMETHASONE (BBD) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM)
Ludwig, H; Kasparu, H; Leitgeb, C; Greil, R; Rauch, E; Linkesch, W; Zojer, N; Pour, L; Fillitz, M; Adam, Z
ANN ONCOL. 2012; 23: 348-349.
Abstracts (Zeitschrift)
Feasibility of anthracycline based treatment in unselected elderly DLBCL patients
Melchardt, T; Weiss, L; Hufnagl, C; Neureiter, D; Kemmerling, R; Hopfinger, G; Greil, R; Egle, A
ONKOLOGIE. 2012; 35: 86-87.
Abstracts (Zeitschrift)
Treatment of Aggressive B-Cell Lymphoma in the Elderly: The Influence of SNPs Affecting Pharmacodynamics Is Different Compared to Younger Patient
Melchardt, T; Weiss, L; Hufnagl, C; Neureiter, D; Kemmerling, R; Morre, P; Boekstegers, A; Hopfinger, G; Greil, R; Egle, A
BLOOD. 2012; 120(21):
Abstracts (Zeitschrift)
Complications of 5-azacytidine: Three cases of severe colitis in a single center cohort
Melchardt, T; Weiss, L; Pleyer, L; Steinkirchner, S; Greil, R; Egle, A
ONKOLOGIE. 2012; 35: 149-149.
Abstracts (Zeitschrift)
Influence of the American ODAC statement upon Austrian prescription practice of bevacizumab in metastatic breast cancer
Preusser, M; Fulop, G; Berghoff, AS; Heinzl, H; Steger, GG; Greil, R; Zielinski, CC; Bartsch, R
ONKOLOGIE. 2012; 35: 66-66.
Abstracts (Zeitschrift)
RITUXIMAB PLUS SUBCUTANEOUS CLADRIBINE IN PATIENTS WITH EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF THE MUCOSA ASSOCIATED TISSUE (MALT-LYMPHOMA): A PHASE II STUDY BY THE AGMT (ARBEITSGEMEINSCHAFT MEDIKAMENTOSE TUMORTHERAPIE)
Troch, M; Kiesewetter, B; Willenbacher, W; Willenbacher, E; Zebisch, A; Linkesch, W; Fridrik, MA; Mullauer, L; Greil, R; Raderer, M
ANN ONCOL. 2012; 23: 352-352.
Abstracts (Zeitschrift)

Beiträge in Sonstigen Zeitschriften

KCa3.1 Blockers Inhibit Cell Proliferation in Chronic Lymphocytic Leukemia
Groessinger, EM; Weiss, L; Hinterseer, E; Schmoelzer, J; Oberascher, K; Asslaber, A; Egle, A; Hartmann, TN; Greil, R; Kerschbaum, HH
Blood (ASH Annual Meeting Abstracts) 2012. 2012. #3887:
Bendamustin-rituximab induction followed by observation or rituximab maintenance for newly diagnosed patients with Waldenstrom’s macroglobulinemia: results from a prospective randomized, multicenter study (StiL NHL 7-2008-MAINTAIN-; Cli nicalTrials. gov I dentifier: NCT00877214)
Rummel, MJ; Lerchenmuller, C; Greil, R; Gorner, M; Hensel, M; Engel, E; Jaeger, U; Breuer, F; Hertenstein, B; Prummer, O; Buske, C; Barth, J; Burchardt, AC; Brugger, W;
Blood, 21 . 2012. 120: 2739-2739.

2011

Beiträge in Fachzeitschriften

Treatment of invasive aspergillosis in cancer patients.
Auberger, J; Russ, G; Greil, R; Egle, A;
memo - Magazine of European Medical Oncology. 2011; 4 (4): 266-272.
Übersichtsarbeiten
Adjuvant Sequencing of Tamoxifen and Anastrozole Is Superior to Tamoxifen Alone in Postmenopausal Women with Low Proliferating Breast Cancer
Bago-Horvath, Z; Rudas, M; Dubsky, P; Jakesz, R; Singer, CF; Kemmerling, R; Greil, R; Jelen, A; Bohm, G; Jasarevic, Z; Haid, A; Gruber, C; Postlberger, S; Filipits, M; Gnant, M
CLIN CANCER RES. 2011; 17(24): 7828-7834.
Originalarbeiten (Zeitschrift)
Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin"s lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group.
Borchmann, P; Haverkamp, H; Diehl, V; Cerny, T; Markova, J; Ho, AD; Eich, HT; Mueller-Hermelink, HK; Kanz, L; Greil, R; Rank, A; Paulus, U; Smardova, L; Huber, C; Dörken, B; Nerl, C; Krause, SW; Mueller, RP; Fuchs, M; Engert, A;
J Clin Oncol. 2011; 29(32): 423-442.
Originalarbeiten (Zeitschrift)
Differential bone marrow homing capacity of VLA-4 and CD38 high expressing chronic lymphocytic leukemia cells.
Brachtl, G; Sahakyan, K; Denk, U; Girbl, T; Alinger, B; Hofbauer, SW; Neureiter, D; Hofbauer, JP; Egle, A; Greil, R; Hartmann, TN;
PLoS One. 2011; 6(8):e23758
Originalarbeiten (Zeitschrift)
Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials.
Darby, S; McGale, P; Correa, C; Taylor, C; Arriagada, R; Clarke, M; Cutter, D; Davies, C; Ewertz, M; Godwin, J; Gray, R; Pierce, L; Whelan, T; Wang, Y; Peto, R;
Lancet. 2011; 378(9804): 1707-1716.
Übersichtsarbeiten
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.
Davies, C; Godwin, J; Gray, R; Clarke, M; Cutter, D; Darby, S; McGale, P; Pan, HC; Taylor, C; Wang, YC; Dowsett, M; Ingle, J; Peto, R;
Lancet. 2011; 378(9793): 771-784.
Originalarbeiten (Zeitschrift)
Successful alemtuzumab retreatment in progressive B-cell chronic lymphocytic leukemia: a multicenter survey in 30 patients.
Fiegl, M; Falkner, F; Steurer, M; Zojer, N; Hopfinger, G; Haslbauer, F; Winder, G; Voskova, D; Andel, J; Lang, A; Brychtova, Y; Mayer, J; Greil, R; Gastl, G;
Ann Hematol. 2011; 90(9):1083-1091
Originalarbeiten (Zeitschrift)
A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors
Filipits, M; Rudas, M; Jakesz, R; Dubsky, P; Fitzal, F; Singer, CF; Dietze, O; Greil, R; Jelen, A; Sevelda, P; Freibauer, C; Muller, V; Janicke, F; Schmidt, M; Kolbl, H; Rody, A; Kaufmann, M; Schroth, W; Brauch, H; Schwab, M; Fritz, P; Weber, KE; Feder, IS; Hennig, G; Kronenwett, R; Gehrmann, M; Gnant, M
CLIN CANCER RES. 2011; 17(18): 6012-6020.
Originalarbeiten (Zeitschrift)
Fludarabine modulates composition and function of the T cell pool in patients with chronic lymphocytic leukaemia.
Gassner, FJ; Weiss, L; Geisberger, R; Hofbauer, JP; Egle, A; Hartmann, TN; Greil, R; Tinhofer, I;
Cancer Immunol Immunother. 2011; 60(1):7-85
Originalarbeiten (Zeitschrift)
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.
Gnant, M; Mlineritsch, B; Stoeger, H; Luschin-Ebengreuth, G; Heck, D; Menzel, C; Jakesz, R; Seifert, M; Hubalek, M; Pristauz, G; Bauernhofer, T; Eidtmann, H; Eiermann, W; Steger, G; Kwasny, W; Dubsky, P; Hochreiner, G; Forsthuber, EP; Fesl, C; Greil, R;
LANCET ONCOL. 2011; 12(7): 63-41.
Originalarbeiten (Zeitschrift)
Liposomal cytarabine is effective and tolerable in the treatment of central nervous system relapse of acute lymphoblastic leukemia and very aggressive lymphoma.
Gökbuget, N; Hartog, CM; Bassan, R; Derigs, HG; Dombret, H; Greil, R; Hernández-Rivas, JM; Huguet, F; Intermesoli, T; Jourdan, E; Junghanss, C; Leimer, L; Moreno, MJ; Reichle, A; Ribera, J; Schmid, M; Serve, H; Stelljes, M; Stuhlmann, R; Hoelzer, D;
Haematologica. 2011; 96(2): 238-244.
Originalarbeiten (Zeitschrift)
Combination therapy of lapatinib and Capecitabine for ErbB2-positive metastatic or locally advanced breast cancer: results from the Lapatinib Expanded Access Program (LEAP) in Central and Eastern Europe.
Greil, R; Borštnar, S; Petráková, K; Marcou, Y; Pikiel, J; Wojtukiewicz, MZ; Koza, I; Steger, GG; Linn, M; Das Gupta, A; Cwiertka, K;
Onkologie. 2011; 34(5): 233-238.
Originalarbeiten (Zeitschrift)
Efficacy of temsirolimus after previous treatment with sunitinib, sorafenib or everolimus in advanced renal cell cancer.
Grundbichler, M; Mlineritsch, B; Ressler, S; Moik, M; Kappacher, A; Rosenlechner, S; Greil, R;
Oncology. 2011; 80(1-2): 3-41.
Originalarbeiten (Zeitschrift)
Development of CLL in the TCL1 transgenic mouse model is associated with severe skewing of the T-cell compartment homologous to human CLL.
Hofbauer, JP; Heyder, C; Denk, U; Kocher, T; Holler, C; Trapin, D; Asslaber, D; Tinhofer, I; Greil, R; Egle, A;
Leukemia. 2011; 25(9): 1452-1458.
Originalarbeiten (Zeitschrift)
Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials.
Hofer, S; Elandt, K; Greil, R; Hottinger, AF; Huber, U; Lemke, D; Marosi, C; Ochsenbein, A; Pichler, J; Roelcke, U; Weder, P; Zander, T; Wick, W; Weller, M;
Acta Oncol. 2011; 50(5): 630-635.
Originalarbeiten (Zeitschrift)
Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases.
Lin, NU; Eierman, W; Greil, R; Campone, M; Kaufman, B; Steplewski, K; Lane, SR; Zembryki, D; Rubin, SD; Winer, EP;
J Neurooncol. 2011; 105(3): 613-620.
Originalarbeiten (Zeitschrift)
ASH Report. Novel agents in diffuse large B-cell lymphoma: A short update including ASH 2010.
Melchardt, T; Hofbauer, SW; Greil, R; Hopfinger, G
memo - Magazine of European Medical Oncology. 2011; 4: 120-123.
Übersichtsarbeiten
Novel Therapeutic Options in Anaplastic Large Cell Lymphoma: Molecular Targets and Immunological Tools
Merkel, O; Hamacher, F; Sifft, E; Kenner, L; Greil, R
MOL CANCER THER. 2011; 10(7): 1127-1136.
Übersichtsarbeiten
Preoperative oxaliplatin, capecitabine, and external beam radiotherapy in patients with newly diagnosed, primary operable, cT₃NxM0, low rectal cancer: a phase II study.
Ofner, D; Devries, AF; Schaberl-Moser, R; Greil, R; Rabl, H; Tschmelitsch, J; Zitt, M; Kapp, KS; Fastner, G; Keil, F; Eisterer, W; Jäger, R; Offner, F; Gnant, M; Thaler, J;
Strahlenther Onkol. 2011; 187(2): 100-107.
Originalarbeiten (Zeitschrift)
Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial.
Pfeiler, G; Königsberg, R; Fesl, C; Mlineritsch, B; Stoeger, H; Singer, CF; Pöstlberger, S; Steger, GG; Seifert, M; Dubsky, P; Taucher, S; Samonigg, H; Bjelic-Radisic, V; Greil, R; Marth, C; Gnant, M;
J Clin Oncol. 2011; 29(19): 2653-2659.
Originalarbeiten (Zeitschrift)
Infusion reactions to the chimeric EGFR inhibitor cetuximab-change to the fully human anti-EGFR monoclonal antibody panitumumab is safe
Resch, G; Schaberl-Moser, R; Kier, P; Kopetzky, G; Scheithauer, W; Sliwa, T; Greil, R; Nosslinger, T; Mayrbaurl, B; Thaler, J
ANN ONCOL. 2011; 22(2): 486-U251.
Letter
Zoledronic acid for adjuvant use in patients with breast cancer.
Ressler, S; Mlineritsch, B; Greil, R;
Expert Rev Anticancer Ther. 2011; 11(3): 333-349.
Übersichtsarbeiten
Sentinel Node Biopsy After Primary Chemotherapy in Breast Cancer: A Note of Caution from Results of ABCSG-14
Tausch, C; Steger, GG; Haid, A; Jakesz, R; Fridrik, MA; Reitsamer, R; Postlberger, S; Lang, A; Gnant, M; Greil, R
BREAST J. 2011; 17(3): 230-238.
Originalarbeiten (Zeitschrift)
Raltegravir in pregnancy: a case series presentation.
Taylor, N; Touzeau, V; Geit, M; Gisinger, M; Egle, A; Greil, R; Rieger, A; Zangerle, R;
Int J STD AIDS. 2011; 22(6): 358-360.
Fallberichte
Regulatory T cells predict the time to initial treatment in early stage chronic lymphocytic leukemia.
Weiss, L; Melchardt, T; Egle, A; Grabmer, C; Greil, R; Tinhofer, I;
Cancer. 2011; 117(10):2163-2169
Originalarbeiten (Zeitschrift)
Complete remission of Waldenström macroglobulinemia with azacitidine and rituximab.
Weiss, L; Melchardt, T; Neureiter, D; Kemmerling, R; Moshir, S; Pleyer, L; Greil, R; Egle, A;
J CLIN ONCOL. 2011; 29(24): e696-e698.
Fallberichte
Oxaliplatin, irinotecan and cetuximab in advanced gastric cancer. A multicenter phase II trial (Gastric-2) of the Arbeitsgemeinschaft Medikamentose Tumortherapie (AGMT).
Wöll, E; Greil, R; Eisterer, W; Bechter, O; Fridrik, MA; Grünberger, B; Zabernigg, A; Mayrbäurl, B; Russ, G; Dlaska, M; Obrist, P; Thaler, J;
Anticancer Res. 2011; 31(12): 4439-4443.
Originalarbeiten (Zeitschrift)

Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen

DOSE-ESCALATION WITH BEACOPP ESCALATED IS SUPERIOR TO ABVD IN THE COMBINED-MODALITY TREATMENT OF EARLY UNFAVORABLE HODGKIN LYMPHOMA (HL): FINAL ANALYSIS OF THE GERMAN HODGKIN STUDY GROUP (GHSG) HD14 TRIAL
Borchmann, P; Diehl, V; Plutschow, A; Von Tresckow, B; Markova, J; Hitz, F; Kra, Z; Greil, R; Topp, MS; Villalobos, M; Zijlstra, JM; Sokler, M; Fuchs, M; Engert, A
ANN ONCOL. 2011; 22: 180-180.
Abstracts (Zeitschrift)
R-CHOP plus thalidomide for previously untreated patients with mantle cell lymphoma (AGMT NHL-11 trial)
Drach, J; Hopfinger, G; Fridrik, M; Greil, R; Thaler, J; Willenbacher, W; Lang, A; Jager, U; Raderer, M
ONKOLOGIE. 2011; 34: 75-75.
Abstracts (Zeitschrift)
CLL CELLS INDUCE CLONAL T CELL SKEWING AND SUBSETSHIFTING IN THE MURINE TCL1 TRANSGENIC CHRONIC LYMPHOCYTIC LEUKEMIA MODEL
Egle, A; Pinon-Hofbauer, J; Heyder, C; Denk, U; Kocher, T; Holler, C; Trapin, D; Asslaber, D; Tinhofer, I; Greil, R
ANN ONCOL. 2011; 22: 144-144.
Abstracts (Zeitschrift)
A Combination of Fludarabine/Rituximab with Escalating Doses of Lenalidomide in Previously Untreated Chronic Lymphocytic Leukemia (CLL): The REVLIRIT CLL5 AGMT Phase I/II Study, Clinical and Exploratory Analyses of Induction Results
Egle, A; Steurer, M; Gassner, F; Geisberger, R; Melchardt, T; Weiss, L; Fridrik, MA; Thaler, J; Lang, A; Greil, R
BLOOD. 2011; 118(21): 135-136.
Abstracts (Zeitschrift)
CD44-hyaluronan interactions in the pathophysiology of chronic lymphocytic leukemia - regulation by cell activation
Girbl, T; Asslaber, D; Brachtl, G; Denk, U; Weiss, L; Naor, D; Greil, R; Hartmann, TN
ONKOLOGIE. 2011; 34: 140-140.
Abstracts (Zeitschrift)
Open-Label, Prospective, Multicentre, Phase I/II Study of AOP2014, a Novel PEG-Proline-Interferon Alpha-2b in Patients with Polycythemia Vera: Update from an Ongoing Study
Gisslinger, H; Kralovics, R; Schoder, R; Gisslinger, B; Buxhofer-Ausch, V; Strecker, K; Wolf, D; Willenbacher, E; Greil, R; Egle, A; Melchardt, T; Burgstaller, S; Tarmann, FJ; Wachter, C; Zahriycick, O; Thaler, J
BLOOD. 2011; 118(21): 762-762.
Abstracts (Zeitschrift)
62-Month follow-up of ABCSG-12: Adjuvant endocrine therapy, alone or in combination with zoledronic acid, in premenopausal patients with endocrine-responsive early breast cancer
Gnant, M; Mlineritsch, B; Stoeger, H; Luschin-Ebengreuth, G; Poestlberger, S; Steger, G; Jakesz, R; Singer, C; Eidtmann, H; Greil, R
BONE. 2011; 48(1): S17-S17.
Abstracts (Zeitschrift)
The oncogenic miR-17-92 cluster and miR-155 define ALK status in anaplastic large cell lymphoma
Griessl, R; Hamacher, F; Sifft, E; Scheideler, M; Kenner, L; Greil, R; Merkel, O
ONKOLOGIE. 2011; 34: 135-135.
Abstracts (Zeitschrift)
Clonal Diversity of the T Cell Repertoire Predicts Disease Progression in Chronic Lymphocytic Leukaemia
Holler, C; Zaborsky, N; Hofbauer, JP; Kocher, T; Trapin, D; Asslaber, D; Greil, R; Egle, A
BLOOD. 2011; 118(21): 365-365.
Abstracts (Zeitschrift)
PHASE II TRIAL OF CONTINUOUS SUNITINIB IN PATIENTS WITH RECURRENT OR PROGRESSIVE GLIOBLASTOMA (SURGE 01-07)
Hutterer, M; Martha, N; Sabine, E; Thaddaus, G; Florian, S; Christine, M; Stefan, O; Richard, G; Martin, M; Johanna, B; Jochen, T; Ullrich, H; Wolfgang, W; Peter, V; Gunther, S
NEURO-ONCOLOGY. 2011; 13: 88-88.
Abstracts (Zeitschrift)
Lower incidence of BCR-ABL mutations and improved molecular response kinetics in newly diagnosed CML patients treated with nilotinib compared with imatinib
Muller, MC; le Coutre, P; Gattermann, N; Scheid, C; Al-Ali, HK; Ottmann, OG; Duyster, J; Blumenstengel, K; Brummendorf, TH; Greil, R; Chalandon, Y; Valent, P; Stegelmann, F; Kneba, M; Schafhausen, P; Saussele, S; Frank, O; Larson, RA; Saglio, G; Hochhaus, A; Lange, T
ONKOLOGIE. 2011; 34: 266-266.
Abstracts (Zeitschrift)
Activity of Azacitidine in 26 Unselected, Consecutive CMML Patients Included in the Austrian Azacitidine Registry (AAR) of the AGMT-Study Group
Pleyer, L; Stauder, R; Burgstaller, S; Schreder, M; Tinchon, C; Pfeilstocker, M; Steinkirchner, S; Melchardt, T; Mitrovic, M; Girschikofsky, M; Lang, A; Krippl, P; Egle, A; Sliwa, T; Linkesch, W; Fridrik, MA; Greil, R
BLOOD. 2011; 118(21): 747-747.
Abstracts (Zeitschrift)
Tumor load reduction and prolongation of overall-survival by actinomycin D in a murine model of high-risk chronic lymphocytic leukemia
Wacht, N; Sifft, E; Melchardt, T; Hamacher, F; Denk, U; Pinon-Hofbauer, J; Egle, A; Kocher, T; Steurer, M; Greil, R; Merkel, O
ONKOLOGIE. 2011; 34: 141-141.
Abstracts (Zeitschrift)

Beiträge in Sonstigen Zeitschriften

VEGF, PARP, mTOR, EGFR und PI3K beim HER2-negativen Mammakarzinom
Gampenrieder, SP; Mlineritsch, B; Greil, R.
Universum für Innere Medizin 2011. 2011. 4: 79-80.
S4-8: First results of AVEREL, a randomized phase III trial to evaluate bevacizumab (BEV) in combination with trastuzumab (H)+ docetaxel (DOC) as first-line therapy for HER2− positive locally recurrent/metastatic breast cancer (LR/mBC)
Gianni, L; Romieu, G; Lichinitser, M; Serrano, S; Mansutti, M Pivot, X; Smirnova, I; Moliterni, A; Andre, F; Chan, A; Lipatov, O; Chan, S; Wardley, A; Greil, R; Provencher, L; Moore, N; Prot, S; Semiglazov, V;
Cancer Research, 24 Supplement . 2011. 71: 4-8.
S1-2: Long-Term Follow-Up in ABCSG-12: Significantly Improved Overall Survival with Adjuvant Zoledronic Acid in Premenopausal Patients with Endocrine-Receptor–Positive Early Breast Cancer.
Gnant, M; Mlineritsch, B; Luschin-Ebengreuth, G; Stoeger, H; Dubsky, P; Jakesz, R; Singer, C, Eidtmann, H; Fesl, C; Eiermann, W; Marth, C; Greil, R;
Cancer Research, 24 Supplement . 2011. 71: 1-2.
Bedeutung des RANK / RANK-Ligand Systems beim Mammakarzinom: Biologische Grundlagen.
Ressler, S; Mlineritsch, B; Greil, R;
Universum Innere Medizin. 2011.
Bisphosphonate in der Therapie des Mammakarzinoms
Ressler, S; Mlineritsch, B; Greil, R;
MEDIUM. 2011. 3: 26-30.
Parp Inhibitoren
Ressler, S; Mlineritsch, B; Greil, R;
Universum Innere Medizin. 2011.

2010

Beiträge in Fachzeitschriften

MicroRNAs as biomarkers for the diagnosis and prognosis of human cancer.
Asslaber, D; Pinon Hofbauer, J; Greil, R; Egle, A
Journal of nucleic acids investigation. 2010; Dec 1, 1(1): 76-80.
Originalarbeiten (Zeitschrift)
microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia.
Asslaber, D; Piñón, JD; Seyfried, I; Desch, P; Stöcher, M; Tinhofer, I; Egle, A; Merkel, O; Greil, R;
Blood. 2010; 115(21):4191-4197
Originalarbeiten (Zeitschrift)
Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast.
Correa, C; McGale, P; Taylor, C; Wang, Y; Clarke, M; Davies, C; Peto, R; Bijker, N; Solin, L; Darby, S;
J Natl Cancer Inst Monogr. 2010; 2010(41): 162-177.
Übersichtsarbeiten
Evidence for the conversion of docetaxel into 7"-epidocetaxel in patients receiving Taxotere-based conventional chemotherapy.
Czejka, M; Greil, R; Ulsperger, E; Schnait, H; Kienesberger, K; Brumnik, T; Farkouh, A; Schierholz, J;
Int J Clin Pharmacol Ther. 2010; 48(7): 483-484.
Abstracts (Zeitschrift)
Inhibition of GLI, but not Smoothened, induces apoptosis in chronic lymphocytic leukemia cells.
Desch, P; Asslaber, D; Kern, D; Schnidar, H; Mangelberger, D; Alinger, B; Stoecher, M; Hofbauer, SW; Neureiter, D; Tinhofer, I; Aberger, F; Hartmann, TN; Greil, R;
Oncogene. 2010; 29(35): 488-495.
Originalarbeiten (Zeitschrift)
Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin"s lymphoma: final analysis of the German Hodgkin Study Group HD11 trial.
Eich, HT; Diehl, V; Görgen, H; Pabst, T; Markova, J; Debus, J; Ho, A; Dörken, B; Rank, A; Grosu, AL; Wiegel, T; Karstens, JH; Greil, R; Willich, N; Schmidberger, H; Döhner, H; Borchmann, P; Müller-Hermelink, HK; Müller, RP; Engert, A;
J Clin Oncol. 2010; 28(27): 4199-4206.
Originalarbeiten (Zeitschrift)
Reduced treatment intensity in patients with early-stage Hodgkin"s lymphoma.
Engert, A; Plütschow, A; Eich, HT; Lohri, A; Dörken, B; Borchmann, P; Berger, B; Greil, R; Willborn, KC; Wilhelm, M; Debus, J; Eble, MJ; Sökler, M; Ho, A; Rank, A; Ganser, A; Trümper, L; Bokemeyer, C; Kirchner, H; Schubert, J; Král, Z; Fuchs, M; Müller-Hermelink, HK; Müller, RP; Diehl, V;
N Engl J Med. 2010; 363(7): 640-652.
Originalarbeiten (Zeitschrift)
Clinical outcome of pretreated B-cell chronic lymphocytic leukemia following alemtuzumab therapy: a retrospective study on various cytogenetic risk categories
Fiegl, M; Erdel, M; Tinhofer, I; Brychtova, Y; Panovska, A; Doubek, M; Eigenberger, K; Fonatsch, C; Hopfinger, G; Muhlberger, H; Zabernigg, A; Falkner, F; Gastl, G; Mayer, J; Greil, R
ANN ONCOL. 2010; 21(12): 2410-2419.
Originalarbeiten (Zeitschrift)
Dose-dense therapy improves survival in aggressive non-Hodgkin"s lymphoma.
Fridrik, MA; Hausmaninger, H; Lang, A; Drach, J; Krieger, O; Geissler, D; Michlmayr, G; Ulsperger, E; Chott, A; Oberaigner, W; Greil, R
ANN HEMATOL. 2010; 89(3): 273-282.
Originalarbeiten (Zeitschrift)
Modifying akt signaling in B-cell chronic lymphocytic leukemia cells.
Hofbauer, SW; Piñón, JD; Brachtl, G; Haginger, L; Wang, W; Jöhrer, K; Tinhofer, I; Hartmann, TN; Greil, R;
Cancer Res. 2010; 70(18):7336-7344
Originalarbeiten (Zeitschrift)
Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study.
Ludwig, H; Adam, Z; Hajek, R; Greil, R; Tóthová, E; Keil, F; Autzinger, EM; Thaler, J; Gisslinger, H; Lang, A; Egyed, M; Womastek, I; Zojer, N;
J Clin Oncol. 2010; 28(30): 4635-4641.
Originalarbeiten (Zeitschrift)
An uncommon cause of anaemia: Sheehan"s syndrome.
Melchardt, T; Namberger, K; Weiss, L; Egle, A; Faber, V; Greil, R;
WIEN KLIN WOCHENSCHR. 2010; 122(23-24): 717-719.
Fallberichte
Interdependent regulation of p53 and miR-34a in chronic lymphocytic leukemia.
Merkel, O; Asslaber, D; Piñón, JD; Egle, A; Greil, R;
Cell Cycle. 2010; 9(14):2764-2768
Originalarbeiten (Zeitschrift)
Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK- anaplastic large-cell lymphoma.
Merkel, O; Hamacher, F; Laimer, D; Sifft, E; Trajanoski, Z; Scheideler, M; Egger, G; Hassler, MR; Thallinger, C; Schmatz, A; Turner, SD; Greil, R; Kenner, L;
Proc Natl Acad Sci U S A. 2010; 107(37):16228-16233
Originalarbeiten (Zeitschrift)
Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value.
Michlmayr, A; Bachleitner-Hofmann, T; Baumann, S; Marchetti-Deschmann, M; Rech-Weichselbraun, I; Burghuber, C; Pluschnig, U; Bartsch, R; Graf, A; Greil, R; Allmaier, G; Steger, G; Gnant, M; Bergmann, M; Oehler, R;
Br J Cancer. 2010; 103(8): 1201-1208.
Originalarbeiten (Zeitschrift)
The Nationwide Austrian Aspergillus Registry: a prospective data collection on epidemiology, therapy and outcome of invasive mould infections in immunocompromised and/or immunosuppressed patients.
Perkhofer, S; Lass-Flörl, C; Hell, M; Russ, G; Krause, R; Hönigl, M; Geltner, C; Auberger, J; Gastl, G; Mitterbauer, M; Willinger, B; Knöbl, P; Resch, G; Waldner, R; Makrai, A; Hartmann, G; Girschikofsky, M; Greil, R;
Int J Antimicrob Agents. 2010; 36(6):531-536
Originalarbeiten (Zeitschrift)
Triple negative breast cancer
Ressler, S; Mlineritsch, B; Greil, R;
memo - Magazine of European Medical Oncology. 2010; 3: 185-189.
Übersichtsarbeiten
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.
Saglio, G; Kim, DW; Issaragrisil, S; le Coutre, P; Etienne, G; Lobo, C; Pasquini, R; Clark, RE; Hochhaus, A; Hughes, TP; Gallagher, N; Hoenekopp, A; Dong, M; Haque, A; Larson, RA; Kantarjian, HM;
NEW ENGL J MED. 2010; 362(24): 2251-2259.
Originalarbeiten (Zeitschrift)
PLZF/ZBTB16, a glucocorticoid response gene in acute lymphoblastic leukemia, interferes with glucocorticoid-induced apoptosis.
Wasim, M; Carlet, M; Mansha, M; Greil, R; Ploner, C; Trockenbacher, A; Rainer, J; Kofler, R
J STEROID BIOCHEM. 2010; 120(4-5): 218-227.
Originalarbeiten (Zeitschrift)
Short review – Management of Immune Thrombocytopenia in adults
Weiss, L; Greil, R
Magazine of European Medical Oncology. 2010; Volume 3, Issue 2: 69-72.
Übersichtsarbeiten

Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen

VLA-4 and CD38 in chronic lymphocytic leukemia - more than prognostic markers?
Brechtl, G; Denk, U; Pinon-Hofbauer, JD; Greil, R; Hartmann, TN
ONKOLOGIE. 2010; 33: 201-202.
Abstracts (Zeitschrift)
Final Analysis of Induction Treatment with Fludarabine, Cyclophosphamide Plus Rituximab (FCR) Followed by Fludarabine Plus Rituximab (FR) and Remission Maintenance Therapy with Rituximab In Previously Untreated B-Chronic Lymphocytic Leukemia (B-CLL): The Chairos AGMT CLL4/Roche ML18434 Study
Egle, A; Weiss, L; Melchardt, T; Gunsilius, E; Petzer, AL; Fridrik, M; Lang, A; Krieger, O; Thaler, J; Greil, R
BLOOD. 2010; 116(21): 593-594.
Abstracts (Zeitschrift)
Dose-Escalation with BEACOPP Escalated Is Superior to ABVD In the Combined-Modality Treatment of Early Unfavorable Hodgkin Lymphoma: Final Analysis of the German Hodgkin Study Group (GHSG) HD14 Trial
Engert, A; Borchmann, P; Pluetschow, A; von Tresckow, B; Markova, J; Hitz, F; Kral, Z; Greil, R; Topp, MS; Villalobos, M; Zijlstra, JM; Soekler, M; Stein, H; Eich, HT; Mueller, RP; Fuchs, M; Diehl, V
BLOOD. 2010; 116(21): 336-336.
Abstracts (Zeitschrift)
Is Liposome Encapsulated Doxorubicin Able to Reduce the Cardiotoxicity of Doxorubicin In the Treatment of DLBCL? A Randomised Study by the Austrian Working Party of Medical Oncology (AGMT-Study NHL-14)
Fridrik, M; Petzer, AL; Keil, F; Willenbacher, W; Jager, U; Lang, A; Andel, J; Krieger, O; Oberaigner, W; Greil, R
BLOOD. 2010; 116(21): 736-737.
Abstracts (Zeitschrift)
ADJUVANT ENDOCRINE THERAPY, ALONE OR IN COMBINATION WITH ZOLEDRONIC ACID (ZOL), IN PREMENOPAUSAL PATIENTS (PTS) WITH ENDOCRINE-RESPONSIVE EARLY BREAST CANCER (EBC): SUBGROUP ANALYSES OF ABCSG-12
Gnant, M; Mlineritsch, B; Stoeger, H; Luschin-Ebengreuth, G; Poestlberger, S; Steger, GG; Jakesz, R; Singer, CF; Eidtmann, H; Greil, R
ANN ONCOL. 2010; 21: 79-79.
Abstracts (Zeitschrift)
Role of miRNAs in ALK(+) and ALK(-) anaplastic large cell lymphoma
Hamacher, F; Laimer, D; Scheideler, M; Trajanoski, Z; Egger, G; Kenner, L; Greil, R; Merkel, O
ONKOLOGIE. 2010; 33: 209-209.
Abstracts (Zeitschrift)
Deletion of Puma and p21(Waf1) In Mice Deactivates p53-Induced Cell Death and Cell Cycle Arrest, but Protects Mice From Irradiation-Induced Lymphomagenesis by a Mechanism Involving Hemopoietic Stem Cell Quiescence
Hofbauer, JP; Holler, C; Denk, U; Asslaber, D; Fastner, G; Labi, V; Villunger, A; Greil, R; Egle, A
BLOOD. 2010; 116(21): 45-46.
Abstracts (Zeitschrift)
Targeting Pim-2, a novel survival protein of myeloma cells, kills malignant plasma cells
Johrer, K; Obkircher, M; Neureiter, D; Parteli, J; Hamacher, F; Merkel, O; Wacht, N; Zidorn, C; Scheideler, M; Greil, R
ONKOLOGIE. 2010; 33: 187-188.
Abstracts (Zeitschrift)
Enzastaurin kills human CLL cells regardless of clinical risk profile, but fails to prolong life in a murine CLL model
Kocher, T; Pinon, HJ; Holler, C; Denk, U; Greil, R; Egle, A
ONKOLOGIE. 2010; 33: 40-40.
Abstracts (Zeitschrift)
HETEROGENEOUS EXPRESSION PATTERN OF HEDGEHOG SIGNALLING PATHWAY IN HEMATOPOIESIS OF MYELODYSPLASTIC SYNDROME
Neureiter, D; Kemmerling, R; Alinger, B; Kiesslich, T; Faber, V; Stocher, M; Pleyer, L; Greil, R; Dietz, O
HAEMATOL-HEMATOL J. 2010; 95: 375-375.
Abstracts (Zeitschrift)
The role of the VLA-4 integrin in adhesion and survival of chronic lymphocytic leukemia (CLL) cells
Sahakyan, K; Hofbauer, S; Brachtl, G; Girbl, T; Henschler, R; Greil, R; Hartmann, TN
ONKOLOGIE. 2010; 33: 201-201.
Abstracts (Zeitschrift)
Antiapoptotic effects of p21 in arsenic trioxide induced apoptosis in CLL
Sifft, E; Asslaber, D; Schweiggl, S; Hamacher, F; Greil, R; Merkel, O
ONKOLOGIE. 2010; 33: 185-185.
Abstracts (Zeitschrift)
Independent prognostic factors for response: updated results of the ABCSG-24 study evaluating the addition of capecitabine to epirubicin-docetaxel neoadjuvant therapy for early breast cancer (EBC)
Steger, GG; Greil, R; Jakesz, R; Lang, A; Mlineritsch, B; Rudas, M; Marth, C; Stoeger, H; Singer, CF; Gnant, M
EJC SUPPL. 2010; 8(3): 60-60.
Abstracts (Zeitschrift)
ABCSG-24: EFFICACY OF ANTHRACYCLINE- AND TAXANE-BASED NEOADJUVANT THERAPY +/- CAPECITABINE (C) IN TRIPLE-NEGATIVE EARLY BREAST CANCER (TNBC)
Steger, GG; Greil, R; Jakesz, R; Mlineritsch, B; Lang, A; Rudas, M; Marth, C; Stoeger, H; Singer, CF; Gnant, M
ANN ONCOL. 2010; 21: 79-79.
Abstracts (Zeitschrift)
Non-pegylated liposomal doxorubicin in metastatic breast cancer (MBC) - Results from an Austrian post marketing surveillance programme
Steger, GG; Mlineritsch, B; Bartsch, R; Pluschnig, U; Petru, E; Peintinger, F; Sevelda, P; Greil, R
ONKOLOGIE. 2010; 33: 55-55.
Abstracts (Zeitschrift)

Originalbeiträge in Sammelwerk (Buchbeitrag)

Rare Clonal Myeloid Diseases
Melchardt, T; Weiss, L; Pleyer, L; Neureiter, D; Faber, V; Greil, R;
In: Greil, R; Pleyer, L; Faber, V; Neureiter, D (Eds.) editors(s). Chronic Myeloid Neoplasias and Clonal Overlap Syndromes. Springer; (ISBN: 978-3-211-79891-1)
Neue Therapie in Sicht.
Merkel, O; Kenner, L; Greil, R
In: SpringerMedizin. 22.09.2010 editors(s).
Primary Myelofibrosis (PMF) [Previously Chronic Idiopathic Mylofibrosis (CIMF), Myelofibrosis with Myeloid Metaplasia (MMM), Agnogenic Myeloid Metaplasia (AMM)].
Pleyer, L; Faber, V; Neureiter, D; Greil, R;
In: Greil, R; Pleyer, L; Neureiter, D; Faber, V (Ed.) editors(s). Chronic Myeloid Neoplasias and Clonal Overlap Syndromes.. p. 81-116.
Essential Thrombocythemia (ET).
Pleyer, L; Faber, V; Neureiter, D; Greil, R;
In: Greil, R; Pleyer, L; Neureiter, D; Faber, V (Ed.) editors(s). Chronic Myeloid Neoplasias and Clonal Overlap Syndromes.. p. 14-50.
Introduction to „Classic' Chronic Myeloproliferative Disoderes (CMPDs)- Molecular and Cellular Biology.
Pleyer, L; Greil, R;
In: Greil, R; Pleyer, L; Neureiter, D; Faber, V (Ed.) editors(s). Chronic Myeloid Neoplasias and Clonal Overlap Syndromes.. p. 1-13.
De novo 'Classic' Paroxysmal Nocturnal Hemoglobinuria (PNH) (Marchiafava-Micheli Syndrome).
Pleyer, L; Greil, R;
In: Greil, R; Pleyer, L; Neureiter, D; Faber, V (Ed.) editors(s). Chronic Myeloid Neoplasias and Clonal Overlap Syndromes.. p. 259-280.
Bewegung und Krebs.
Pleyer, L; Kappacher, A; Rosenlechner, S; Greil, R;
In: Braumann, KM; Stiller, N (Ed.) editors(s). Bewegungstherapie bei internistischen Erkrankungen.. p. 223-240.
Clonal Bone Marrow Failure Overlap Syndromes.
Pleyer, L; Neureiter, D; Faber, V; Greil, R;
In: Greil, R; Pleyer, L; Neureiter, D; Faber, V (Ed.) editors(s). Chronic Myeloid Neoplasias and Clonal Overlap Syndromes.. p. 281-288.
Myelodysplastic Syndromes (MDS).
Pleyer, L; Neureiter, D; Faber, V; Greil, R;
In: Greil, R; Pleyer, L; Neureiter, D; Faber, V (Ed.) editors(s). Chronic Myeloid Neoplasias and Clonal Overlap Syndromes.. p. 153-222.
Chronic Myelomonocytic Leukemia (CMML).
Pleyer, L; Neureiter, D; Faber, V; Greil, R;
In: Greil, R; Pleyer, L; Neureiter, D; Faber, V (Ed.) editors(s). Chronic Myeloid Neoplasias and Clonal Overlap Syndromes.. p. 223-234.
Polycythemia Vera (PV).
Pleyer, L; Neureiter, D; Greil, R;
In: Greil, R; Pleyer, L; Neureiter, D; Faber, V (Ed.) editors(s). Chronic Myeloid Neoplasias and Clonal Overlap Syndromes.. p. 51-80.

Herausgeberschaft von Sammelwerken

Chronic Myeloid Neoplasias and Clonal Overlap Syndromes.

Greil, R; Pleyer, L; Neureiter, D; Faber, V. (editor(s)). 2010.

Beiträge in Sonstigen Zeitschriften

The addition of cetuximab to cisplatin increases overall response rate (ORR) and progression-free survival (PFS) in metastatic triple-negative breast cancer (TNBC): results of a randomized phase II study (BALI-1)
Baselga, J, Gomez, P; Awada, A; Greil, R; Braga, S; Climent, MA; Wardley, A; Zubel, A; Groos, J; Kaufmann, B;
Annals of Oncology . 2010. 21: 96-96.
Sunitinib (SU) in combination with docetaxel (D) versus D alone for the first-line treatment of advanced breast cancer (ABC)
Bergh, J; Greil, R; Voytko, N; Makhson, A; Cortes, J; Lortholary, A; Huang, X; Giorgetti, C; Kern, KA; Lichinitser, M;
ASCO Annual Meeting Proceedings, 18_suppl, LBA1010 . 2010. 28:
Mature results from ABCSG-12: Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with endocrine-responsive early breast cancer
Gnant, M; Mlineritsch, B; Stoeger, H; Luschin-Ebengreuth, G; Poestlberger, S; Dubsky, PC; Jakesz, R; Singer, CF; Eidtmann, H; Greil, R
J Clin Oncol, 18S . 2010. 28: 533-533.
Pathologic complete response (pCR) in patient subgroups: An analysis of ABCSG-24, a phase III, randomized study of anthracycline- and taxane-based neoadjuvant therapy with or without capecitabine in early breast cancer (EBC).
Günther G Steger, Richard Greil, Raimund Jakesz, Alois Lang, Brigitte Mlineritsch, Margaretha Rudas, Christian Marth, Herbert Stoeger, Christian F Singer, Michael Gnant
Breast cancer . 2010. 6: 7-7.
Impact of body mass index (BMI) on endocrine therapy in premenopausal breast cancer patients: An analysis of the ABCSG-12 trial.
Pfeiler, G; Konigsberg, R; Singer, CF; Seifert, M; Dubsky, PC; Samonigg, H; Bjelic-Radisic, V; Greil, R; Marth, C; Gnant, M;
ASCO Annual Meeting Proceedings, 15_suppl . 2010. 28: 512-512.
Short review – Management of Immune Thrombocytopenia in adults
Weiss, L; Greil, R
memo - Magazine of European Medical Oncology (2010) . 2010.

2009

Beiträge in Fachzeitschriften

The Austrian fulvestrant registry: results from a prospective observation of fulvestrant in postmenopausal patients with metastatic breast cancer.
Bartsch, R; Mlineritsch, B; Gnant, M; Niernberger, T; Pluschnig, U; Greil, R; Wenzel, C; Sevelda, P; Thaler, J; Rudas, M; Pober, M; Zielinski, CC; Steger, GG;
Breast Cancer Res Treat. 2009; 115(2):373-380
Originalarbeiten (Zeitschrift)
Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
Baselga, J; Semiglazov, V; van Dam, P; Manikhas, A; Bellet, M; Mayordomo, J; Campone, M; Kubista, E; Greil, R; Bianchi, G; Steinseifer, J; Molloy, B; Tokaji, E; Gardner, H; Phillips, P; Stumm, M; Lane, HA; Dixon, JM; Jonat, W; Rugo, HS;
J CLIN ONCOL. 2009; 27(16): 2630-2637.
Originalarbeiten (Zeitschrift)
Low p27 expression predicts early relapse and death in postmenopausal hormone receptor-positive breast cancer patients receiving adjuvant tamoxifen therapy.
Filipits, M; Rudas, M; Heinzl, H; Jakesz, R; Kubista, E; Lax, S; Schippinger, W; Dietze, O; Greil, R; Stiglbauer, W; Kwasny, W; Nader, A; Stierer, M; Gnant, MF;
CLIN CANCER RES. 2009; 15(18): 5888-5894.
Originalarbeiten (Zeitschrift)
Hodgkin lymphoma in Tyrol-a population-based study.
Fong, D; Steurer, M; Greil, R; Gunsilius, E; Spizzo, G; Gastl, G; Tzankov, A;
ANN HEMATOL. 2009; 88(5): 449-456.
Originalarbeiten (Zeitschrift)
Maintaining bone density in patients undergoing treatment for breast cancer: is there an adjuvant benefit?
Gnant, M; Dubsky, P; Fitzal, F; Blaha, P; Schoppmann, S; Steger, G; Marth, C; Samonigg, H; Hüttner, K; Fohler, H; Ruecklinger, E; Jakesz, R; Greil, R;
CLIN BREAST CANCER. 2009; 9 Suppl 1: S18-S27.
Übersichtsarbeiten
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Gnant, M; Mlineritsch, B; Schippinger, W; Luschin-Ebengreuth, G; Postlberger, S; Menzel, C; Jakesz, R; Seifert, M; Hubalek, M; Bjelic-Radisic, V; Samonigg, H; Tausch, C; Eidtmann, H; Steger, G; Kwasny, W; Dubsky, P; Fridrik, M; Fitzal, F; Stierer, M; Rucklinger, E; Greil, R
NEW ENGL J MED. 2009; 360(7): 67-91.
Originalarbeiten (Zeitschrift)
The Dark Side of the Moon - the Side Effects of Therapy in a Dynamic Era of Breast Cancer Management
Greil, R
BREAST CARE. 2009; 4(3): 144-147.
Editorials
Neoadjuvant bevacizumab, docetaxel and capecitabine combination therapy for HER2/neu-negative invasive breast cancer: Efficacy and safety in a phase II pilot study.
Greil, R; Moik, M; Reitsamer, R; Ressler, S; Stoll, M; Namberger, K; Menzel, C; Mlineritsch, B;
EJSO-EUR J SURG ONC. 2009; 35(10): 1048-1054.
Originalarbeiten (Zeitschrift)
Circulating B-cell chronic lymphocytic leukemia cells display impaired migration to lymph nodes and bone marrow.
Hartmann, TN; Grabovsky, V; Wang, W; Desch, P; Rubenzer, G; Wollner, S; Binsky, I; Vallon-Eberhard, A; Sapoznikov, A; Burger, M; Shachar, I; Haran, M; Honczarenko, M; Greil, R; Alon, R;
Cancer Res. 2009; 69(7):3121-3130
Originalarbeiten (Zeitschrift)
Novel therapeutics approaches to chronic lymphocytic leukemia based on recent biological insights.
Hartmann, TN; Pleyer, L; Desch, P; Egle, A; Greil, R;
Discov Med. 2009; 8(42): 157-164.
Übersichtsarbeiten
PKCbeta is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: validation of PKCbeta as a therapeutic target in chronic lymphocytic leukemia.
Holler, C; Piñón, JD; Denk, U; Heyder, C; Hofbauer, S; Greil, R; Egle, A;
Blood. 2009; 113(12):2791-2794
Originalarbeiten (Zeitschrift)
Vincristine, idarubicin, dexamethasone and thalidomide in scleromyxoedema.
Laimer, M; Namberger, K; Massone, C; Koller, J; Emberger, M; Pleyer, L; Hintner, H; Greil, R;
Acta Derm Venereol. 2009; 89(6): 631-635.
Fallberichte
Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.
Lin, NU; Diéras, V; Paul, D; Lossignol, D; Christodoulou, C; Stemmler, HJ; Roché, H; Liu, MC; Greil, R; Ciruelos, E; Loibl, S; Gori, S; Wardley, A; Yardley, D; Brufsky, A; Blum, JL; Rubin, SD; Dharan, B; Steplewski, K; Zembryki, D; Oliva, C; Roychowdhury, D; Paoletti, P; Winer, EP;
CLIN CANCER RES. 2009; 15(4): 1452-1459.
Originalarbeiten (Zeitschrift)
Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma.
Ludwig, H; Hajek, R; Tóthová, E; Drach, J; Adam, Z; Labar, B; Egyed, M; Spicka, I; Gisslinger, H; Greil, R; Kuhn, I; Zojer, N; Hinke, A;
BLOOD. 2009; 113(15): 3435-3442.
Originalarbeiten (Zeitschrift)
Multicenter phase II study of pegylated liposomal doxorubicin in combination with vinorelbine as first-line treatment in elderly patients with metastatic breast cancer.
Mlineritsch, B; Schabel-Moser, R; Andel, J; Fridrik, M; Moik, M; Mayer, P; Russ, G; Rass, C; Greil, R;
ONKOLOGIE. 2009; 32(1-2): 18-24.
Originalarbeiten (Zeitschrift)
The involvement of the fractalkine receptor in the transmigration of neuroblastoma cells through bone-marrow endothelial cells.
Nevo, I; Sagi-Assif, O; Meshel, T; Ben-Baruch, A; Jöhrer, K; Greil, R; Trejo, LE; Kharenko, O; Feinmesser, M; Yron, I; Witz, IP;
Cancer Lett. 2009; 273(1): 127-139.
Originalarbeiten (Zeitschrift)
Molecular and cellular mechanisms of CLL: novel therapeutic approaches.
Pleyer, L; Egle, A; Hartmann, TN; Greil, R;
NAT REV CLIN ONCOL. 2009; 6(7): 405-418.
Übersichtsarbeiten
Initial evaluation of the Roche COBAS TaqMan HIV-1 v2.0 assay for determining viral load in HIV-infected individuals.
Taylor, N; Schmid, I; Egle, A; Greil, R; Patsch, W; Oberkofler, H;
Antivir Ther. 2009; 14(8): 118-193.
Originalarbeiten (Zeitschrift)
Difference in the relative distribution of CD4+ T-cell subsets in B-CLL with mutated and unmutated immunoglobulin (Ig) VH genes: implication for the course of disease.
Tinhofer, I; Weiss, L; Gassner, F; Rubenzer, G; Holler, C; Greil, R;
J Immunother. 2009; 32(3):302-309
Originalarbeiten (Zeitschrift)
Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3.
Van Cutsem, E; Labianca, R; Bodoky, G; Barone, C; Aranda, E; Nordlinger, B; Topham, C; Tabernero, J; André, T; Sobrero, AF; Mini, E; Greil, R; Di Costanzo, F; Collette, L; Cisar, L; Zhang, X; Khayat, D; Bokemeyer, C; Roth, AD; Cunningham, D;
J CLIN ONCOL. 2009; 27(19): 3117-3125.
Originalarbeiten (Zeitschrift)

Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen

Combined modality treatment with intensified chemotherapy and dose-reduced involved field radiotherapy in patients with early unfavourable Hodgkin lymphoma (HL): final analysis of the German Hodgkin Study Group (GHSG) HD11 Trial.
Borchmann, P; Diehl, V; Goergen, H; Mueller, H; Mueller, RP; Eich, HT; Mueller-Hermelink, HK; Herrmann, R; Markova, J; Ho, AD; Hiddemann, W; Doerken, B; Greil, R; Engert, A;
Blood. 2009; 114(22):717--51st annual meeting of the American Society of Hematology; 05.-08.12.2009; New Orleans, LA.
Abstracts (Zeitschrift)
FINAL RESULTS OF ORAL FLUDARABINE WITH CONCOMITANT SUBCUTANEOUS ALEMTUZUMAB IN RELAPSED/REFRACTORY B-CHRONIC LYMPHOCYTIC LEUKAEMIA (B-CLL): THE FLUSALEM STUDY
Egle, A; Melchardt, T; Pleyer, L; Tinhofer, I; Lang, A; Keil, F; Thaler, J; Gunsilius, E; Fridrik, M; Greil, R
HAEMATOL-HEMATOL J. 2009; 94: 140-140.
Abstracts (Zeitschrift)
The REVLIRIT CLL5 AGMT Study - a Phase I/II Trial Combining Fludarabine/Rituximab with Escalating Doses of Lenalidomide Followed by Rituximab/Lenalidomide in Untreated Chronic Lymphocytic Leukemia (CLL): Results of a Planned Interim Analysis
Egle, A; Steurer, M; Melchardt, T; Stoll, M; Greil, R
BLOOD. 2009; 114(22): 1341-1342.
Abstracts (Zeitschrift)
Neoadjuvant chemoradiation therapy with capecitabine (X) plus cetuximab (C), and external beam radiotherapy (RT) in locally advanced rectal cancer (LARC): ABCSG trial R03
Eisterer, WM; De Vries, A; Oefner, D; Greil, R; Rabl, H; Tschmelitsch, J; Schmid, R; Kapp, K; Zehentmayr, F; Thaler, J
J CLIN ONCOL. 2009; 27(15):
Abstracts (Zeitschrift)
Two Cycles of ABVD Followed by Involved Field Radiotherapy with 20 Gray (Gy) Is the New Standard of Care in the Treatment of Patients with Early-Stage Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group (GHSG) HD10. Study Supported by the Deutsche Krebshilfe and in Part by the Competence Network Malignant Lymphoma.
Engert, A; Diehl, V; Pluetschow, A; Eich, HT; Herrmann, R; Doerken, B; Kanz, L; Greil, R; Markova, J; Fuchs, M; Borchmann, P; Mueller-Hermelink, HK; Mueller, RP;
Blood. 2009; 114(22):716--51st annual meeting of the American Society of Hematology; 05.-08.12.2009; New Orleans, LA.
Abstracts (Zeitschrift)
ADDITION OF ZOLEDRONIC ACID (ZOL) TO ADJUVANT ENDOCRINE THERAPY IMPROVES DISEASE-FREE (DFS) AND RECURRENCE-FREE SURVIVAL (RFS) IN PREMENOPAUSAL WOMEN WITH HORMONE-RESPONSIVE EARLY BREAST CANCER (HREBC): MULTIVARIATE ANALYSES OF THE AUSTRIAN BREAST AND COLORECTAL CANCER STUDY GROUP 12 (ABCSG-12) TRIAL
Gnant, M; Mlineritsch, B; Schippinger, W; Luschin-Ebengreuth, G; Poestlberger, S; Menzel, C; Jakesz, R; Kubista, E; Marth, C; Greil, R
ANN ONCOL. 2009; 20: 30-30.
Abstracts (Zeitschrift)
Number needed to treat (NNT) as a drug efficacy measure: Zoledronic acid (ZOL) for early hormone-responsive breast cancer in the ABCSG-12 trial
Gnant, M; Mlineritsch, B; Schippinger, W; Luschin-Ebengreuth, G; Steger, G; Bjelic-Radisic, V; Jakesz, R; Kubista, E; Marth, C; Greil, R
BREAST. 2009; 18: S59-S59.
Abstracts (Zeitschrift)
The number needed to treat (NNT) as a measure of drug efficacy: the case of zoledronic acid for early hormone-responsive breast cancer in the ABCSG-12 trial
Gnant, M; Mlineritsch, B; Schippinger, W; Luschin-Ebengreuth, G; Steger, G; Bjelic-Radisic, V; Jakesz, R; Kubista, E; Marth, C; Greil, R
CANCER RES. 2009; 69(2): 191S-191S.
Abstracts (Zeitschrift)
NUMBER NEEDED TO TREAT (NNT) AS A MEASURE OF ZOLEDRONIC ACID (ZOL) EFFICACY IN PATIENTS WITH HORMONE-RESPONSIVE EARLY BREAST CANCER (BC) IN THE AUSTRIAN BREAST AND COLORECTAL CANCER STUDY GROUP (ABCSG)-12 TRIAL
Gnant, M; Mlineritsch, B; Schippinger, W; Luschin-Ebengreuth, G; Steger, GG; Bjelic-Radisic, V; Jakesz, R; Kubista, E; Marth, C; Greil, R
ANN ONCOL. 2009; 20: 30-30.
Abstracts (Zeitschrift)
Pharmacogenetic (CYP2D6) and gene expression profiles (HOXB13/IL17BR and molecular grade index) for prediction of adjuvant endocrine therapy benefit in the ABCSG 8 trial.
Goetz, M; Ames, M; Gnant, M; Filpits, M; Jakesz, R; Greil, R; Marth, C; Samonigg, H; Suman, V; Safgren, S; Kuffel, M; Weinshilboum, R; Erlander, M; Ma, XJ; Ingle, J
CANCER RES. 2009; 69(2): 77S-77S.
Abstracts (Zeitschrift)
Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC): the CECOG phase III TURANDOT trial
Lang, I; Inbar, M; Steger, G; Greil, R; Zvirbule, Z; Beslija, S; Kahan, Z; Taskova, V; Kaufmann, B; Zielinski, CC
EJC SUPPL. 2009; 7(2): 277-278.
Abstracts (Zeitschrift)
REVERSAL OF ACUTE RENAL IMPAIRMENT BY BORTEZOMIB-DOXORUBICIN-DEXAMETHASONE IN MULTIPLE MYELOMA. RESULTS FROM AN PHASE II STUDY
Ludwig, H; Adam, Z; Greil, R; Tothova, E; Keil, F; Zojer, N; Thaler, J; Gisslinger, H; Egyed, M; Lang, A
HAEMATOL-HEMATOL J. 2009; 94: 154-154.
Abstracts (Zeitschrift)
Final Results of ABCSG-24, a Randomized Phase III Study Comparing Epirubicin, Docetaxel, and Capecitabine (EDC) to Epirubicin and Docetaxel (ED) as Neoadjuvant Treatment for Early Breast Cancer and Comparing ED/EDC plus Trastuzumab (T) to ED/EDC as Neoadjuvant Treatment for Early HER-2 Positive Breast Cancer
Steger, GG; Greil, R; Jakesz, R; Lang, A; Mlineritsch, B; Melbinger-Zeinitzer, E; Marth, C; Samonigg, H; Kubista, E; Gnant, M
CANCER RES. 2009; 69(24): 564S-564S.
Abstracts (Zeitschrift)
A randomized phase III study comparing epirubicin, docetaxel, and capecitabine (EDC) to epirubicin and docetaxel (ED) as neoadjuvant treatment for early breast cancer - first results of the Austrian Breast and Colorectal Cancer Study Group-Trial 24 (ABCSG-24)
Steger, GG; Greil, R; Jakesz, R; Lang, A; Mlineritsch, B; Melbinger-Zeinitzer, E; Martin, C; Samonigg, H; Kubista, E; Gnant, M
EJC SUPPL. 2009; 7(3): 3-3.
Abstracts (Zeitschrift)
The Inverse Correlation of Regulatory T Cells and Time to Initial Treatment in Chronic Lymphocytic B-Cell Leukemia
Weiss, L; Melchardt, T; Grabmer, C; Egle, A; Tinhofer, I; Greil, R
BLOOD. 2009; 114(22): 510-510.
Abstracts (Zeitschrift)

Beiträge in Sonstigen Zeitschriften

Oxaliplatin, irinotecan, and cetuximab in advanced gastric cancer. First efficacy results of a multicenter phase II trial (AGMT Gastric-2) of the Arbeitsgemeinschaft Medikamentoese Tumortherapie (AGMT)
Woell, E; Greil, R; Eisterer, W; Fridrik, M; Grunberger, B; Zabernigg, A; Mayrbaurl, B; Russ, G; Thaler, J;
ASCO Annual Meeting Proceedings, 15S . 2009. 27: 4538-4538.

2008

Beiträge in Fachzeitschriften

Oxaliplatin in combination with 5-fluorouracil/leucovorin or capecitabine in elderly patients with metastatic colorectal cancer.
Arkenau, HT; Graeven, U; Kubicka, S; Grothey, A; Englisch-Fritz, C; Kretzschmar, A; Greil, R; Freier, W; Seufferlein, T; Hinke, A; Schmoll, HJ; Schmiegel, W; Porschen, R;
CLIN COLORECTAL CANC. 2008; 7(1): 60-64.
Originalarbeiten (Zeitschrift)
Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy.
Dubsky, P; Sevelda, P; Jakesz, R; Hausmaninger, H; Samonigg, H; Seifert, M; Denison, U; Mlineritsch, B; Steger, G; Kwasny, W; Stöger, H; Bartsch, R; Stierer, M; Taucher, S; Fridrik, M; Schippinger, W; Greil, R; Pötter, R; Gnant, M;
Clin Cancer Res. 2008; 14(7):2082-2087
Originalarbeiten (Zeitschrift)
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
Gnant, M; Mlineritsch, B; Luschin-Ebengreuth, G; Kainberger, F; Kässmann, H; Piswanger-Sölkner, JC; Seifert, M; Ploner, F; Menzel, C; Dubsky, P; Fitzal, F; Bjelic-Radisic, V; Steger, G; Greil, R; Marth, C; Kubista, E; Samonigg, H; Wohlmuth, P; Mittlböck, M; Jakesz, R;
Lancet Oncol. 2008; 9(9):840-849
Originalarbeiten (Zeitschrift)
Is Chemoendocrine Treatment without Alternative?
Greil, R;
Breast Care (Basel). 2008; 3(4): 231-235.
Originalarbeiten (Zeitschrift)
Hematopoietic growth factors: ESMO recommendations for the applications.
Greil, R; Psenak, O; Roila, F;
ANN ONCOL. 2008; 19 Suppl 2: ii116-ii118.
Kurzberichte/Notes
Erythropoietins in cancer patients: ESMO Recommendations for use
Greil, R; Thodtman, R; Roila, F
ANN ONCOL. 2008; 19: 113-115.
Kurzberichte/Notes
MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia.
Gryshchenko, I; Hofbauer, S; Stoecher, M; Daniel, PT; Steurer, M; Gaiger, A; Eigenberger, K; Greil, R; Tinhofer, I;
J Clin Oncol. 2008; 26(14): 2252-2257.
Originalarbeiten (Zeitschrift)
Tumour-immune cell interactions modulated by chemokines.
Jöhrer, K; Pleyer, L; Olivier, A; Maizner, E; Zelle-Rieser, C; Greil, R;
EXPERT OPIN BIOL TH. 2008; 8(3): 26-90.
Übersichtsarbeiten
Arsenic trioxide induces apoptosis preferentially in B-CLL cells of patients with unfavourable prognostic factors including del17p13.
Merkel, O; Heyder, C; Asslaber, D; Hamacher, F; Tinhofer, I; Holler, C; Stöcher, M; Prokesch, A; Papak, C; Scheideler, M; Trajanoski, Z; Greil, R;
J Mol Med (Berl). 2008; 86(5):541-552
Originalarbeiten (Zeitschrift)
Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17).
Mlineritsch, B; Tausch, C; Singer, C; Luschin-Ebengreuth, G; Jakesz, R; Ploner, F; Stierer, M; Melbinger, E; Menzel, C; Urbania, A; Fridrik, M; Steger, G; Wohlmuth, P; Gnant, M; Greil, R;
Breast Cancer Res Treat. 2008; 112(1):20-13
Originalarbeiten (Zeitschrift)
Differential diagnostic challenge of chronic neutrophilic leukemia in a patient with prolonged leukocytosis.
Neureiter, D; Kemmerling, R; Ocker, M; Seidlhofer, C; Faber, V; Stöcher, M; Greil, R; Dietze, O;
J Hematop. 2008; 1(1): 23-27.
Fallberichte
Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy.
Rudas, M; Lehnert, M; Huynh, A; Jakesz, R; Singer, C; Lax, S; Schippinger, W; Dietze, O; Greil, R; Stiglbauer, W; Kwasny, W; Grill, R; Stierer, M; Gnant, MF; Filipits, M;
Clin Cancer Res. 2008; 14(6):176-174
Originalarbeiten (Zeitschrift)
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
San Miguel, JF; Schlag, R; Khuageva, NK; Dimopoulos, MA; Shpilberg, O; Kropff, M; Spicka, I; Petrucci, MT; Palumbo, A; Samoilova, OS; Dmoszynska, A; Abdulkadyrov, KM; Schots, R; Jiang, B; Mateos, MV; Anderson, KC; Esseltine, DL; Liu, K; Cakana, A; van de Velde, H; Richardson, PG;
N Engl J Med. 2008; 359(9):906-917
Originalarbeiten (Zeitschrift)
A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines.
Schmid, P; Kühnhardt, D; Kiewe, P; Lehenbauer-Dehm, S; Schippinger, W; Greil, R; Lange, W; Preiss, J; Niederle, N; Brossart, P; Freier, W; Kümmel, S; Van de Velde, H; Regierer, A; Possinger, K;
Ann Oncol. 2008; 19(5):871-876
Originalarbeiten (Zeitschrift)
SNP309 as predictor for sensitivity of CLL cells to the MDM2 inhibitor nutlin-3a.
Seyfried, I; Hofbauer, S; Stoecher, M; Greil, R; Tinhofer, I;
Blood. 2008; 112(5):2168; author reply 2169
Kommentare
Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.
Sonneveld, P; Hajek, R; Nagler, A; Spencer, A; Bladé, J; Robak, T; Zhuang, SH; Harousseau, JL; Orlowski, RZ;
Cancer. 2008; 112(7): 1529-1537.
Originalarbeiten (Zeitschrift)
The potential risk of neoadjuvant chemotherapy in breast cancer patients--results from a prospective randomized trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-07).
Taucher, S; Steger, GG; Jakesz, R; Tausch, C; Wette, V; Schippinger, W; Kwasny, W; Reiner, G; Greil, R; Dubsky, P; Poestlberger, S; Tschmelitsch, J; Samonigg, H; Gnant, M;
Breast Cancer Res Treat. 2008; 112(2):309-316
Originalarbeiten (Zeitschrift)
Diagnostic algorithms, monitoring, prognostication, and therapy in chronic myeloid leukemia (CML): a proposal of the Austrian CML platform
Valent, P; Lion, T; Wolf, D; Sillaber, C; Agis, H; Petzer, A; Lang, A; Kalhs, P; Geissler, D; Greil, R; Linkesch, W; Burgstaller, S; Thaler, J; Gastl, G
WIEN KLIN WOCHENSCHR. 2008; 120(21-22): 697-709.
Übersichtsarbeiten
Renal safety profiles of ibandronate 6 mg infused over 15 and 60 min: a randomized, open-label study.
von Moos, R; Caspar, CB; Thürlimann, B; Angst, R; Inauen, R; Greil, R; Bergstrom, B; Schmieding, K; Pecherstorfer, M;
Ann Oncol. 2008; 19(7):1266-1270
Originalarbeiten (Zeitschrift)
Chemotherapy in gastric cancer.
Wöll, E; Devries, A; Eisterer, W; Hejna, M; Keil, F; Stein, H; Zacherl, J; Greil, R;
Anticancer Res. 2008; 28(2B):1213-1219
Übersichtsarbeiten
Biweekly oxaliplatin and irinotecan chemotherapy in advanced gastric cancer. A first-line multicenter phase II trial of the Arbeitsgemeinschaft Medikamentöse Tumortherapie (AGMT).
Wöll, E; Kühr, T; Eisterer, W; Gattringer, K; Greil, R; Zabernigg, A; Hilbe, W; Thaler, J;
Anticancer Res. 2008; 28(5B):2901-2905
Originalarbeiten (Zeitschrift)

Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen

The Austrian Fulvestrant Registry: Results from a prospective observation of fulvestrant in postmenopausal patients
Bartsch, R; Mlineritsch, B; Gnant, M; Niernberger, T; Pluschnig, U; Greil, R; Pober, M; Sevelda, P; Thaler, J; Steger, GG
J CLIN ONCOL. 2008; 26(15):
Abstracts (Zeitschrift)
Dose-intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by 2 cycles of ABVD and involved field radiotherapy (IF-RT) is superior to 4 cycles of ABVD and IFRT in patients with early unfavourable Hodgkin lymphoma (HL): an analysis of the German Hodgkin Study Group (GHSG) HD14 trial.
Borchmann, P; Engert, A; Pluetschow, A; Fuchs, M; Markova, J; Lohri, A; Kral, Z; Greil, R; Topp, M; Villalobos, M; Zijlstra, J; Soekler, M; Stein, H; Eich, HT; Mueller, RP; Diehl, V;
Blood. 2008; 112(11):367--50th Annual Meeting of American Society of Hematology (ASH); 06.-09.12.2008; San Francisco, California.
Abstracts (Zeitschrift)
R-CHOP plus thalidomide for previously untreated mantle cell lymphoma
Drach, J; Hopfinger, G; Fridrik, M; Greil, R; Thaler, J; Keil, F; Lang, A; Jaeger, U; Raderer, M
ANN ONCOL. 2008; 19: 214-215.
Abstracts (Zeitschrift)
R-CHOP plus THALIDOMIDE FOR PREVIOUSLY UNTREATED MANTLE CELL LYMPHOMA
Drach, W; Hopfinger, G; Fridrik, M; Greil, R; Thaler, J; Keil, F; Lang, A; Jaeger, U; Raderer, M
HAEMATOL-HEMATOL J. 2008; 93: 394-395.
Abstracts (Zeitschrift)
T Cell Dynamics during the Pretumor and Tumor Phase in the Murine Tcll Transgenic Chronic Lymphocytic Leukemia Model
Egle, A; Pinon, JD; Heyder, C; Holler, C; Denk, U; Tinhofer, I; Greil, R
BLOOD. 2008; 112(11): 1078-1078.
Abstracts (Zeitschrift)
Minimal Residual Disease (MRD) and T/NK Cell Dynamics during Fludarabine, Cyclophosphamide Plus Rituximab (FCR) Followed by Fludarabine Plus Rituximab (FR) and Remission Maintenance Therapy with Rituximab in Previously Untreated B-Chronic Lymphocytic Leukemia (B-CLL): Riskfactor Stratification in the Chairos Study.
Egle, A; Weiss, L; Gassner, F; Russ, G; Pleyer, L; Gunsilius, E; Tinhofer, I; Thaler, J; Petzer, AL; Greil, R
BLOOD. 2008; 112(11): 1089-1089.
Abstracts (Zeitschrift)
Twelve-year retrospective analysis of lung cancer-The TYROL Study: Daily routine in 1,424 patients (1995-2006)
Fiegl, M; Hilbe, W; Auberger, J; Schmid, T; Auberger, T; Tzankov, A; Sterlacci, W; Denz, H; Jamnig, H; Greil, R
J CLIN ONCOL. 2008; 26(15):
Abstracts (Zeitschrift)
Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with hormone-responsive, stage I and II breast cancer: First efficacy results from ABCSG-12
Gnant, M; Mlineritsch, B; Schippinger, W; Luschin-Ebengreuth, G; Poestlberger, S; Menzel, C; Jakesz, R; Kubista, E; Marth, C; Greil, R
J CLIN ONCOL. 2008; 26(15):
Abstracts (Zeitschrift)
ZOLEDRONIC ACID (ZOL) IMPROVES DISEASE-FREE (DFS) AND RECURRENCE-FREE SURVIVAL (RFS) IN PREMENOPAUSAL WOMEN WITH EARLY BREAST CANCER (ERBC) RECEIVING ADJUVANT ENDOCRINE THERAPY: MULTIVARIATE ANALYSIS OF EFFICACY DATA FROM THE AUSTRIAN BREAST AND COLORECTAL CANCER STUDY GROUP (ABCSG)-12
Gnant, M; Mlineritsch, B; Schippinger, W; Luschin-Ebengreuth, G; Steger, GG; Bjelic-Radisic, V; Jakesz, R; Kubista, E; Marth, C; Greil, R
ANN ONCOL. 2008; 19: 44-44.
Abstracts (Zeitschrift)
IMMUNOMODULATORY CAPACITY OF MYELOMA-DERIVED CHEMOKINE CCL27
Johrer, K; Olivier, A; Unger, M; Maizner, E; Neureiter, D; Greil, R
ANTICANCER RES. 2008; 28(5C): 3336-3337.
Abstracts (Zeitschrift)
MULTIPLE MYELOMA - CHEMOKINE NETWORK: CCL27/CTACK - A NEW PLAYER IN MYELOMA PROGRESSION
Olivier, A; Unger, M; Maizner, E; Neureiter, D; Greil, R; Johrer, K
ANTICANCER RES. 2008; 28(5C): 3429-3429.
Abstracts (Zeitschrift)
The single nucleotide polymorphism MDM2-SNP309 influences sensitivity of B-CLL cells to the non-genotoxic activator of the p53 pathway Nutlin-3a
Tinhofer, I; Seyfried, I; Stoecher, M; Hofbauer, S; Daniel, PT; Greil, R
J CLIN ONCOL. 2008; 26(15):
Abstracts (Zeitschrift)

Beiträge in Sonstigen Zeitschriften

Improved clinical and cell cycle response with an mTOR inhibitor, daily oral RAD001 (everolimus) plus letrozole versus placebo plus letrozole in a randomized phase II neoadjuvant trial in ER+ breast cancer
Baselga, J; Van Dam, PA; Greil, R; Gardner, H; Bandaru, R; Molloy, B; Steinseifer, J; Phillips, P; Dixon, JM; Rugo, HS;
ASCO Annual Meeting Proceedings, 15_suppl . 2008. 26: 530-530.
Experimental treatment of brain metastases
Greil, R
memo - Magazine of European Medical Oncology (2008) . 2008.
Academic clinical trials in the 21st century – where do we go from here? The research approach of the Arbeitsgemeinschaft Medikamentöse Tumortherapie (AGMT)
Kurtev, V; Greil, R;
memo - Magazine of European Medical Oncology, 2008/4. 2008.

2007

Beiträge in Fachzeitschriften

Hematopoietic growth factors: ESMO recommendations for the application.
Greil, R; Psenak, O;
Ann Oncol. 2007; 18 Suppl 2: ii89-ii91.
Originalarbeiten (Zeitschrift)
Is it time to consider neoadjuvant treatment as the standard of care in oesophageal cancer?
Greil, R; Stein, HJ
LANCET ONCOL. 2007; 8(3): 189-190.
Editorials
Erythropoietins in cancer patients: ESMO recommendations for use.
Greil, R; Thödtmann, R;
Ann Oncol. 2007; 18 Suppl 2: ii86-ii88.
Originalarbeiten (Zeitschrift)
[Expert recommendations 2006 on the rationale for second-line therapy for non-small cell bronchial neoplasms].
Hilbe, W; Aigner, K; Dittrich, C; Eckmayr, J; Fiegl, M; Flicker, M; Forstner, B; Greil, R; Jamnig, H; Krajnik, G; Lang, A; Mohn-Staudner, A; Schinko, H; Studnicka, M; Pirker, R; Ploner, F; Rothmund, J; Schiller, L; Zabernigg, A; Zöchbauer-Müller, S;
Wien Klin Wochenschr. 2007; 119(7-8):259-266
Übersichtsarbeiten
Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.
Jakesz, R; Greil, R; Gnant, M; Schmid, M; Kwasny, W; Kubista, E; Mlineritsch, B; Tausch, C; Stierer, M; Hofbauer, F; Renner, K; Dadak, C; Rücklinger, E; Samonigg, H;
J Natl Cancer Inst. 2007; 99(24):1845-1853
Originalarbeiten (Zeitschrift)
Fulvestrant ("Faslodex") in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the compassionate use programme.
Mlineritsch, B; Psenak, O; Mayer, P; Moik, M; Namberger, K; Hauser-Kronberger, C; Greil, R;
BREAST CANCER RES TR. 2007; 106(1): 105-112.
Originalarbeiten (Zeitschrift)
The Role of Imaging in Malignant Lymphoma: A Critical View on PET Scanning in Current Clinical Practice
Namberger, K; Greil, R;
Imaging decisions (Berlin, Germany). 2007; 10(4): 22-31.
Originalarbeiten (Zeitschrift)
Massive infiltration of bone marrow in colon carcinoma after treatment with activated protein C.
Pleyer, L; Went, P; Russ, G; Prinz, E; Faber, V; Röwert, HJ; Karlbauer, R; Greil, R;
WIEN KLIN WOCHENSCHR. 2007; 119(7-8): 254-258.
Fallberichte
Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group.
Porschen, R; Arkenau, HT; Kubicka, S; Greil, R; Seufferlein, T; Freier, W; Kretzschmar, A; Graeven, U; Grothey, A; Hinke, A; Schmiegel, W; Schmoll, HJ;
J CLIN ONCOL. 2007; 25(27): 4217-4223.
Originalarbeiten (Zeitschrift)
A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer.
Schippinger, W; Samonigg, H; Schaberl-Moser, R; Greil, R; Thödtmann, R; Tschmelitsch, J; Jagoditsch, M; Steger, GG; Jakesz, R; Herbst, F; Hofbauer, F; Rabl, H; Wohlmuth, P; Gnant, M; Thaler, J;
Br J Cancer. 2007; 97(8):1021-1027
Originalarbeiten (Zeitschrift)
Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: results of ABCSG-14.
Steger, GG; Galid, A; Gnant, M; Mlineritsch, B; Lang, A; Tausch, C; Rudas, M; Greil, R; Wenzel, C; Singer, CF; Haid, A; Postlberger, S; Samonigg, H; Luschin-Ebengreuth, G; Kwasny, W; Klug, E; Kubista, E; Menzel, C; Jakesz, R
J CLIN ONCOL. 2007; 25(15): 2012-2018.
Originalarbeiten (Zeitschrift)
A new sesquiterpene lactone sulfate from Reichardia gaditana (Asteraceae)
Zidorn, C; Ellmerer, EP; Heller, W; Johrer, K; Frommberger, M; Greil, R; Guggenberger, M; Ongania, KH; Stuppner, H
Z NATURFORSCH B. 2007; 62(1): 132-134.
Originalarbeiten (Zeitschrift)

Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen

Planned first efficacy and safety analysis of de-intensified induction with fludarabine, cyclophosphamide plus rituximab (FCR) followed by fludarabine plus rituximab (FR) and remission maintenance therapy with rituximab in previously untreated B-chronic lymphocytic leukemia (B-CLL): The chairos study
Egle, A; Weiss, L; Russ, G; Thoedtmann, R; Pleyer, L; Gastl, G; Thaler, J; Petzer, A; Tinhofer, I; Greil, R
BLOOD. 2007; 110(11): 609A-609A.
Abstracts (Zeitschrift)
Incidence and other aspects of myelodysplastic syndrome in the Austrian federal state Salzburg
Kemmerling, R; Neuretter, D; Faber, V; Stocher, M; Greil, R; Dietze, O
PATHOL RES PRACT. 2007; 203(5): 392-392.
Abstracts (Zeitschrift)
Recovery of Renal Impairment by Bortezomib-Doxorubicin-Dexamethasone (BDD) in Multiple Myeloma (MM) Patients with Acute Renal Failure. Results from an Ongoing Phase II Study.
Ludwig, H; Adam, Z; Hajek, R; Greil, R; Keil, F; Zojer, N; Thaler, J; Gisslinger, H; Lang, A;
Blood. 2007; 110: 3603--49th Annual Meeting of American Society of Hematology (ASH); 08.-11.12.2007; Atlanta, Georgia.
Abstracts (Zeitschrift)
Therapy of antibody-mediated factor VIII deficiency by immunosuppressive therapy containing cyclophosphamide, dexamethasone and rituximab: A case report
Thoedtmann, R; Rosenlechner, S; Unger, J; Patsch, W; Greil, R
HAEMATOL-HEMATOL J. 2007; 92: 546-546.
Abstracts (Zeitschrift)
MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukaemia but can be preferentially targeted by the MDM2 inhibitor Nutlin-3a
Tinhofer, I; Gryshchenko, I; Stoecher, M; Hofbauer, S; Daniel, PT; Greil, R
EJC SUPPL. 2007; 5(4): 347-347.
Abstracts (Zeitschrift)

Originalbeiträge in Sammelwerk (Buchbeitrag)

Morbus Hodgkin.
Greil, R;
In: Greil, R (Ed.) editors(s). Lymphoproliferative Erkrankungen..
Entwicklungen und Perspektiven in der Behandlung der Lymphatischen Neoplasien.
Pleyer, L; Desch, P; Greil, R;
In: Greil, R (Ed.) editors(s). Lymphoproliferative Erkrankungen.. p. 139-155.
Regulation of apoptosis.
Pleyer, L; Tinhofer, I; Greil, R;
In: Hakan Mellstedt DSDBRG (Ed.) editors(s). ESMO Handbook of principles of translational Research.. p. 67-69.

Beiträge in Sonstigen Zeitschriften

Phase II double-blind randomized trial of daily oral RAD001 (everolimus) plus letrozole (LET) or placebo (P) plus LET as neoadjuvant therapy for ER plus breast cancer
Baselga, J; Semiglazov, V; Van Dam, P; Manikhas, A; Bellet, M; Mayordomo, J; Campone, M; Kubista, E; Greil, R; Bianchi, G; Steinseifer, J; Molloy, B; Tokaji, E; Dixon, JM; Jonat, W; Rugo, HS;
BREAST CANCER RESEARCH AND TREATMENT . 2007. 106: 107-107.
Bone mineral density (BMD) at 5 years after diagnosis in premenopausal patients with endocrine-responsive breast cancer, after 3 years of adjuvant endocrine treatment with goserelin and tamoxifen or anastrozole or both treatments in combination with zoledronic acid-new results from ABCSG-12
Gnant, M; Mlineritsch, B; Luschin-Ebengreuth, G; Kainberger, F; Kaessmann, H; Piswanger-Soelkner, C; Seifert, M; Schippinger, W; Menzel, C; Dubsky, P; Fitzal, F; Steger, G; Greil, R; Marth, C; Kubista, E; Samonigg, H; Jakesz, R;
BREAST CANCER RESEARCH AND TREATMENT . 2007. 106: 8-8.
Lapatinib and capecitabine for the treatment of brain metastases in patients with HER2+ breast cancer-an updated analysis from EGF105084.
Lin, NU; Paul, D; Dieras, V; Liu, M; Greil, R; Roche, H; Rubin, SD; Zembryki, D; Oliva, C; Jayawardene, D; Winer, EP;
Breast cancer research and treatment . 2007. 106: 272-273.

2006

Beiträge in Fachzeitschriften

IL-4 inhibits the TNF-alpha induced proliferation of renal cell carcinoma (RCC) and cooperates with TNF-alpha to induce apoptotic and cytokine responses by RCC: implications for antitumor immune responses.
Falkensammer, C; Jöhrer, K; Gander, H; Ramoner, R; Putz, T; Rahm, A; Greil, R; Bartsch, G; Thurnher, M;
Cancer Immunol Immunother. 2006; 55(10): 1228-1237.
Originalarbeiten (Zeitschrift)
Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: a nation-wide retrospective study in Austria.
Fiegl, M; Falkner, A; Hopfinger, G; Brugger, S; Zabernigg, A; Bauer, F; Haslbauer, F; Demirtas, D; Grossschmidt, P; Tatzreiter, G; Gastl, G; Greil, R;
CANCER. 2006; 107(10): 2408-2416.
Originalarbeiten (Zeitschrift)
The still long and winding road to neoadjuvant sytemic therapy as the standard of care in breast cancer
Greil, R
BREAST CARE. 2006; 1(6): 352-357.
Editorials
Clinical practice aromatase inhibitors: Upfront, switch or extended?
Greil, R; Jonat, W; Maass, N; Kaufmann, M; Ortmann, O; Possinger, K; Steger, G
BREAST CARE. 2006; 1(1): 37-43.
Editorials
Diffuse large B-cell lymphoma as a second, clonally unrelated lymphoproliferative disease in a patient with IgM monoclonal gammopathy of undetermined significance (MGUS) and concomitant polycythemia vera rubra.
Mian, M; Psenak, O; Greil, R; Fiegl, M; Tzankov, A;
LEUKEMIA LYMPHOMA. 2006; 47(5): 940-943.
Letter
Extensive organizing pneumonia during chemo-immunotherapy containing rituximab and G-CSF in a patient with diffuse large B-cell lymphoma: case report and review of the literature.
Mian, M; Rass, C; Hutarew, G; Kofler, B; Fiegl, M; Greil, R;
LEUKEMIA LYMPHOMA. 2006; 47(8): 1683-1685.
Letter
Adjuvant treatment with trastuzumab in clinical practice outside clinical studies
Senn, HJ; Thurlimann, B; von Minckwitz, G; Herrmann, R; Jakesz, R; Gnant, M; Greil, R
BREAST CARE. 2006; 1(2): 96-101.
Editorials
Purine antagonists for chronic lymphocytic leukaemia.
Steurer, M; Pall, G; Richards, S; Schwarzer, G; Bohlius, J; Greil, R;
Cochrane Database Syst Rev. 2006; (3): CD004270
Übersichtsarbeiten
Single-agent purine analogues for the treatment of chronic lymphocytic leukaemia: a systematic review and meta-analysis.
Steurer, M; Pall, G; Richards, S; Schwarzer, G; Bohlius, J; Greil, R;
CANCER TREAT REV. 2006; 32(5): 377-389.
Übersichtsarbeiten
A role of TRAIL in killing osteoblasts by myeloma cells
Tinhofer, I; Biedermann, R; Krismer, M; Crazzolara, R; Greil, R
FASEB J. 2006; 20(1): 759-+.
Originalarbeiten (Zeitschrift)
Expression levels of CD38 in T cells predict course of disease in male patients with B-chronic lymphocytic leukemia.
Tinhofer, I; Rubenzer, G; Holler, C; Hofstaetter, E; Stoecher, M; Egle, A; Steurer, M; Greil, R;
Blood. 2006; 108(9):2950-2956
Originalarbeiten (Zeitschrift)
The effect of IgVH mutational status on the induction of apoptosis by rituximab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: evidence from a clinical phase I/II trial.
Tinhofer, I; Steurer, M; Leitinger, G; Rumpold, H; Egle, A; Erdel, M; Greil, R;
Haematologica. 2006; 91(9): 1291-1293.
Letter

Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen

Planned first safety and efficacy analysis of oral fludarabine combined with subcutaneous alemtuzumab in 2(nd) line therapy of B-chronic lymphocytic leukaemia (B-CLL): The FLUSALEM study.
Egle, A; Tinhofer, I; Russ, G; Rass, C; Greil, R
BLOOD. 2006; 108(11): 336B-336B.
Abstracts (Zeitschrift)

Monographien (Bücher mit wissenschaftlichem Inhalt)

Lymphoproliferative Erkrankungen.
Greil, R;
2006.

Originalbeiträge in Sammelwerk (Buchbeitrag)

Wie sterben wir? Wie schön ist der Tod? Wie teuer ist der Tod? - Die Palliativmedizin im Spannungsfeld der Ressourcenallokation
Greil, R;
In: Fischer, M; Zänker, KS; editors(s). Medizin- und Bioethik. (ISBN: 978-3-631-54744-1 )

Beiträge in Sonstigen Zeitschriften

The impact of treatment-induced amenorrhea on survival of premenopausal patients with endocrine-responsive breast cancer: 10-year results of ABCSG-05 (CMF vs. goserelin plus tamoxifen).
Gnant, M; Greil, R; Kubista, E; Menzel, C; Schippinger, W; Seifert, M; Haider, K; Mlineritsch, B; Samonigg, H; Kwasny, W; Fridrik, M; Steger, G; Steindorfer, P; Schmelitsch, J; Poetter, R; Jakesz, R;
BREAST CANCER RESEARCH AND TREATMENT . 2006. 100: 10-11.

2005

Beiträge in Fachzeitschriften

ESMO Minimum Clinical Recommendations for the diagnosis, treatment and follow-up of acute myeloblastic leukemia (AML) in adult patients
Fey, MF; Greil, R; Jost, LM
ANN ONCOL. 2005; 16: 48-49.
Kurzberichte/Notes
Long-term results of dose density therapy in patients with aggressive lymphoma.
Fridrik, MA; Hausmaninger, H; Linkesch, W; Greil, R; Krieger, O; Baldinger, C; Klocker, J; Pont, J; Oberaigner, W;
ANN HEMATOL. 2005; 84(4): 217-222.
Originalarbeiten (Zeitschrift)
ESMO recommendations for the application of hematopoietic growth factors.
Greil, R; Jost, LM;
Ann Oncol. 2005; 16 Suppl 1:i80-i82
Originalarbeiten (Zeitschrift)
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of chronic lymphocytic leukemia.
Hallek, M; Stahel, RA; Greil, R;
Ann Oncol. 2005; 16 Suppl 1:i50-i51
Originalarbeiten (Zeitschrift)
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of multiple myeloma.
Harrouseau, JL; Greil, R; Kloke, O;
Ann Oncol. 2005; 16 Suppl 1:i45-i47
Originalarbeiten (Zeitschrift)
Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years" adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.
Jakesz, R; Jonat, W; Gnant, M; Mittlboeck, M; Greil, R; Tausch, C; Hilfrich, J; Kwasny, W; Menzel, C; Samonigg, H; Seifert, M; Gademann, G; Kaufmann, M; Wolfgang, J;
Lancet. 2005; 366(9484):455-462
Originalarbeiten (Zeitschrift)
Up-regulation of functional chemokine receptor CCR3 in human renal cell carcinoma.
Jöhrer, K; Zelle-Rieser, C; Perathoner, A; Moser, P; Hager, M; Ramoner, R; Gander, H; Höltl, L; Bartsch, G; Greil, R; Thurnher, M;
Clin Cancer Res. 2005; 11(7):2459-2465
Originalarbeiten (Zeitschrift)
Continuous prednisolone versus conventional prednisolone with VMCP-interferon-alpha2b as first-line chemotherapy in elderly patients with multiple myeloma.
Ludwig, H; Spicka, I; Klener, P; Greil, R; Adam, Z; Gisslinger, H; Tarkovács, G; Linkesch, W; Maniatis, A; Morant, R; Drach, J; Kuhn, I; Schuster, J; Hinke, A;
Br J Haematol. 2005; 131(3):329-337
Originalarbeiten (Zeitschrift)
1,10-epoxyhypocretenolides from the Azorean Endemic Leontodon rigens (Asteraceae)
Zidorn, C; Ellmerer, EP; Konwalinka, G; Ongania, KH; Schwaha, R; Greil, R; Joehrer, K; Perry, NB; Stuppner, H
LETT ORG CHEM. 2005; 2(5): 461-464.
Originalarbeiten (Zeitschrift)
Polyacetylenes from the Apiaceae vegetables carrot, celery, fennel, parsley, and parsnip and their cytotoxic activities.
Zidorn, C; Jöhrer, K; Ganzera, M; Schubert, B; Sigmund, EM; Mader, J; Greil, R; Ellmerer, EP; Stuppner, H;
J Agric Food Chem. 2005; 53(7):2518-2523
Originalarbeiten (Zeitschrift)

Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen

Recent interim analysis of the HD11 trial of the GHSG: intensification of chemotherapy and reduction of radiation dose in early unfavorable stage Hodgkin's lymphoma.
Diehl, V; Brillant, C; Engert, A; Mueller, RP; Eich, HT; Mueller-Hermelink, K; Herrmann, R; Markova, J; Ho, A; Hiddemann, W; Doerken, B; Greil, R; Josting, A; Pfistner, B;
Blood. 2005; 106(11):816--47th Annual Meeting of the American Society of Hematology (ASH); 10.-13.12.2005; Atlanta, Georgia.
Abstracts (Zeitschrift)
Combined Modality Treatment of Two or Four Cycles of ABVD Followed by Involved Field Radiotherapy in the Treatment of Patients with Early Stage Hodgkin's Lymphoma: Update Interim Analysis of the Randomised HD10 Study of the German Hodgkin Study Group (GHSG).
Engert, A; Pluetschow, A; Eich, HT; Herrmann, R; Doerken, B; Kanz, L; Greil, R; Markova, J; Pfistner, B; Josting, A; Mueller-Hermelink, K; Mueller, RP; Diehl, V;
Blood. 2005; 106(11):2673--47th Annual Meeting of the American Society of Hematology (ASH); 10.-13.12.2005; Atlanta, Georgia.
Abstracts (Zeitschrift)
Alemtuzumab is effective in patients with advanced, pretreated B-cell chronic lymphocytic leukemia: A nationwide study of routine use in Austria
Fiegl, M; Falkner, A; Hopfinger, G; Brugger, S; Zabernigg, A; Haslbauer, F; Andel, J; Thaler, J; Fridrik, M; Bauer, F; Mian, M; Tatzreiter, G; Zoier, N; Demirtas, D; Postner, G; Auberger, J; Gastl, G; Greil, R
BLOOD. 2005; 106(11): 833A-833A.
Abstracts (Zeitschrift)
Purine antagonists for chronic lymphocytic leukemia: Results of a comprehensive meta-analysis
Steurer, M; Pall, G; Richards, S; Schwarzer, G; Bohlius, J; Greil, R
ANN ONCOL. 2005; 16: 203-204.
Abstracts (Zeitschrift)
Expression levels of CD38 in tumor cells and T-cells are of prognostic value in B-CLL
Tinhofer, I; Rubenzer, G; Egle, A; Greil, R
BLOOD. 2005; 106(11): 347A-347A.
Abstracts (Zeitschrift)

Originalbeiträge in Sammelwerk (Buchbeitrag)

Chemotherapie im Alter
Greil, R; Faber, V;
In: Likar, R; Bernatzky, G; Pipam, W; Janig, H; Sadjak, A; editors(s). Lebensqualität im Alter. Springer; p. 257-264. (ISBN: 978-3-211-21197-7)

Beiträge in Sonstigen Zeitschriften

HD10: Investigating reduction of combined modality treatment intensity in early stage Hodgkin's lymphoma. Interim analysis of a randomized trial of the German Hodgkin Study Group (GHSG)
Diehl, V; Brillant, C; Engert, A; Mueller, RP; Mueller-Hermelink, HK; Hermann, R; Doerken, B; Kanz, L; Greil, R; Pfistner, B;
ASCO Annual Meeting Proceedings . 2005.
The benefits of sequencing adjuvant tamoxifen and anastrozole in postmenopausal women with hormone-responsive early breast cancer: 5 year-analysis of ABCSG Trial 8
Jakesz, R; Gnant, M; Greil, R; Tausch, C; Samonigg, H; Kwasny, W; Kubista, E; Stierer, M; Luschin, G; Mittlboeck, M;
Breast Cancer Research and Treatment, 2005, Band 94, S10-S10 . 2005.
Extended adjuvant treatment with anastrozole: Results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a)
Jakesz, R; Samonigg, H; Greil, R; Gnant, M; Schmid, M; Kwasny, W; Kubista, E; Mlineritsch, B; Tausch, C; Stierer, M; on behalf of the ABCSG
Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. Vol 23, No 16S (June 1 Supplement), 2005: 527. 2005.
Comparison of BEACOPP and ABVD chemotherapy in intermediate stage Hodgkin's lymphoma: Results of the fourth interim analysis of the HD 11 trial of the GHSG
Klimm, BC; Engert, A; Brillant, C; Eich, HT; Mueller-Hermelink, HK; Herrmann, R; Ho, A; Hiddemann, W; Greil, R; Diehl, V;
ASCO Annual Meeting Proceedings, 16_suppl . 2005. 23: 6507-6507.
Thalidomide-dexamethasone versus melphalan-prednisolone as first line treatment in elderly patients with multiple myeloma: An interim analysis
Ludwig, H; Drach, J; Tothova, E; Gisslinger, H; Jaksic, B; Linkesch, W; Hajek, R; Greil, R; Fridrik, M; Labar, B; Zojer, N
ASCO Annual Meeting Proceedings, 16_suppl . 2005. 23: 6537-6537.

2004

Beiträge in Fachzeitschriften

Elevated levels of soluble CD44 are associated with advanced disease and in vitro proliferation of neoplastic lymphocytes in B-cell chronic lymphocytic leukaemia.
Eisterer, W; Bechter, O; Söderberg, O; Nilsson, K; Terol, M; Greil, R; Thaler, J; Herold, M; Finke, L; Günthert, U; Montserrat, E; Stauder, R;
LEUKEMIA RES. 2004; 28(10): 1043-1051.
Originalarbeiten (Zeitschrift)
Biomarkers in non-small cell lung cancer prevention.
Hilbe, W; Dirnhofer, S; Greil, R; Wöll, E;
Eur J Cancer Prev. 2004; 13(5):425-436
Übersichtsarbeiten
Is higher income and educational status associated with poorer outcome in patients with Hodgkin"s disease?
Holzner, B; Fischhofer, M; Kemmler, G; Kopp, M; Sperner-Unterweger, B; Krugmann, J; Dirnhofer, S; Greil, R;
EUR J HAEMATOL. 2004; 73(5): 318-324.
Originalarbeiten (Zeitschrift)
Normative data for functional assessment of cancer therapy--general scale and its use for the interpretation of quality of life scores in cancer survivors.
Holzner, B; Kemmler, G; Cella, D; De Paoli, C; Meraner, V; Kopp, M; Greil, R; Fleischhacker, WW; Sperner-Unterweger, B;
Acta Oncol. 2004; 43(2):153-160
Originalarbeiten (Zeitschrift)
Quality of life of patients with chronic lymphocytic leukemia: results of a longitudinal investigation over 1 yr.
Holzner, B; Kemmler, G; Kopp, M; Nguyen-Van-Tam, D; Sperner-Unterweger, B; Greil, R;
Eur J Haematol. 2004; 72(6):381-389
Originalarbeiten (Zeitschrift)
Transendothelial migration of myeloma cells is increased by tumor necrosis factor (TNF)-alpha via TNF receptor 2 and autocrine up-regulation of MCP-1
Johrer, K; Janke, K; Krugmann, J; Fiegl, M; Greil, R
CLIN CANCER RES. 2004; 10(6): 1901-1910.
Originalarbeiten (Zeitschrift)
Unfavourable prognosis of patients with trisomy 18q21 detected by fluorescence in situ hybridisation in t(11;18) negative, surgically resected, gastrointestinal B cell lymphomas.
Krugmann, J; Tzankov, A; Dirnhofer, S; Fend, F; Greil, R; Siebert, R; Erdel, M;
J CLIN PATHOL. 2004; 57(4): 360-364.
Originalarbeiten (Zeitschrift)
Treatment of advanced Hodgkinxxxs disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkinxxxs Lymphoma Study Group HD6 trial
Sieber, M; Tesch, H; Pfistner, B; Rueffer, U; Paulus, U; Munker, R; Hermann, R; Doelken, G; Koch, P; Oertel, J; Roller, S; Worst, P; Bischof, H; Glunz, A; Greil, R; von Kalle, K; Schalk, KP; Hasenclever, D; Brosteanu, O; Duehmke, E; Georgii, A; Engert, A; Loeffler, M; Diehl, V
ANN ONCOL. 2004; 15(2): 276-282.
Originalarbeiten (Zeitschrift)

Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen

Reduction of Combined Modality Treatment Intensity in Early Stage Hodgkin’s Lymphoma: Interim Analysis of the HD 10 Trial of the GHSG.
Diehl, V; Brillant, C; Engert, A; Wolf, J; Nogova, L; Mueller, RP; Eich, H; Mueller-Hermelink, HK; Herrmann, R; Doerken, B; Kanz, L; Greil, R; Pfistner, B;
Blood. 2004; 104(11):1307--46th Annual Meeting of American Society of Hematology (ASH); 04.-07.12.2004; San Diego, California.
Abstracts (Zeitschrift)
Beacopp Chemotherapy for Advanced Hodgkin’s Disease: Results of Further Analyses of the HD9- and HD12- Trials of the German Hodgkin Study Group (GHSG).
Diehl, V; Brillant, C; Franklin, J; Hermann, R; Greil, R; Engert, A; Pfistner, B;
Blood. 2004; 104(11):307--46th Annual Meeting of American Society of Hematology (ASH); 04.-07.12.2004; San Diego, California.
Abstracts (Zeitschrift)

Beiträge in Sonstigen Zeitschriften

Pegfilgrastim Supports Delivery of CHOP-R Chemotherapy Administered Every 14 Days: A Randomised Phase II Study.
Lopez, A; de Sevilla, AF; Castaigne, S; Greil, R; Sierra, J; Sanchez, J; Easton, V; Bacon, P;
ashmtg, 11 . 2004. 104: 3311-3311.

2003

Beiträge in Fachzeitschriften

Tetrocarcin-A--induced ER stress mediates apoptosis in B-CLL cells via a Bcl-2--independent pathway.
Anether, G; Tinhofer, I; Senfter, M; Greil, R;
BLOOD. 2003; 101(11): 4561-4568.
Originalarbeiten (Zeitschrift)
Tuning the rheostat of the myelopoietic system via Fas and TRAIL.
Greil, R; Anether, G; Johrer, K; Tinhofer, I;
CRIT REV IMMUNOL. 2003; 23(4): 301-322.
Übersichtsarbeiten
Tracking death dealing by Fas and TRAIL in lymphatic neoplastic disorders: pathways, targets, and therapeutic tools.
Greil, R; Anether, G; Johrer, K; Tinhofer, I;
J LEUKOCYTE BIOL. 2003; 74(3): 311-330.
Übersichtsarbeiten
Longer failure-free survival interval of Epstein-Barr virus-associated classical Hodgkin"s lymphoma: a single-institution study.
Krugmann, J; Tzankov, A; Gschwendtner, A; Fischhofer, M; Greil, R; Fend, F; Dirnhofer, S;
Mod Pathol. 2003; 16(6):566-573
Originalarbeiten (Zeitschrift)
A randomized study comparing interferon (IFN alpha) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia (CML).
Kühr, T; Burgstaller, S; Apfelbeck, U; Linkesch, W; Seewann, H; Fridrik, M; Michlmayr, G; Krieger, O; Lutz, D; Lin, W; Pont, J; Köck, L; Abbrederis, K; Baldinger, C; Buder, R; Geissler, D; Hausmaninger, H; Lang, A; Zabernigg, A; Duba, C; Hilbe, W; Eisterer, W; Fiegl, M; Greil, R; Gastl, G; Thaler, J;
Leuk Res. 2003; 27(5):405-411
Originalarbeiten (Zeitschrift)
Prognostic significance of CD20 expression in classical Hodgkin lymphoma: a clinicopathological study of 119 cases.
Tzankov, A; Krugmann, J; Fend, F; Fischhofer, M; Greil, R; Dirnhofer, S;
Clin Cancer Res. 2003; 9(4):1381-1386
Originalarbeiten (Zeitschrift)

Beiträge in Sonstigen Zeitschriften

O-253 Early intervention with epoetin alfa maintains hemoglobin (HB) in advanced non-small-cell lung cancer (NSCLC) patients
Milroy, R; Scagliotti, G; van den Berg, PM; Galanis, NE; García Gómez, R; Greil, R; Krzakowski, R;
Lung Cancer . 2003. 41: 74-74.

2002

Beiträge in Fachzeitschriften

Interleukin-15 as a potential costimulatory cytokine in CD154 gene therapy of chronic lymphocytic leukemia.
Anether, G; Marschitz, I; Tinhofer, I; Greil, R;
Blood. 2002; 99(2): 722-723.
Letter
Histone deacetylase inhibitors potently repress CXCR4 chemokine receptor expression and function in acute lymphoblastic leukaemia.
Crazzolara, R; Jöhrer, K; Johnstone, RW; Greil, R; Kofler, R; Meister, B; Bernhard, D;
Br J Haematol. 2002; 119(4): 965-969.
Originalarbeiten (Zeitschrift)
Monoclonal gammopathy of undetermined significance.
Fiegl, M; Greil, R;
N Engl J Med. 2002; 346(26): 2087-2088.
Letter
Intravascular large B-cell lymphoma with a fulminant clinical course: a case report with definite diagnosis post mortem.
Fiegl, M; Greil, R; Pechlaner, C; Krugmann, J; Dirnhofer, S;
Ann Oncol. 2002; 13(9): 1503-1506.
Fallberichte
Diffuse large B-cell lymphoma with infiltration-associated peripheral neuropathy and paraneoplastic myopathy with a prolonged course over seven years.
Fiegl, M; Muigg, A; Smekal, A; Krugmannd, J; Dirnhofer, S; Greil, R;
Leuk Lymphoma. 2002; 43(8): 1687-1690.
Originalarbeiten (Zeitschrift)
Splenectomy versus medical treatment for idiopathic thrombocytopenic purpura.
Gadenstätter, M; Lamprecht, B; Klingler, A; Wetscher, GJ; Greil, R; Schmid, T;
Am J Surg. 2002; 184(6): 606-609.
Originalarbeiten (Zeitschrift)
Dose escalation of ara-c may improve response rates in a subgroup of chronic myeloid leukemia patients with poor response to interferon-alpha and low-dose ara-C.
Hilbe, W; Kühr, T; Apfelbeck, U; Fridrik, M; Seewann, H; Stöger, M; Linkesch, W; Pont, J; Baldinger, C; Hartner, E; Bernhart, M; Geissler, D; Krieger, O; Lang, A; Lin, W; Ludwig, H; Duba, C; Greil, R; Gast, G; Thaler, J;
Leuk Lymphoma. 2002; 42(6): 1283-1288.
Originalarbeiten (Zeitschrift)
The impact of hemoglobin levels on fatigue and quality of life in cancer patients.
Holzner, B; Kemmler, G; Greil, R; Kopp, M; Zeimet, A; Raderer, M; Hejna, M; Zöchbauer, S; Krajnik, G; Huber, H; Fleischhacker, WW; Sperner-Unterweger, B;
Ann Oncol. 2002; 13(6): 965-973.
Originalarbeiten (Zeitschrift)
Multidimensional scaling as a tool for analysing quality of life data.
Kemmler, G; Holzner, B; Kopp, M; Dünser, M; Greil, R; Hahn, E; Sperner-Unterweger, B;
Qual Life Res. 2002; 11(3): 22-33.
Übersichtsarbeiten
The role of soluble CD23 in distinguishing stable and progressive forms of B-chronic lymphocytic leukemia.
Schwarzmeier, JD; Shehata, M; Hilgarth, M; Marschitz, I; Louda, N; Hubmann, R; Greil, R;
Leuk Lymphoma. 2002; 43(3): 549-554.
Originalarbeiten (Zeitschrift)
Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin"s lymphoma: final results of the German Hodgkin"s Lymphoma Study Group Trial HD5.
Sieber, M; Tesch, H; Pfistner, B; Rueffer, U; Lathan, B; Brosteanu, O; Paulus, U; Koch, T; Pfreundschuh, M; Loeffler, M; Engert, A; Josting, A; Wolf, J; Hasenclever, D; Franklin, J; Duehmke, E; Georgii, A; Schalk, KP; Kirchner, H; Doelken, G; Munker, R; Koch, P; Herrmann, R; Greil, R; Anselmo, AP; Diehl, V;
J Clin Oncol. 2002; 20(2): 476-484.
Originalarbeiten (Zeitschrift)
Stressful death of T-ALL tumor cells after treatment with the anti-tumor agent Tetrocarcin-A.
Tinhofer, I; Anether, G; Senfter, M; Pfaller, K; Bernhard, D; Hara, M; Greil, R;
FASEB J. 2002; 16(10): 1295-1297.
Originalarbeiten (Zeitschrift)

Beiträge in Sonstigen Zeitschriften

Multimodality treatment approaches in pancreatic cancer: Current status and future perspectives
Greil, R;
European Surgery (2002) . 2002.

2001

Beiträge in Fachzeitschriften

Inhibition of histone deacetylase activity enhances Fas receptor-mediated apoptosis in leukemic lymphoblasts.
Bernhard, D; Skvortsov, S; Tinhofer, I; Hübl, H; Greil, R; Csordas, A; Kofler, R;
Cell Death Differ. 2001; 8(10): 1014-1021.
Originalarbeiten (Zeitschrift)
Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin"s disease: long-term results of a randomized trial of radiotherapy alone.
Dühmke, E; Franklin, J; Pfreundschuh, M; Sehlen, S; Willich, N; Rühl, U; Müller, RP; Lukas, P; Atzinger, A; Paulus, U; Lathan, B; Rüffer, U; Sieber, M; Wolf, J; Engert, A; Georgii, A; Staar, S; Herrmann, R; Beykirch, M; Kirchner, H; Emminger, A; Greil, R; Fritsch, E; Koch, P; Drochtert, A; Brosteanu, O; Hasenclever, D; Loeffler, M; Diehl, V;
J Clin Oncol. 2001; 19(11): 2905-2914.
Originalarbeiten (Zeitschrift)
Quality of life measurement in oncology--a matter of the assessment instrument?
Holzner, B; Kemmler, G; Sperner-Unterweger, B; Kopp, M; Dünser, M; Margreiter, R; Marschitz, I; Nachbaur, D; Fleischhacker, WW; Greil, R;
Eur J Cancer. 2001; 37(18): 2349-2356.
Originalarbeiten (Zeitschrift)
Primary gastrointestinal B-cell lymphoma. A clincopathological and immunohistochemical study of 61 cases with an evaluation of prognostic parameters.
Krugmann, J; Dirnhofer, S; Gschwendtner, A; Berresheim, U; Greil, R; Krugmann, K; Fend, F;
Pathol Res Pract. 2001; 197(6): 385-393.
Originalarbeiten (Zeitschrift)
Epstein-Barr virus-associated extranodal NK/T-cell lymphoma, nasal type of the hypopharynx, in a renal allograft recipient: case report and review of literature.
Stadlmann, S; Fend, F; Moser, P; Obrist, P; Greil, R; Dirnhofer, S;
Hum Pathol. 2001; 32(11): 1264-1268.
Fallberichte
Resveratrol, a tumor-suppressive compound from grapes, induces apoptosis via a novel mitochondrial pathway controlled by Bcl-2.
Tinhofer, I; Bernhard, D; Senfter, M; Anether, G; Loeffler, M; Kroemer, G; Kofler, R; Csordas, A; Greil, R;
FASEB J. 2001; 15(9): 1613-1615.
Originalarbeiten (Zeitschrift)

Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen

Stepping up treatment with Rituxan (R) (rituximab, Mabthera (R)) for CLL patients with advanced stage of disease relapsing after or refractory to conventional chemotherapy.
Greil, R; Steurer, M; Egle, A; Stauder, R; Anether, G; Ulmer, L; Tinhofer, I; Gastl, G
BLOOD. 2001; 98(11): 289B-290B.
Abstracts (Zeitschrift)

2000

Beiträge in Fachzeitschriften

Resveratrol causes arrest in the S-phase prior to Fas-independent apoptosis in CEM-C7H2 acute leukemia cells.
Bernhard, D; Tinhofer, I; Tonko, M; Hübl, H; Ausserlechner, MJ; Greil, R; Kofler, R; Csordas, A;
Cell Death Differ. 2000; 7(9): 834-842.
Originalarbeiten (Zeitschrift)
Vinorelbine-gemcitabine in advanced non-small-cell lung cancer (NSCLC): an AASLC phase II trial. Austrian Association for the Study of Lung Cancer.
Krajnik, G; Mohn-Staudner, A; Thaler, J; Greil, R; Schmeikal, S; Marhold, F; Deutsch, J; Preiss, P; Malayeri, R; Schäfer-Prokop, C; Wein, W; Huber, H; Pirker, R;
Ann Oncol. 2000; 11(8): 993-998.
Originalarbeiten (Zeitschrift)
Analysis of Bcl-2 protein expression in chronic lymphocytic leukemia. A comparison of three semiquantitation techniques.
Marschitz, I; Tinhofer, I; Hittmair, A; Egle, A; Kos, M; Greil, R;
Am J Clin Pathol. 2000; 113(2): 21-29.
Originalarbeiten (Zeitschrift)
Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma.
Tinhofer, I; Marschitz, I; Henn, T; Egle, A; Greil, R;
Blood. 2000; 95(2): 610-618.
Originalarbeiten (Zeitschrift)
Gastric cancer cell lines lack Fas ligand (FasL) expression but kill T cells via a FasL independent pathway.
Tinhofer, I; Wykypiel, H; Marschitz, I; Henn, T; Greil, R;
Gut. 2000; 46(5): 738-740.
Letter

1999

Beiträge in Fachzeitschriften

Retrospective assessment of quality of life and treatment outcome in patients with Hodgkin"s disease from 1969 to 1994.
Greil, R; Holzner, B; Kemmler, G; Kopp, M; Buchowski, A; Oberaigner, W; Fritsch, E; Dirnhofer, S; Rueffer, U; Diehl, V; Sperner-Unterweger, B;
Eur J Cancer. 1999; 35(5): 698-706.
Originalarbeiten (Zeitschrift)
Comparison of two quality-of-life instruments for cancer patients: the functional assessment of cancer therapy-general and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30.
Kemmler, G; Holzner, B; Kopp, M; Dünser, M; Margreiter, R; Greil, R; Sperner-Unterweger, B;
J Clin Oncol. 1999; 17(9): 2932-2940.
Originalarbeiten (Zeitschrift)
Thymic Hodgkin"s disease--a histological and immunohistochemical study of three cases.
Krugmann, J; Feichtinger, H; Greil, R; Fend, F;
Pathol Res Pract. 1999; 195(10): 681-687.
Fallberichte
Synergistic action of protein kinase C theta and calcineurin is sufficient for Fas ligand expression and induction of a crmA-sensitive apoptosis pathway in Jurkat T cells.
Villunger, A; Ghaffari-Tabrizi, N; Tinhofer, I; Krumböck, N; Bauer, B; Schneider, T; Kasibhatla, S; Greil, R; Baier-Bitterlich, G; Uberall, F; Green, DR; Baier, G;
Eur J Immunol. 1999; 29(11): 3549-3561.
Originalarbeiten (Zeitschrift)

Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen

Cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP) versus cyclophosphamide, epirubicin, vincristine, prednisolone, ifosfamide, VP-16, methotrexate, dexamethasone (CEOP/IMVP-Dexa) for aggressive non-Hodgkinxxxs lymphoma. A multicenter randomized trial of the Austrian working party medical oncology.
Fridrik, MA; Hausmaninger, H; Greil, R; Lang, A; Drach, J; Fortelny, A; Krieger, O; Lin, W
BLOOD. 1999; 94(10): 261B-261B.
Abstracts (Zeitschrift)

1998

Beiträge in Fachzeitschriften

Prognosis and management strategies of lymphatic neoplasias in the elderly. II. Hodgkin"s disease.
Greil, R;
Oncology. 1998; 55(4): 265-275.
Übersichtsarbeiten
Prognosis and management strategies of lymphatic neoplasias in the elderly. I. Aggressive non-Hodgkin"s lymphomas.
Greil, R;
Oncology. 1998; 55(3): 189-217.
Übersichtsarbeiten
On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.
Greil, R; Egle, A; Villunger, A;
Leuk Lymphoma. 1998; 31(5-6): 477-490.
Übersichtsarbeiten
Interferon-alpha for the treatment of elderly patients with chronic myeloid leukaemia.
Hilbe, W; Apfelbeck, U; Fridrik, M; Bernhart, M; Niessner, H; Abbrederis, K; Michlmayr, G; Pont, J; Linkesch, W; Hausmaninger, H; Arneitz, K; Baldinger, C; Duba, C; Eisterer, W; Greil, R; Konwalinka, G; Niederwieser, D; Gastl, G; Thaler, J;
Leuk Res. 1998; 22(10): 881-886.
Originalarbeiten (Zeitschrift)
Vinorelbine/gemcitabine in advanced non-small cell lung cancer (NSCLC): a phase I trial.
Krajnik, G; Wein, W; Greil, R; Marhold, F; Mohn-Staudner, A; Kummer, F; Malayeri, R; Zöchbauer-Müller, S; Huber, H; Pirker, R;
Eur J Cancer. 1998; 34(12): 1977-1980.
Originalarbeiten (Zeitschrift)
Differential sensitivity of CD4+ and CD8+ T lymphocytes to the killing efficacy of Fas (Apo-1/CD95) ligand+ tumor cells in B chronic lymphocytic leukemia.
Tinhofer, I; Marschitz, I; Kos, M; Henn, T; Egle, A; Villunger, A; Greil, R;
Blood. 1998; 91(11): 4273-4281.
Originalarbeiten (Zeitschrift)
Urticaria pigmentosa: a clinical, hematopathologic, and serologic study of 30 adults.
Topar, G; Staudacher, C; Geisen, F; Gabl, C; Fend, F; Herold, M; Greil, R; Fritsch, P; Sepp, N;
Am J Clin Pathol. 1998; 109(3):279-285
Originalarbeiten (Zeitschrift)
Functional granulocyte/macrophage colony stimulating factor receptor is constitutively expressed on neoplastic plasma cells and mediates tumour cell longevity.
Villunger, A; Egle, A; Kos, M; Egle, D; Tinhofer, I; Henn, T; Uberall, F; Maly, K; Greil, R;
Br J Haematol. 1998; 102(4): 1069-1080.
Originalarbeiten (Zeitschrift)
Leg ulcers associated with long-term hydroxyurea therapy.
Weinlich, G; Schuler, G; Greil, R; Kofler, H; Fritsch, P;
J Am Acad Dermatol. 1998; 39(2 Pt 2): 372-374.
Fallberichte

Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen

Inversion of CD4(+)/CD8(+) ratio in B chronic lymphocytic leukemia correlates with differential sensitivity of CD4(+) and CD8(+) T lymphocytes to the killing efficacy of Fas (APO-1/CD95) ligand(+) tumor cells.
Tinhofer, I; Marschitz, I; Kos, M; Henn, T; Egle, A; Villunger, A; Greil, R
BLOOD. 1998; 92(10): 271B-271B.
Abstracts (Zeitschrift)

1997

Beiträge in Fachzeitschriften

Expression of Apo-1/Fas (CD95), Bcl-2, Bax and Bcl-x in myeloma cell lines: relationship between responsiveness to anti-Fas mab and p53 functional status.
Egle, A; Villunger, A; Marschitz, I; Kos, M; Hittmair, A; Lukas, P; Grünewald, K; Greil, R;
BRIT J HAEMATOL. 1997; 97(2): 41-28.
Originalarbeiten (Zeitschrift)
Randomized open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkin"s lymphoma (NHL). A multicenter trial by the Austrian Working Group for Medical Tumor Therapy.
Fridrik, MA; Greil, R; Hausmaninger, H; Krieger, O; Oppitz, P; Stöger, M; Klocker, J; Neubauer, M; Helm, W; Pont, J; Fazeny, B; Hudec, M; Simonitsch, I; Radaszkiewicz, T;
Ann Hematol. 1997; 75(4):135-140
Originalarbeiten (Zeitschrift)
The interleukin 1beta-converting enzyme inhibitor CrmA prevents Apo1/Fas- but not glucocorticoid-induced poly(ADP-ribose) polymerase cleavage and apoptosis in lymphoblastic leukemia cells.
Geley, S; Hartmann, BL; Kapelari, K; Egle, A; Villunger, A; Heidacher, D; Greil, R; Auer, B; Kofler, R;
FEBS Lett. 1997; 402(1): 36-40.
Originalarbeiten (Zeitschrift)
Interferon-alpha-2C and LD ara-C for the treatment of patients with CML: results of the Austrian multi-center phase II study.
Thaler, J; Hilbe, W; Apfelbeck, U; Linkesch, W; Sill, H; Seewann, H; Pont, J; Bernhart, M; Stöger, M; Niessner, H; Abbrederis, K; Geissler, D; Hausmaninger, H; Lin, W; Ludwig, H; Lang, A; Duba, C; Fluckinger, T; Greil, R; Grünewald, K; Konwalinka, G; Niederwieser, D; Fridrik, M;
Leuk Res. 1997; 21(1):75-80
Originalarbeiten (Zeitschrift)
Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/CD95) signaling in human T-acute lymphatic leukemia cells.
Villunger, A; Egle, A; Kos, M; Hartmann, BL; Geley, S; Kofler, R; Greil, R;
Cancer Res. 1997; 57(16): 3331-3334.
Originalarbeiten (Zeitschrift)
Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance.
Villunger, A; Egle, A; Marschitz, I; Kos, M; Böck, G; Ludwig, H; Geley, S; Kofler, R; Greil, R;
BLOOD. 1997; 90(1): 12-20.
Originalarbeiten (Zeitschrift)
Cytokine priming of the granulocyte respiratory burst in myelodysplastic syndromes.
Zabernigg, A; Hilbe, W; Eisterer, W; Greil, R; Ludescher, C; Thaler, J;
Leuk Lymphoma. 1997; 27(1-2):137-143
Originalarbeiten (Zeitschrift)

Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen

Fas (Apo-1/CD95) - Ligand expression on neoplastic plasma cells and its role for the expansion of the neoplastic clone.
Greil, R; Villunger, A; Egle, A; Marschitz, L; Kos, M; Bock, G; Ludwig, H; Geley, S; Kofler, R
BLOOD. 1997; 90(10): 1578-1578.
Abstracts (Zeitschrift)

1996

Beiträge in Fachzeitschriften

IL-10 serum levels in B-cell chronic lymphocytic leukaemia.
Egle, A; Marschitz, I; Posch, B; Herold, M; Greil, R;
Br J Haematol. 1996; 94(1):211-212
Letter
Modulation of Apo-1/Fas (CD95)-induced programmed cell death in myeloma cells by interferon-alpha 2.
Egle, A; Villunger, A; Kos, M; Böck, G; Gruber, J; Auer, B; Greil, R;
Eur J Immunol. 1996; 26(12): 3119-3126.
Originalarbeiten (Zeitschrift)
2",2"-Difluorodeoxycytidine (gemcitabine) induces apoptosis in myeloma cell lines resistant to steroids and 2-chlorodeoxyadenosine (2-CdA).
Gruber, J; Geisen, F; Sgonc, R; Egle, A; Villunger, A; Boeck, G; Konwalinka, G; Greil, R;
Stem Cells. 1996; 14(3):351-362
Originalarbeiten (Zeitschrift)
Constituents of autocrine IL-6 loops in myeloma cell lines and their targeting for suppression of neoplastic growth by antibody strategies.
Villunger, A; Egle, A; Kos, M; Hittmair, A; Maly, K; Greil, R;
Int J Cancer. 1996; 65(4):498-505
Originalarbeiten (Zeitschrift)

1995

Beiträge in Fachzeitschriften

Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin"s lymphoma: dose finding and identification of predictors of response.
Cazzola, M; Messinger, D; Battistel, V; Bron, D; Cimino, R; Enller-Ziegler, L; Essers, U; Greil, R; Grossi, A; Jäger, G; LeMevel, A; Najman, A; Silingardi, V; Spriano, M; van Hoof, A; Ehmer, B;
Blood. 1995; 86(12):4446-4453
Originalarbeiten (Zeitschrift)
Gastric malt lymphoma with crystalline immunoglobulin inclusions and secondary immunoblastic lymphoma in a cervical lymph node.
Fend, F; Gabl, C; Hittmair, A; Greil, R; Feichtinger, H;
Pathol Res Pract. 1995; 191(10):1053-1058
Originalarbeiten (Zeitschrift)
Multimodal therapy in life-threatening cerebral lupus erythematosus: the benefit of cerebrospinal fluid pheresis.
Pfausler, B; Bösch, S; Grubwieser, G; Vollert, H; Greil, R; Hagn, C; Schmutzhard, E;
Int Arch Allergy Immunol. 1995; 107(4):592-594
Fallberichte
Necrotizing vasculitis associated with hepatitis C virus infection: successful treatment of vasculitis with interferon-alpha despite persistence of mixed cryoglobulinemia.
Sepp, NT; Umlauft, F; Illersperger, B; Grünewald, K; Schuler, G; Greil, R; Vogel, W;
Dermatology. 1995; 191(1):43-45
Fallberichte

1994

Beiträge in Fachzeitschriften

Apoptosis and therapy of malignant diseases of the hematopoietic system.
Gruber, J; Greil, R;
Int Arch Allergy Immunol. 1994; 105(4):368-373
Übersichtsarbeiten

Originalbeiträge in Sammelwerk (Buchbeitrag)

In situ-Hybridisierung
Greil, R;
In: Huber, H; Löffler, H; Faber, V (Hrsg.); editors(s). Methoden der diagnostischen Hämatologie. Berlin: Springer; p. 183-214.

1993

Beiträge in Fachzeitschriften

Extensive meningeal involvement as the primary manifestation of a systemic small lymphocytic lymphoma: favourable outcome after neuraxial irradiation without chemotherapy.
Soucek, D; Ransmayr, G; Twerdy, K; Zwierzina, H; Greil, R; Fritsch, E; Maier, H; Pallua, A; Gerstenbrand, F;
Br J Haematol. 1993; 83(4):674-675
Fallberichte

1992

Beiträge in Fachzeitschriften

Investigation of nuclear c-MYC oncoprotein expression in human hematopoiesis: suitability of a rapid and reliable semiquantitative evaluation system.
Greil, R; Fasching, B; Weger, A; Loidl, P;
Lab Invest. 1992; 66(2):251-260
Originalarbeiten (Zeitschrift)
Differential expression of c-myc-mRNA and c-MYC-protein during terminal neoplastic B-cell differentiation.
Greil, R; Loidl, P; Fasching, B; Huber, H;
Curr Top Microbiol Immunol. 1992; 182:215-221
Originalarbeiten (Zeitschrift)

1991

Beiträge in Fachzeitschriften

[Urticarial vasculitis as a symptom of Muckle-Wells syndrome?].
Grassegger, A; Greil, R; Feichtinger, J; Fritsch, P; Hintner, H;
Hautarzt. 1991; 42(2):116-119
Originalarbeiten (Zeitschrift)
Expression of the c-myc proto-oncogene in multiple myeloma and chronic lymphocytic leukemia: an in situ analysis.
Greil, R; Fasching, B; Loidl, P; Huber, H;
Blood. 1991; 78(1):180-191
Originalarbeiten (Zeitschrift)

1990

Beiträge in Fachzeitschriften

A monoclonal antibody directed against the human intercellular adhesion molecule (ICAM-1) modulates the release of tumor necrosis factor-alpha, interferon-gamma and interleukin 1.
Geissler, D; Gaggl, S; Möst, J; Greil, R; Herold, M; Dietrich, M;
Eur J Immunol. 1990; 20(12):2591-2596
Originalarbeiten (Zeitschrift)
[Cytologic molecular detection of oncogene expression: possibilities and prospects in hemato-oncology].
Greil, R; Fasching, B; Huber, H;
Acta Med Austriaca. 1990; 17(1): 6-10.
Übersichtsarbeiten
Monoclonal antibody B-ly7: a sensitive marker for detection of minimal residual disease in hairy cell leukemia.
Thaler, J; Dietze, O; Faber, V; Greil, R; Gastl, G; Denz, H; Ho, AD; Huber, H;
Leukemia. 1990; 4(3): 170-176.
Originalarbeiten (Zeitschrift)

1989

Beiträge in Fachzeitschriften

In situ hybridization for the detection of low copy numbers of c-abl oncogene mRNA in lymphoma cells: technical approach and comparison with results with anti-oncoprotein antibodies.
Greil, R; Fasching, B; Huber, H;
Lab Invest. 1989; 60(4): 574-582.
Originalarbeiten (Zeitschrift)
Expression of leucocyte function-associated antigen-1 and 7F7-antigen, an adhesion molecule related to intercellular adhesion molecule-1 (ICAM-1) in non-Hodgkin lymphomas and leukaemias: possible influence on growth pattern and leukaemic behaviour.
Stauder, R; Greil, R; Schulz, TF; Thaler, J; Gattringer, C; Radaskiewicz, T; Dierich, MP; Huber, H;
Clin Exp Immunol. 1989; 77(2): 234-238.
Originalarbeiten (Zeitschrift)
Immunohistological assessment of bone marrow biopsies from patients with hairy cell leukemia: changes following treatment with alpha-2-interferon and deoxycoformycin.
Thaler, J; Denz, H; Dietze, O; Gastl, G; Ho, AD; Gattringer, C; Greil, R; Lechleitner, M; Huber, C; Huber, H;
Leuk Res. 1989; 13(5): 377-383.
Originalarbeiten (Zeitschrift)
Immunohistology for quantification of normal bone marrow lymphocyte subsets.
Thaler, J; Greil, R; Dietze, O; Huber, H;
Br J Haematol. 1989; 73(4):576-577
Letter

1988

Beiträge in Fachzeitschriften

Importance of an 85 kDa membrane glycoprotein for a variety of cell-cell interactions.
Schulz, TF; Vogetseder, W; Mitterer, M; Neumayer, HP; Myones, BL; Stauder, R; Greil, R; Böck, G; Feichtinger, H; Huber, H;
Mol Immunol. 1988; 25(11):1053-1061
Originalarbeiten (Zeitschrift)

1987

Beiträge in Sonstigen Zeitschriften

Teniposide (VM-26) and cytosine arabinoside as consolidation therapy in adult high-risk patients with acute lymphoblastic leukemia
Hoelzer, D; Thiel, E; Löffler, H; Büchner, T; Ganser, A; Heil, G; Kurrle, E; Heimpel, H; Koch, P; Lipp, T; Kaboth, W; Kuse, R; Küchler, R; Sodomann, H; Maschmeyer, G; Freund, M; Diedrich, H; von Paleske, A; Weh, J; Kolb, H, Müller, U; Bross, K; Fuhr, G; Gassmann, W; Gerecke, D; Kress, M; Busch, FW; Nowrousian, RM; Schneider, W; Aul, C; Rühl, H; Bartels, H; Harms, F; Weiss, A; Löffler, B; Glöckner, W; Fülle, H; Pralle, H; Ho, AD; Bonfert, B; Emmerich, B; Braumann, D; Brenner-Serke, M; Planker, M; Straif, K; Meyer, P; Greil, R; Petsch, S; Görg, C; Grüneisen, A; Vaupel, HA; Bodenstein, H; Overkamp, F; Schlimock, G; Augener, W; Ohl, S; Nowicki, L; Raeth, U; Zurborn, KH; Neiss, A; Messerer, D;
Semin Oncol, Suppl 1. 1987. 14: 92-97.

1986

Beiträge in Fachzeitschriften

In situ quantification of T-cell subsets, NK-like cells and macrophages in Hodgkin"s disease: quantity and quality of infiltration density depends on histopathological subtypes.
Gattringer, G; Greil, R; Radaszkiewicz, T; Huber, H;
Blut. 1986; 53(1): 49-58.
Originalarbeiten (Zeitschrift)
Growth fraction of tumour cells and infiltration density with natural killer-like (HNK1+) cells in non-Hodgkin lymphomas.
Greil, R; Gattringer, C; Knapp, W; Huber, H;
Br J Haematol. 1986; 62(2): 29-300.
Originalarbeiten (Zeitschrift)
Receptors for the third component of complement: their association with maturation stage in non-Hodgkin lymphomas (NHL) and their possible implication with the development of follicular structures.
Greil, R; Gattringer, C; Schulz, T; Knapp, W; Radaskiewicz, T; Dierich, MP; Huber, H;
Clin Exp Immunol. 1986; 64(2):42-31
Originalarbeiten (Zeitschrift)
[Studies of immunologic markers in malignant lymphomas: diagnostic and prognostic relevance].
Huber, H; Thaler, J; Greil, R; Gattringer, C; Radaszkiewicz, T;
Onkologie. 1986; 9(2): 108-113.
Originalarbeiten (Zeitschrift)

1985

Beiträge in Fachzeitschriften

[Infiltration pattern of immunocompetent lymphocytes in the tissue of malignant non-Hodgkin"s lymphoma: relationship to histological and clinical parameters].
Gattringer, C; Radaszkiewicz, T; Greil, R; Pfaller, W; Huber, H;
Wien Klin Wochenschr. 1985; 97(5):258-263
Originalarbeiten (Zeitschrift)
[Rhabdomyolysis as a late complication of anesthesia--a case of malignant hyperthermia?].
Greil, R; Gattringer, C; Abbrederis, K;
Wien Klin Wochenschr. 1985; 97(21):813-816
Originalarbeiten (Zeitschrift)